

AUTHOR INDEX

- Aalders, N.L., 1606
 Abassi, Z., 115
 Abdelnoor, M., 611
 Abdolell, M., 549
 Adams, P.C., 1016
 Adibi, S.A., 1243
 Agosto, A., 1513
 Aguirre, J., 149
 Ahmad, F., 1175
 Aihara, N., 1410
 Ai-Homs, B., 1308
 Aizawa, T., 207
 Alayoff, A., 982
 Albers, C.J., 1016
 Alberti, K.G.M.M., 1016
 Albrecht, B.N., 1038
 Aldred, H.E., 390
 Almario, R., 1223
 Alvarez, C., 1519
 Alvarez, W., 149
 Alyassin, A., 1617
 Amado, J.A., 812
 Amatruda, J.M., 1413
 Andersen, P., 611
 Anderson, J.W., 848
 Anderson, R., 954
 Anderson, R.A., 1314
 Andrikopoulos, S., 1298
 Anner, H., 982
 Annuzzi, G., 712
 Aoki, K., 1194
 Appendino, M., 673
 Applegate, W.B., 1082
 Apweiler, R., 577
 Arai, T., 478
 Arata, M., 1435
 Arem, N., 1559
 Arem, R., 1559
 Arends, J., 1253
 Arii, H., 1194
 Arisaka, M., 419
 Arisaka, O., 419
 Arnesen, H., 611
 Arnone, S., 1417
 Arsenijevic, D., 800
 Arvat, E., 134
 Asakura, Y., 315
 Asfour, M., 1013
 Assimacopoulos-Jeannet, F., 228
 Astrup, A., 1570
 Atsopardis, S., 681
 Attvall, S., 52
 Avellone, G., 1417
 Aversa, R., 1283
 Aw, T.Y., 1462

 Bailbe, D., 1519
 Bak, J.F., 1570
 Baldo-Enzi, G., 161
 Bangalore, S.A., 532
 Baracos, V.E., 1340
 Barbagallo, C.M., 1283

 Bard, J.M., 1447
 Barkan, A.L., 667
 Barnard, R., 1413
 Barrett, E.J., 424
 Barrett, P.H.R., 1058
 Baruffaldi, L., 883
 Basabe, J.C., 1435
 Bauman, W.A., 1612
 Baumstark, M.W., 1384
 Båvenholm, P., 1481
 Beaumont, K., 1581
 Beck, B., 972
 Bélanger, A., 513
 Bell, B.M., 1264
 Bell-Farrow, A., 954
 Benford, S., 677
 Bengtsson, B.-Å., 67, 1126
 Benthem, L., 245, 1332
 Berg, A., 1384
 Berga, S.L., 1121
 Berlin, E., 1428
 Bernal, C.A., 1243
 Berne, C., 557
 Berry, G.T., 597
 Bertaglia, M., 161
 Berthold, H.K., 466
 Bertolotti, R., 730
 Bertrand, M., 652
 Bessone, A., 281
 Beylot, M., 639
 Bhathena, S.J., 1314
 Bhuiyan, J., 1185
 Bianchi, G.P., 899
 Bier, D.M., 1253
 Biggerstaff, K.D., 1536
 Billiar, T.R., 166
 Bilotta, T., 796
 Biolo, G., 719
 Bircher, J., 1253
 Birkeland, K., 611
 Bistran, B.R., 1365
 Bittle, J.B., 1082
 Bjerre, U., 1570
 Björntorp, P., 35
 Blaak, E.E., 183, 520
 Blair, J.B., 1380
 Blakemore, W.S., 59
 Blas, S.D., 865
 Blomqvist, B.L., 1215
 Blum, W.F., 605
 Blumberg, D., 145
 Bocharov, A.V., 730
 Boden, G., 1590
 Boegner, C., 833
 Boer, P., 1469
 Boggs, K.P., 348
 Boivin, A., 1540
 Bond, M.G., 1082
 Bonfatti, D., 1153
 Bonora, E., 1617
 Bories, P.N., 765
 Bosaeus, I., 67

 Boscherini, B., 1033
 Bouchard, C., 96, 491
 Boudriau, S., 652
 Bouix, O., 833
 Bouma, B.N., 1606
 Bowers, C.Y., 1199
 Brabant, G., 605
 Brazier, J.-L., 699
 Brennan, M.F., 145
 Brenner, M.A., 193
 Bresciani, E., 379
 Breum, L., 1570
 Brichard, S., 228
 Brighenti, F., 549
 Brixen, K., 725
 Brizi, M., 899
 Broderick, T.L., 499
 Brooks, S.W., 59
 Broussard, J.D., 287
 Brown, T.R., 1527
 Brun, J.F., 833
 Brun, L.-D., 652
 Bryer-Ash, M., 705
 Buckley, G., 549
 Bugari, G., 1028
 Bugianesi, E., 899
 Buist, A.S., 90
 Bulatov, A.A., 1199
 Burke, J.F., 659
 Burlet, C., 972
 Buroker, C.A., 532
 Bursztyn, M., 982
 Burt, M., 145
 Buscema, M., 261
 Buse, M.G., 348
 Bussi, A.R., 379
 Byrne, M.M., 1067

 Caffarra, P., 474, 538
 Caffarri, G., 474, 538
 Caiazza, A., 474
 Caldara, R., 1153
 Caltabiano, V., 261
 Cam, M.C., 332
 Camanni, F., 134
 Cameron, N.E., 1209
 Campillo, B., 765
 Can, S., 946
 Cantin, B., 652
 Capretti, L., 474, 538
 Carbonnel, F., 1110
 Carey, K.D., 1058
 Carnaghi, L.R., 320
 Carrero, P., 929
 Cartaia, J., 119
 Casanueva, F.F., 745
 Casimiro, L., 1283
 Castelli, A., 538
 Castillo, L., 659
 Caumo, A., 1153
 Cavallo-Perin, P., 281
 Cefalù, A.B., 1283

AUTHOR INDEX

- Aalders, N.L., 1606
 Abassi, Z., 115
 Abdelnoor, M., 611
 Abdolell, M., 549
 Adams, P.C., 1016
 Adibi, S.A., 1243
 Agosto, A., 1513
 Aguirre, J., 149
 Ahmad, F., 1175
 Aihara, N., 1410
 Ai-Homs, B., 1308
 Aizawa, T., 207
 Alayoff, A., 982
 Albers, C.J., 1016
 Alberti, K.G.M.M., 1016
 Albrecht, B.N., 1038
 Aldred, H.E., 390
 Almario, R., 1223
 Alvarez, C., 1519
 Alvarez, W., 149
 Alyassin, A., 1617
 Amado, J.A., 812
 Amatruda, J.M., 1413
 Andersen, P., 611
 Anderson, J.W., 848
 Anderson, R., 954
 Anderson, R.A., 1314
 Andrikopoulos, S., 1298
 Anner, H., 982
 Annuzzi, G., 712
 Aoki, K., 1194
 Appendino, M., 673
 Applegate, W.B., 1082
 Apweiler, R., 577
 Arai, T., 478
 Arata, M., 1435
 Arem, N., 1559
 Arem, R., 1559
 Arends, J., 1253
 Arii, H., 1194
 Arisaka, M., 419
 Arisaka, O., 419
 Arnesen, H., 611
 Arnone, S., 1417
 Arsenijevic, D., 800
 Arvat, E., 134
 Asakura, Y., 315
 Asfour, M., 1013
 Assimacopoulos-Jeannet, F., 228
 Astrup, A., 1570
 Atsoparidis, S., 681
 Attvall, S., 52
 Avellone, G., 1417
 Aversa, R., 1283
 Aw, T.Y., 1462

 Bailbe, D., 1519
 Bak, J.F., 1570
 Baldo-Enzi, G., 161
 Bangalore, S.A., 532
 Baracos, V.E., 1340
 Barbagallo, C.M., 1283

 Bard, J.M., 1447
 Barkan, A.L., 667
 Barnard, R., 1413
 Barrett, E.J., 424
 Barrett, P.H.R., 1058
 Baruffaldi, L., 883
 Basabe, J.C., 1435
 Bauman, W.A., 1612
 Baumstark, M.W., 1384
 Båvenholm, P., 1481
 Beaumont, K., 1581
 Beck, B., 972
 Bélanger, A., 513
 Bell, B.M., 1264
 Bell-Farrow, A., 954
 Benford, S., 677
 Bengtsson, B.-Å., 67, 1126
 Benthem, L., 245, 1332
 Berg, A., 1384
 Berga, S.L., 1121
 Berlin, E., 1428
 Bernal, C.A., 1243
 Berne, C., 557
 Berry, G.T., 597
 Bertaglia, M., 161
 Berthold, H.K., 466
 Bertolotti, R., 730
 Bertrand, M., 652
 Bessone, A., 281
 Beylot, M., 639
 Bhathena, S.J., 1314
 Bhuiyan, J., 1185
 Bianchi, G.P., 899
 Bier, D.M., 1253
 Biggerstaff, K.D., 1536
 Billiar, T.R., 166
 Bilotta, T., 796
 Biolo, G., 719
 Bircher, J., 1253
 Birkeland, K., 611
 Bistran, B.R., 1365
 Bittle, J.B., 1082
 Bjerre, U., 1570
 Björntorp, P., 35
 Blaak, E.E., 183, 520
 Blair, J.B., 1380
 Blakemore, W.S., 59
 Blas, S.D., 865
 Blomqvist, B.L., 1215
 Blum, W.F., 605
 Blumberg, D., 145
 Bocharov, A.V., 730
 Boden, G., 1590
 Boegner, C., 833
 Boer, P., 1469
 Boggs, K.P., 348
 Boivin, A., 1540
 Bond, M.G., 1082
 Bonfatti, D., 1153
 Bonora, E., 1617
 Bories, P.N., 765
 Bosaeus, I., 67

 Boscherini, B., 1033
 Bouchard, C., 96, 491
 Boudriau, S., 652
 Bouix, O., 833
 Bouma, B.N., 1606
 Bowers, C.Y., 1199
 Brabant, G., 605
 Brazier, J.-L., 699
 Brennan, M.F., 145
 Brenner, M.A., 193
 Bresciani, E., 379
 Breum, L., 1570
 Brichard, S., 228
 Brighenti, F., 549
 Brixen, K., 725
 Brizi, M., 899
 Broderick, T.L., 499
 Brooks, S.W., 59
 Broussard, J.D., 287
 Brown, T.R., 1527
 Brun, J.F., 833
 Brun, L.-D., 652
 Bryer-Ash, M., 705
 Buckley, G., 549
 Bugari, G., 1028
 Bugianesi, E., 899
 Buist, A.S., 90
 Bulatov, A.A., 1199
 Burke, J.F., 659
 Burlet, C., 972
 Buroker, C.A., 532
 Bursztyn, M., 982
 Burt, M., 145
 Buscema, M., 261
 Buse, M.G., 348
 Bussi, A.R., 379
 Byrne, M.M., 1067

 Caffarra, P., 474, 538
 Caffarri, G., 474, 538
 Caiazza, A., 474
 Caldara, R., 1153
 Caltabiano, V., 261
 Cam, M.C., 332
 Camanni, F., 134
 Cameron, N.E., 1209
 Campillo, B., 765
 Can, S., 946
 Cantin, B., 652
 Capretti, L., 474, 538
 Carbonnel, F., 1110
 Carey, K.D., 1058
 Carnaghi, L.R., 320
 Carrero, P., 929
 Cartaia, J., 119
 Casanueva, F.F., 745
 Casimiro, L., 1283
 Castelli, A., 538
 Castillo, L., 659
 Caumo, A., 1153
 Cavallo-Perin, P., 281
 Cefalù, A.B., 1283

- Cefalu, W.T., 954
 Celentano, E., 1293
 Centanni, M., 1239
 Cerci, S., 1239
 Ceriello, A., 363
 Cerutti, F., 281
 Cesareo, R., 1239
 Chambless, L.E., 914
 Chang, H.R., 800
 Chapman, T.E., 659
 Charach, G., 1401
 Charzewska, J., 35
 Chen, S.-J., 126
 Chen, X., 1590
 Cherrington, A.D., 452
 Chiesa, L., 379, 1028
 Chiodera, P., 474, 538
 Cho, J.H., 1509
 Christiansen, C., 369
 Christopher, M.M., 287
 Christos, S.C., 499
 Cianfarani, S., 1033
 Ciaraldi, T.P., 976
 Cigarini, C., 474
 Cigolini, M., 398
 Cimmino, M., 1513
 Cincotta, A.H., 1349
 Clarke, M.R., 166
 Clegg, M.S., 1495
 Clements, J.P., 1371
 Cobelli, C., 452
 Cogolini, M., 35
 Coiro, V., 474, 538, 1577
 Colca, J.R., 384
 Colman, E., 1502
 Condo, C., 281
 Coon, P.J., 307, 438, 1502
 Cordido, F., 745
 Corey, P., 549
 Corrao, S., 1417
 Corssmit, E.P.M., 1564
 Costa, S., 883
 Cottam, G.L., 1170
 Cotter, M.A., 1209
 Cozzolino, D., 1278
 Craven, P.A., 695
 Crecca, R., 161
 Crook, D., 1481
 Crook, M.A., 147
 Crouse, J.R., III, 954
 Cruz, A., 35
 Cullinane, E.M., 965
 Cummings, M.H., 1052
 Cunnane, S.C., 549
 Cunningham, J., 996
 Cusin, I., 228
 Cutler, D.L., 1264
 Cvetkovska, E., 445
 Cynober, L., 1340

 Dale, P.O., 611
 Dallongeville, J., 1447
 D'Ambrosio, C., 1239
 Darmaun, D., 1110
 Davalli, A.M., 261
 Davidson, M.B., 75
 Davies, J.E., 791
 Davis, F.B., 865
 Davis, P.J., 865
 Davis, S.N., 452
 De Bruno, L.F., 1435
 De Ciocchis, A., 1239
 De Deyn, P.P., 584
 DeFronzo, R.A., 1617
 Deghenghi, R., 134
 De Grange, L.M., 1105
 De Groot, L.C.P.G.M., 1046
 Deicher, H., 1159
 Delbart, C., 1139
 Demigné, C., 200, 1146
 Dengel, J., 307
 Dériaz, O., 96
 DeRubertis, F.R., 695
 Deshaies, Y., 1540
 Desjeux, J.F., 1110
 Deslypere, J.P., 35
 Després, J.-P., 96, 491, 513
 Deurenberg, P., 1046
 Devanlay, M., 765
 Diamanti-Kandarakis, E., 525
 Di Carlo, V., 261, 1153
 Di Chiara, T., 1417
 DiDomenico, D., 499
 Dieguez, C., 745
 Dillon, D.W., 848
 Di Marino, L., 712
 Dines, K.C., 1209
 Ditzler, T.M., 41
 Dobbins, R.L., 452
 Dobias, S.B., 239
 Doga, M., 379
 Doi, K., 1397
 Donovan, S.M., 1495
 D'Orta, G., 712
 Dowling, H.J., 987
 Drost, N.J., 287
 Dulloo, A.B., 273
 Dulloo, A.G., 800
 Dupont, A., 513
 Duran, Z., 149
 Duriez, P., 1447
 Dwyer, J.T., 749

 Ebener, K., 617
 Eckel, R.H., 786, 1475
 Eckfeldt, J.H., 914
 Edström, S., 445
 Edvell, A., 906
 Egawa, K., 430
 Eide, I., 1303
 Ekman, A.-C., 1356
 Ekman, M., 1356
 Elam, M.B., 1082
 El-Andere, W., 923
 Elizarova, G.P., 1199
 Ellsinger, B.M., 35
 Elsas, L.J., II, 597
 Endert, E., 1564
 Escalante, D.A., 1559
 Espina, L., 149

 Fabbri, A., 899
 Faergeman, O., 725
 Fallin, C.W., 287
 Fallucca, F., 796
 Fantus, I.G., 506
 Fasulo, J.M., 1326
 Fau, D., 19
 Faun, J., 332
 Favier, M.-L., 200
 Federlin, K., 617
 Feinglos, M.N., 645
 Feliú, J.E., 1000
 Fellin, R., 161
 Fermo, I., 883
 Fernandez, M.L., 855
 Ferrara, A., 1293
 Ferrara, L.A., 712
 Ferrer, M., 1016
 Filippini, M., 562
 Flam, B.R., 1074
 Flamia, R., 899
 Floore, T.L., 848
 Florkiewicz, R.Z., 1038
 Flynn, N.E., 1247
 Follett, L., 705
 Folsom, A.R., 914
 Forbes, G.B., 1442
 Fouet, P., 765
 Fowelin, J., 1126
 Francalanci, I., 562
 Francis, G.L., 234
 Frandina, C., 796
 French, L.R., 1371
 Freund, P., 570, 577
 Frey, I., 1384
 Friberg, R.D., 667
 Fried, S.K., 987
 Frolova, E.G., 730
 Floyd, K.K., 786
 Fruchart, J.-C., 1139, 1447
 Fujinami, T., 460
 Fujitani, J., 1397
 Fujiwara, S., 419
 Fujiwara, T., 486
 Fukagawa, N.K., 630
 Fukushima, M., 1397
 Fukushima, N., 4
 Fukuzawa, H., 1397
 Fulcher, G., 1016
 Fumarola, A., 1239

 Gagliardi, G., 1435
 Gagné, C., 652
 Galasso, R., 1293
 Galli-Kienle, M., 883
 Gandy, R.E., 59
 Ganguzza, A., 1417
 Gao, K.-M., 1489
 García-Unzueta, M.T., 812
 Gardner, A.W., 340
 Gasic, S., 239
 Gasperino, J.A., 30
 Gastaldi, C., 1028
 Gedulin, B., 1581
 Geiger, J.W., 59

- Gelfand, R.A., 424
 Géloën, A., 1513
 Gensini, G.F., 562
 Georgiadou, E., 525
 Gesundheit, N., 667
 Gettys, T.W., 771
 Getz, G.S., 1058
 Ghiatas, A.A., 1617
 Ghigo, E., 134
 Ghosh, P., 890
 Giada, F., 161
 Gianchandani, R., 757
 Gianotti, L., 134
 Gibbons, G.F., 841
 Gibson, J.B., 597
 Giddings, S.J., 320
 Gingerich, R.L., 1371
 Giorda, C., 673
 Girardier, L., 273, 800
 Gitomer, W.L., 1170
 Giugliano, D., 363, 1278
 Giustina, A., 224, 379, 1028
 Giustina, G., 379
 Glimm, D.R., 325
 Godfried, M.H., 1564
 Goers, J.W.F., 1596
 Goetz, F.C., 1371
 Goji, K., 430
 Goldberg, A.P., 307, 438, 1502
 Goldin, B.R., 749
 Goldstein, B.J., 1175
 Gombas, D.Z., 865
 Gorbach, S.L., 749
 Gramellini, C.D., 474
 Gray, C.G., 1264
 Gray, K., 1130
 Graziani, M.S., 398
 Green, A., 239
 Griffaton, G., 19
 Grigolini, L., 398
 Grossi, G., 899
 Grosskopf, I., 1401
 Grottoli, S., 134
 Grunberger, G., 1308
 Gugins, S., 1340
 Guijarro, C., 1000
 Guinrand-Hugret, R., 833
 Gustafsson, B., 445
 Gutierrez, C., 691

 Haak, T., 8
 Hagen, E., 1447
 Haji, M., 543
 Halle, M., 1384
 Hammarqvist, F., 1215
 Hamsten, A., 1481
 Hannah, J.S., 1428
 Hansen, P.S., 725
 Haq, S., 147
 Harada, Y., 1626
 Harano, Y., 315
 Hardman, A.E., 390
 Hargrove, D.M., 1231
 Harmatz, P., 996
 Harry, D.S., 254

 Haruta, T., 430
 Hashimoto, H., 806
 Hashimoto, T., 739
 Haskell, W.L., 106
 Hassager, C., 369
 Hatsushika, S., 1410
 Hawkins, M., 549
 Hayashi, T., 1190
 Heidendal, G.A.K., 183
 Heiss, G., 914
 Hellerstein, M.K., 172
 Hems, R., 841
 Hendler, R.G., 1413
 Henkel, E., 1159
 Hennes, M.M.I., 525
 Henriksen, E.J., 267
 Henry, R.R., 41
 Herbert, P.N., 965
 Herrmann, R., 1223
 Hertzmark, E., 749
 Hess, D.L., 90
 Heymsfield, S.B., 30
 Hibino, T., 460
 Hickman, M., 976
 Hickman, M.G., 1264
 Higashino, K., 779
 Hinds, A., 13
 Hinson, W.H., 954
 Hirano, N., 1410
 Hirose, H., 358
 Hirose, J., 315
 Ho, P.J., 667
 Hochwald, S., 145
 Hodges, N., 705
 Hoeft, B., 605
 Hoffmann, R.G., 525
 Hofmann, C., 384
 Høieggen, A., 1303
 Holaday, N.J., 1205
 Holvoet, J., 584
 Home, P.D., 254
 Hong, T., 234
 Hoogerbrugge, N., 374
 Horikawa, K., 1410
 Horikoshi, H., 486
 Horio, T., 10, 404
 Horwitz, M.J., 1121
 Howard, B.V., 1428
 Huang, S.H., 667
 Huang, T.-S., 1116
 Huang, W., 730
 Huber-Knudsen, K., 976
 Huff, M.W., 410
 Hughes, S.M., 1082
 Hughes, T.A., 1082
 Huh, K.B., 1509

 Iaina, A., 1401
 Ichikawa, T., 460
 Ikebuchi, M., 315
 Ikeuchi, R., 460
 Illingworth, R., 549
 Imai, Y., 825
 Imamura, T., 430
 Imbimbo, B.P., 134

 Imperatore, G., 1293
 Imperiale, E., 673
 Inada, M., 825
 Inoue, I., 1626
 Isaacson, I.A., 166
 Ishida, K., 940
 Ishii, J., 1626
 Ishizuka, T., 298
 Istfan, N.W., 1365
 Istvan, J.A., 90
 Itabashi, A., 1626
 Ito, K., 358
 Ito, T., 806, 825
 Itoh, K., 1410
 Iwakiri, R., 1462
 Iwanishi, M., 430
 Iwata, S., 460

 Jacob, S., 267
 Jacobs, D.B., 1308
 Jacobsen, S., 1570
 Jansson, P.-A., 52
 Jaspán, J., 452
 Jeanrenaud, B., 228
 Jeevanandam, M., 1205
 Jefferson, L.S., 126
 Jenkins, A.L., 549
 Jenkins, D.J.A., 549
 Jensen, D.R., 786
 Johansson, J., 212
 Johansson, J.-O., 1126
 Jones, P.J.H., 218
 Jongkind, J.F., 374
 Josse, R.G., 549
 Joyce, M., 41
 Judevics, R., 1401
 Julien, P., 652
 Jungmann, E., 8
 Jurasinski, C., 1130

 Kaartinen, J.M., 1288
 Kaempfer, S., 172
 Kageyama, A., 315
 Kahn, S.E., 1259
 Kajihara, S., 4
 Kajio, H., 869
 Kajita, K., 298
 Kajiyama, G., 1410
 Kakimoto, H., 825
 Kaklas, N., 525
 Kalopissis, A.-D., 19
 Kameda-Takemura, K., 478
 Kamiya, Y., 460
 Kang, E.S., 1082
 Kano, H., 10
 Kappler, F., 1527
 Karlsson, A.-K., 52
 Karpe, F., 1481
 Kashiwagi, A., 1455
 Kasim-Karakas, S., 1223
 Kassem, M., 725
 Kastrup, J., 876
 Kataoka, K., 358
 Katayama, S., 1626
 Kato, Y., 1360

- Katsumori, K., 1194
 Katzeff, H.L., 188
 Katzel, L.I., 307, 1502
 Kaufman, L.N., 1105
 Kawaguchi, M., 460, 1360
 Kawahara, H., 460
 Kawai, M., 1190
 Kawamura, H., 1397
 Kawata, S., 825
 Keegan, A., 1209
 Keen, C.L., 1495
 Keiser, H.R., 115
 Kelly, C.M., 506
 Kemerink, G.J., 183
 Kennedy, J.A., 1008
 Kennelly, J.J., 325
 Kern, P.A., 1596
 Kester, A.D.M., 520
 Khadir, M.M.A., 1013
 Khaled, M.A., 1
 Khan, A., 549
 Khoursheed, M., 1489
 Kido, K., 358
 Kikkawa, R., 1455
 Kikuchi, M., 806
 Kim, K.R., 1509
 Kim, S.-B., 532
 Kimball, S.R., 126
 Kissebah, A.H., 525
 Kjeldsen, S.E., 1303
 Klausen, I.C., 725
 Klein, H., 115
 Klein, I., 188
 Klein, P.D., 466
 Kleinveld, H.A., 1606
 Kluft, C., 1548
 Knip, M., 1356
 Knudsen, P., 589
 Kobayashi, K., 739
 Kobayashi, M., 430
 Kobayashi, T., 869
 Kofoed-Enevoldsen, A., 791
 Kohn, M., 10, 404
 Kolterman, O.G., 1264
 Komiya, I., 207
 König, D., 1384
 Koopmans, S.J., 291
 Korthals, J., 677
 Korytkowski, M.T., 1121
 Kosaka, K., 869
 Kotani, K., 478
 Kotzamanidis, C., 681
 Koutsari, C., 681
 Koyama, K., 358
 Koziat, J., 1110
 Kraemer, F.B., 1391
 Krans, H.M.J., 291
 Krauss, R.M., 106
 Krumdieck, C.L., 1
 Kruszynska, Y.T., 254
 Kuel, J., 1384
 Kuhn, C.M., 645
 Kühnle, H.F., 570, 577
 Kullmer, T., 8
 Kunimatsu, M., 460
 Kunita, T., 1410
 Kuroki, H., 1194
 Kushwaha, R.S., 1058
 Kvist, H., 67
 Laakso, M., 1099
 Labrie, F., 513
 Lager, I., 1126
 La Grutta, S., 1283
 Lakshman, M.R., 890
 Lamarche, B., 491
 Lamon-Fava, S., 749
 Lancaster, J.L., 1617
 Landin, K., 1126
 Lanes, R., 149
 Langeloh, G., 630
 LaNoue, K.F., 1288
 Lasunción, M.A., 929
 Laube, H., 617
 Laville, M., 639
 Law, J.S., 1314
 Le Bricon, T., 1340
 Lecerf, J.-M., 1139
 Lee, D.B.N., 141
 Lee, E.J., 1509
 Lee, H.C., 1509
 Lee, M.-K., 1166, 1489
 Leffell, M., 996
 Leluan, M., 765
 Lemieux, S., 491
 Lenaerts, V., 134
 Leppäluoto, J., 1356
 Lerário, A.C., 923
 Letizia, C., 1239
 Leure-duPree, A.E., 126
 Levitsky, L.L., 1553
 Levrat, M.-A., 1136
 Levy, H.L., 597
 Lewis, D.S., 1058
 Licata, G., 1417
 Lichtenstein, A.H., 749
 Lien, I.-N., 1116
 Lillioja, S., 797
 Lim, C.-F., 1008
 Lim, S.K., 1509
 Lind, L., 557
 Lindstedt, G., 67
 Lindström, P., 906
 Linn, T., 617
 Liotta, A., 1283
 Lithell, H.O., 212, 557
 Liu, Q.-H., 890
 Loda, G., 1028
 Loidl, N.M., 1008
 Long, C.L., 59
 Long, P.R., 1365
 Longcope, C., 749
 Lönn, L., 67
 Lönnroth, P., 52
 López-Alarcón, L., 1000
 López-Cordovilla, J.J., 812
 López-Espadas, F., 812
 Lorenz, K., 384
 Louard, R.J., 424
 Løvik, A., 611
 Lovine, C., 1293
 Lowe, W.L., 1038
 Lowitt, S., 677
 Lucarelli, C., 712
 Lueder, F.L., 532
 Lupien, P.-J., 491, 513, 652
 Lydén, E., 445
 Maassen, J.A., 291
 Maccario, M., 134
 McGill, H.C., Jr., 1058
 McIntyre, N., 254
 McMillan, D.C., 1159
 McNamara, D.J., 855
 McNamara, J.R., 749
 McNeill, J.H., 332
 Maggio, C., 1283
 Magni, F., 883
 Mahler, C., 584
 Malone, J.I., 677
 Malvezzi, L., 538
 Mancini, M., 712
 Mandal, A.K., 404
 Mandalia, S., 147
 Marchesini, G., 899
 Marchi, M., 883
 Marescau, B., 584
 Marotta, T., 712
 Martin, K.R., 59
 Martin, L.F., 1288
 Maruyama, A., 1194
 Maruyama, H., 358
 Mason, M.G., 673
 Matsui, H., 806
 Matsuo, T., 934, 1271, 1377
 Matsuzawa, Y., 478, 825
 Maymind, M., 1321, 1532
 Mearkle, P., 996
 Meier, A.H., 1349
 Meijer, P., 1548
 Melzer, A., 1159
 Mensi, N., 273
 Messing, B., 1110
 Micciolo, R., 1617
 Miles, P.D.G., 1489
 Miller, B.C., 1170
 Milligan, G., 239
 Mimura, K., 739
 Min, Z., 940
 Minaire, Y., 699, 1513
 Mink, K., 1553
 Mion, F., 699
 Misitano, V., 379
 Mitrakou, A., 525
 Miura, H., 1410
 Miura, K., 298
 Mizuma, T., 4
 Mizuno, A., 940
 Mizuno, T., 1410
 Moan, A., 1303
 Moffatt, R.J., 1536
 Mohamed-Ali, V., 254
 Montano, C., 855
 Monti, L.D., 883, 1153
 Mooradian, A.D., 320

- Moorjani, S., 491, 513
 Moossa, A.R., 1489
 Mor, R., 1401
 Moriaki, Y., 779
 Morrill-LaBrode, A., 749
 Morrisett, J.D., 1559
 Mosekilde, L., 725
 Mougious, V., 681
 Moundras, C., 200, 1146
 Muggeo, M., 398, 1617
 Muller, D., 1502
 Müller, M.-J., 1159
 Muñoz-Alonso, M.J., 1000
 Murase, T., 869
 Murata, C., 41
 Murray, E.J.B., 141
 Murray, S.S., 141
- Nabulsi, A.A., 914
 Nadeau, A., 96
 Nagasaki, T., 47
 Nagashima, T., 298
 Nagata, I., 1397
 Nagaya, T., 1190
 Nagels, G., 584
 Nakai, Y., 1397
 Nakamura, S., 1360
 Nakamura, T., 478
 Nakanishi, K., 869
 Nakashima, N., 543
 Nakayama, T., 869
 Nakayama, Y., 419
 Nam, M.S., 1509
 Nam, S.Y., 1509
 Namchuk, G.L., 218
 Naoumova, R., 1052
 Nardone, N.A., 1231
 Naruse, K., 806
 Nasser, R., 883
 Navarro, J.F., 929
 Nawata, H., 543, 739
 Neal, D.W., 452
 Negishi, K., 1626
 Negro-Vilar, A., 1028
 Neil, H.A.W., 1016
 Nelson, K.M., 59
 Nephes, I., 982
 Netto, D.G., 923
 Ney, D.M., 152
 Ng, L.L., 791
 Nicolas, J.-P., 972
 Nilsson, P.M., 557
 Nishida, M., 478
 Niskanen, L., 1099
 Nordby, G., 1303
 Notarbartolo, A., 1283
 Nuttens, M.-C., 1139
- Ochi, H., 1410
 Oeltgen, P.R., 848
 Ogata, E.S., 532
 Ogawa, T., 1455
 Ohisalo, J.J., 1288
 Ohneda, A., 47
 Ohneda, K., 47
- Ohrvall, M., 212
 Ohte, N., 460
 Ohya, T., 1410
 Ojamaa, K.M., 188
 Okine, E.K., 325
 Okubo, M., 869
 Okumura, K., 806
 Okuno, A., 486
 Oldfors, A., 445
 Olefsky, J.M., 976, 1166, 1489
 Omac, T., 315
 O'Meara, N.M., 1067
 Omori, Y., 1194
 O'Neal, D.S., 848
 Ong, J.L., 1
 Ong, J.M., 1596
 Ono, Y., 543
 Opara, E.C., 645
 Oppert, J.-M., 96
 Ordoas, J.M., 1326
 Orešković, I., 701
 Orsetti, A., 833
 Ortuño, J., 929
 Os, I., 1303
 Ose, L., 1447
 Ozaki, I., 4
- Pacini, G., 281
 Pagano, G., 281, 673
 Pakbiers, M.T.W., 183
 Palacios, E., 1631
 Palazuk, B.J., 384
 Palmieri, M.J., 597
 Pande, S.V., 1185
 Paniccia, R., 562
 Paolisso, G., 363
 Papadia, C., 474
 Pappu, A.S., 549
 Park, S.W., 1264
 Parker, J.C., 1231
 Paroni, R., 883
 Parsons, H.G., 13
 Pascual-Leone, A.-M., 1519
 Pasquino, A.M., 1033
 Pastor, R., 691
 Patsch, W., 1559
 Patten, R., 549
 Patton, G.M., 1326
 Paul, H.S., 166
 Paulson, D.J., 499
 Pedersen, O., 876
 Pederson, R.A., 218
 Peino, R., 745
 Pekelharing, H.L.M., 1606
 Peñalva, A., 745
 Persson, L.M., 1231
 Peterkova, V.A., 1199
 Petersen, K.F., 1380
 Petersen, S.R., 1205
 Peterson, M.E., 287
 Peterson, M.M., 1105
 Petro, A.E., 645
 Pfister, P., 1447
 Piatti, P.M., 883
 Picarel-Blanchot, F., 1519
- Pierson, R.N., Jr., 30
 Piga, A., 281
 Piñon-López, M.J., 1631
 Pi-Sunyer, F.X., 987
 Pittner, R., 1581
 Platanissiotis, D., 525
 Poehlman, E.T., 340
 Polansky, M.M., 1314
 Pollare, T., 557
 Polonsky, K.S., 1067
 Pontiroli, A.E., 261, 883
 Poretsky, L., 946
 Pornin, B., 765
 Porte, D., Jr., 1259
 Portha, B., 1519
 Possemiers, I., 584
 Poth, M., 234
 Pozza, G., 261, 883, 1153
 Pratley, R.E., 438
 Prigeon, R.L., 1259
 Prisco, D., 562
 Pritchard, P.H., 1185
 Procopio, M., 134
 Proietto, J., 1298
 Proudler, A., 1481
 Prud'homme, D., 491, 513
 Purrello, F., 261
- Quintans, C.J., 1435
- Rabuazzo, A.M., 261
 Racotta, L.S., 1631
 Racotta, R., 1631
 Radder, J.K., 291
 Ramkumar, V., 771
 Rampal, P., 730
 Randall, W.C., 1527
 Rao, A.V., 549
 Rao, R.H., 812, 1422
 Raptis, G., 617
 Raptis, S., 525
 Raz, I., 982
 Reardon, C.A., 1058
 Rebouche, C.J., 624, 1639
 Rebuffé-Scrive, M., 645
 Reeds, P.J., 466
 Reid, J.S., 172
 Rémésy, C., 200, 1146
 Rennecure, F., 228
 Reynolds, R.A., 597
 Rhoads, C.A., 1462
 Rhoads, D.B., 1553
 Riancho, J.A., 812
 Riccardi, G., 1293
 Ricciardi, M.R., 796
 Richards, E.W., 59
 Richart, C., 691
 Riddell-Mason, S., 848
 Riedel, M., 605
 Rigal, O., 1110
 Rigalleau, V., 639
 Rimbart, A., 1110
 Rink, T.J., 1581
 Riou, J.-P., 639
 Risica, R., 126

- Ritter, G., 577
 Rivellese, A., 1293
 Robins, S.J., 1326
 Rodin, J., 645
 Rogers, P.A., 652
 Rogus, E.M., 438, 1502
 Romijn, J.A., 1564
 Romon, M., 1139
 Rongier, M., 1110
 Rossi, F., 712
 Rossi, G., 538
 Rousseau, M., 699
 Rubinstein, A., 1401
 Ruiz, J., 1590
 Russo, O., 712
 Ryan, C.M., 659
- Saad, M.F., 757
 Sacchetti, L., 281
 Sadur, C.N., 1475
 Saghizadeh, M., 1596
 Saito, S., 1194
 Saitoh, S., 934
 Sakai, T., 4
 Sakai, Y., 543
 Sakuma, N., 460
 Salas, E., 812
 Salem, A.F., 677
 Salomez, J.-L., 1139
 Salvatore, T., 1278
 Sane, T., 589
 Sano, T., 940
 Santambrogio, G., 883
 Saris, W.H.M., 183, 520
 Saritelli, A.L., 965
 Sarlund, H., 1099
 Sartori, A., 398
 Saruta, T., 358
 Sasaki, K., 47
 Sasaki, M., 1410
 Sasso, F.C., 1278
 Sato, A., 207
 Sauer, E.P., 1442
 Sauerwein, H.P., 1564
 Sawicki, D.R., 1074
 Saxena, V., 584
 Scaglione, R., 1417
 Scaglioni, A., 538
 Scavo, D., 1239
 Schaefer, E.J., 749, 1326
 Schäfer, G., 1253
 Schattenkerk, J.K.E., 1564
 Schauder, P., 1253
 Schell, R., 577
 Schwartz, E., 1612
 Scuro, L., 1239
 Secchi, A., 1153
 Seccombe, D.W., 1185
 Segal, S., 597
 Seidell, J.C., 35
 Sekas, G., 166
 Selberg, O., 1159
 Seljeflot, I., 611
 Serner, G.G.N., 562
 Sessa, G., 1278
- Setoguchi, Y., 4
 Seydoux, J., 273
 Shackleton, C.H.L., 172
 Sheehan, A.G., 13
 Shigeta, Y., 1455
 Shima, K., 940
 Shimizu, K., 806
 Shimomura, Y., 934
 Shinoda, T., 207
 Shirota, T., 207
 Shug, A.L., 499
 Shulman, G.I., 1380
 Siczkowski, M., 791
 Sierra, P., 1365
 Simpson, L., 1308
 Simsolo, R.B., 1596
 Sips, H.C.M., 291
 Sjöström, L., 67
 Skøtt, P., 876
 Slavin, B.M., 1052
 Smith, D.E., 1326
 Smith, S.M., 152
 Soggi, C., 261
 Sokol, R., 1308
 Soliman, A.T., 1013
 Song, Y.D., 1509
 Song, Y.-M., 41
 Sönksen, P.H., 1052
 Soussi, B., 445
 Sowers, J.R., 1308
 Spanheimer, R.G., 1038
 Sperling, O., 1469
 Speroni, G., 538
 Spiegelman, D., 749
 Spina, J., 525
 Sredy, J., 1074
 St-Amand, J., 491
 Stamford, B.A., 1536
 Stanko, R.T., 166
 Statt, M.C., 1413
 Steffens, A.B., 245, 1332
 Steffensen, R., 876
 Stenlöf, K., 67
 Stentz, F.B., 1082
 Sterling, K., 193
 Stevenson, R.W., 1231
 Stock, M.J., 119
 Stockigt, J.R., 1008
 Striffler, J.S., 1314
 Studer, R.K., 695
 Sturis, J., 1067
 Su, B., 1527
 Sučić, M., 701
 Suda, M., 779
 Suh, K.-I., 41
 Sullivan, D., 1074
 Sullivan, L., 52
 Sumida, H., 1271, 1377
 Sun, D.-M., 855
 Surwit, R.S., 645, 771
 Sutherland, A., 645
 Süttmann, U., 1159
 Suzuki, M., 315, 934, 1271, 1377, 1397
 Svendsen, O.L., 369
 Sweetney, F.P., 791
- Swinburn, B.A., 757
 Sztalryd, C., 1391
 Swergold, S., 1527
- Takahashi, H., 1190
 Takahashi, K., 1626
 Takahashi, S., 779
 Takeda, T., 10, 404
 Takemura, Y., 207
 Takeuchi, H., 934
 Takizawa, I., 1410
 Tamura, K., 1360
 Tanaka, H., 1397
 Tanigawa, K., 1360
 Taniguchi, A., 1397
 Taniguchi, O., 298
 Targhr, G., 35
 Taskinen, M.-R., 589
 Taylor, I.L., 771
 Taylor, S., 390
 Tazuma, S., 1410
 Tchernof, A., 513
 Teik, J., 224
 Teramen, K., 1410
 Terry, J.G., 954
 Teruel, J.L., 929
 Thérét, N., 1139
 Thériault, G., 96
 Thomas, W., 1371
 Thompson, G.R., 1052
 Thompson, J.R., 325
 Thompson, P.D., 965
 Thorburn, A., 1298
 Thuillier, F., 1110
 Tironi, C., 1028
 Toki, Y., 806
 Tokunaga, K., 478
 Tokuyama, K., 1397
 Tolley, E.A., 1082
 Tölle, J., 67
 Tompkins, R.G., 659
 Topliss, D.J., 1008
 Torella, R., 1278
 Tornvall, P., 1481
 Toth, M.J., 340
 Tram, K.K.-T., 141
 Travia, D., 398
 Tremblay, A., 96
 Trimeloni, S., 398
 Tsukada, T., 869
 Tuilpakov, A.N., 1199
 Tukuyama, K., 934
- Umeda, F., 543, 739
 Umpleby, A.M., 1052
 Unterman, T.G., 152
 Usadel, K.H., 8
- Vaccaro, F., 1033
 Vaccaro, O., 1293
 Vakkuri, O., 1356
 Van Baak, M.A., 183, 520
 Van den Berg, H., 1548
 Van der Leest, J., 245, 1046, 1332
 Van der Pijl, T., 1564

- Van Doormaal, J.J., 1606
 Van Rijn, H.J.M., 1606
 Van Staveren, W.A., 1046
 Vary, T.C., 1130
 Vazquez, J.A., 1243
 Vázquez-Barquero, A., 812
 Veirs, H., 630
 Velthuis-te Wierik, E.J.M., 1548
 Vendrell, J., 691
 Venkatesan, N., 75
 Ven Murthy, M.R., 652
 Verkerk, A., 374
 Vernia, P., 796
 Vescovi, P.P., 1577
 Vessby, B., 212
 Vestergaard, H., 876
 Vigna, G.B., 161
 Vigneri, R., 261
 Vikman, H.-L., 1288
 Villaroel, O., 149
 Villotti, G., 796
 Vishniakova, T.G., 730
 Visser, G.H.A., 1606
 Visser, M., 1046
 Vitale, E., 161
 Vladoianu, I.-R., 800
 Voelker, H., 90
 Volevodz, N.N., 1199
 Volpi, R., 474, 538
 Volpini, W.G., 1435
 Voltz, D.M., 224
 Von der Decken, A., 1215
 Von zur Mühlen, A., 605
 Vranizan, K.M., 106
 Vuksan, V., 549
 Vuorinen-Markkola, H., 85, 589

 Wajchenberg, L., 923
 Waliul Islam, A.H.M., 478

 Wang, J., 30
 Wang, M.-W., 1581
 Wang, X., 1082
 Wang, Y.-H., 1116
 Wang, Z.Q., 954
 Wasada, T., 1194
 Watanabe, T., 1410
 Watson, M.E., 234
 Watson, R.L., 914
 Watts, G.F., 147, 1052
 Wehrenberg, W.B., 224
 Weintraub, M.S., 1401
 Weir, S.S., 914
 Weiss, O., 982
 Weitkamp, L.W., 1442
 Welch, C., 234
 Welle, S.L., 1413
 Werbel, S., 954
 Wernerman, J., 1215
 Westin, T., 445
 Weverling, G.J., 1564
 Wiggins, D., 841
 Williams, D., 384
 Williams, P.T., 106
 Wimalawansa, S., 705
 Wolever, T.M.S., 549
 Wolf, B.A., 499
 Wolfe, B.M., 410
 Wolfe, R.D., 719
 Wolff, H.P., 570
 Wollman, Y., 1401
 Wong, W.-L., 667
 Woods, M.N., 749
 Wroblewski, H., 876
 Wu, G., 1247
 Wu, K., 172

 Xu, G., 1360

 Yabuta, K., 419
 Yamada, N., 869
 Yamada, T., 207
 Yamamoto, K., 4
 Yamamoto, M., 298
 Yamamoto, T., 779
 Yamane, K., 1428
 Yamashita, S., 478
 Yamashita, T., 739
 Yamashita, Y., 1410
 Yanagita, T., 4
 Yang, H., 152
 Yasuda, K., 298
 Yasunari, K., 10, 404
 Yazaki, T., 869
 Yki-Järvinen, H., 85, 589
 Yokokawa, K., 10, 404
 Yokota, T., 315
 Yorek, M.A., 1038
 Yoshida, H., 1190
 Yoshioka, S., 486
 Yost, T.J., 786, 1475
 Young, A.A., 1581
 Young, V.R., 659
 Yu, Y.-M., 659
 Yudkin, J.S., 254
 Yurgalevitch, S.M., 965

 Zaitseva, E.V., 730
 Zdanowicz, M., 149
 Zenti, M.G., 398
 Zhang, X.-J., 719
 Zheng, Q., 1553
 Zhong, Y.-G., 1612
 Zijlstra, W.G., 245, 1332
 Zimmerman, R.S., 1321, 1532
 Zoli, M., 899
 Zumoff, B., 946

SUBJECT INDEX

- AAs, *see* Amino acid(s)
 Abdominal adipose tissue (AT)
 age- and menopause-associated variations in, in healthy women, 371, 372
 effects of beef tallow and safflower oil on, 936, 937
 intraabdominal AT contribution to insulin resistance of aging, 954-959
 in NIDDM, 941
 in obese subjects, β -adrenergic stimulation of BF in, 183-187
 subcutaneous, *see* Subcutaneous abdominal adipose tissue
 weight loss by middle-aged and older men with IGT reducing, and improving insulin action, 1502-1508
 Abdominal symptoms, nonspecific, in NIDDM, malabsorption of sorbitol and, 796-799
 Absorptiometry, dual-energy x-ray, age- and menopause-associated variations in AT distribution and body composition in healthy women measured with, 369-373
 Acetaldehyde, effects of, on xanthine dehydrogenase, 783
 Acetate, sodium, effects of, on xanthine dehydrogenase, 783
 Acetic acid, plasma, ethanol effects on, 782

 Acetoacetate
 LPS effects on, 1171
 plasma, in elderly subjects with femoral neck fracture, 61
 α (alpha)-N-Acetylarginine in cirrhosis
 serum levels of, 585
 urinary excretion of, 586
 Acetyl-L-carnitine (ALC), effects of, on peripheral nerve function in STZ-DM, 677-680
 and on vascular supply in diabetes, 1209-1214
 Acid phosphatase, and long-term ethanol exposure, 892
 Acipimox, GH response to GHRH potentiated by, by decreasing serum FFA levels in hyperthyroidism, 1509-1512
 N-Ac-Leu-Leu-norleucinal (ALLN), effects of, on PTH-induced retraction of MC3T3-E1 osteoblastic cells, 141-144
 Acquired immunodeficiency syndrome, *see* AIDS
 Acromegaly
 changes in concentrations of GHBP in normal subjects and in, effects of short-term fasting on, 667-672
 children with, RBC IGF-I receptor in, 923-928
 glucocorticoid effects on GH response to TRH in, 379-383

- ACTH (adrenocorticotropin hormone; corticotropin), low-dose CRH stimulation tests effects on levels of, in IDDM with and without neuropathy, 541
- Acute hypoxia, exhaustive exercise at high altitude with, ET-1 responses to, 8-9
- Acute-phase reactants, blood cytokine levels in brain-dead patients and their relationship with circulating hormones and, 812-816
- Acute trauma, plasma IGFBP-3 in, 1205-1208
- Acyl-CoA (coenzyme A) binding protein, effect of high-fat diet and fasting on levels of, in liver, kidney, and heart, 1185-1189
- Acyltransferase, *see* Lecithin-cholesterol acyltransferase
- Adaptation
- cardiovascular and metabolic, to brisk walking by sedentary middle-aged women, 393
 - in glucose homeostasis during chronic malnutrition, 817-824
- Adenine nucleotide translocase (AdNT), mitochondrial, T₃ effects on, 193-199
- Adenosine monophosphate, cyclic, *see* cAMP
- Adenosine triphosphatase, *see* ATPase
- Adenosine triphosphate, *see* ATP
- Adenylate cyclase, β -adrenergic responsiveness of, in adipocyte plasma membrane in obesity and after weight loss, 1288-1292
- Adenylate cyclase, sensitivity of, to inhibitory and stimulatory agonists, increased concentrations of proteins G_{i1} and G_{i2} in elderly subjects altering, 239-244
- Adipocyte(s)
- increased concentrations of G_{i1} and G_{i2} proteins in elderly subjects', altering sensitivity of adenylate cyclase to inhibitory and stimulatory agonists, 239-244
 - of obese women, effects of AT distribution and race on insulin resistance in, 987-995
 - prednisolone and dexamethasone effects on insulin-induced activation of PKC in, 298-306
 - see also* Adipocyte plasma membrane
- Adipocyte plasma membrane
- β -adrenergic responsiveness of adenylate cyclase in, in obesity and after weight loss, 1288-1292
 - effects of beef tallow diet on FA composition of, 1273
- Adipose tissue (AT; body fat)
- and age-related changes in musculoskeletal mass in postmenopausal women, 31-33
 - arginine and proline synthesis and, 467
 - beef tallow decreasing lipolytic activities and binding capacities of β -adrenergic receptor in, 1271-1277
 - bromocriptine effects on, 1351
 - differential effects of HF diet varying in FAs on efficiency of deposition of, during weight recovery following low food intake, 273-279
 - distribution of, *see* Adipose tissue distribution
 - and effects of weight loss on norepinephrine and insulin levels, 440
 - exercise and, *see* Adipose tissue, exercise and
 - hyperinsulinemia effects on GLUT4 mRNA expression and lipogenic enzymes in, 228-233
 - and insulin resistance in GH-deficient adults, 1127
 - and insulin sensitivity, *see* Adipose tissue, insulin sensitivity and
 - lipase activity and protective profile of Lps and, 492
 - long-term overfeeding effects on, in identical twins, 98
 - in obese men, *see* Men, obese, AT in
 - and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086
- Adipose tissue (AT; body fat) (*Continued*)
- relation between GHb levels and response of LPL of, to glucose and insulin in obese women with NIDDM, 1475-1480
 - see also* Adipocyte(s); Adipose tissue phenotypes
- Adipose tissue (AT; body fat), exercise and
- brisk walking effects on AT in sedentary middle-aged women, 393
 - effects of exercise and fed state on LPL gene expression in AT, 1596-1605
 - in elderly women, energy expenditure and, 1047
 - in middle-aged men, training status and, 342
- Adipose tissue (AT; body fat), insulin sensitivity and, 1123
- sympathetic nervous system influence on insulin sensitivity and metabolism of, in SCI subjects, 52-58
- Adipose tissue (AT; body fat) distribution
- effects of race and, on insulin resistance in adipocytes of obese women, 987-995
 - effects of weight loss to ideal body weight on, 1413-1416
 - regional, associated with HDL subclasses in men with CAD, 106-114; *see also* Abdominal adipose tissue; Epididymal adipose tissue; Subcutaneous adipose tissue; Visceral adipose tissue
 - variations in, associated with age and menopause in healthy women, DEXA in measurement of, 369-373
- Adipose tissue (AT; body fat) phenotypes in long-term overfed identical twins, 102, 104
- AdNT (adenine nucleotide translocase), mitochondrial, T₃ effects on, 193-199
- Adolescent males
- exercise-induced changes in concentrations of plasma NEFAs and triacylglycerols in, 681-688
 - T effects in, *see* Adolescent males, T effects in
- Adolescent males, T effects in
- in adolescents with constitutional delay of growth and development, 1013-1015
 - in adolescents with hypogonadism, T effects on bone density and bone metabolism in, 419-423
- Adrenal C₁₉ steroids, levels of testosterone and, in obese men, 513-519
- Adrenaline, *see* Epinephrine
- β (beta)-Adrenergic blockers, effects of, on hepatic conversion of AA nitrogen and urea synthesis in cirrhosis, 899-905
- β (beta)-Adrenergic mediation of thermogenic and heart rate responses, in obese men, effects of weight loss on, 520-524
- β (beta)-Adrenergic receptor, binding and lipolytic activities of, in AT, decreased by beef tallow diet, 1271-1277
- β (beta)-Adrenergic responsiveness of adenylate cyclase in adipocyte plasma membrane in obesity and after weight loss, 1288-1292
- β (beta)-Adrenergic stimulation, and abdominal subcutaneous fat BF in lean, obese, and reduced-obese subjects, 183-187
- β_2 (beta₂)-Adrenoceptor agonists, *see* Clenbuterol; Salbutamol
- α (alpha)- and β (beta)-Adrenoceptor antagonists, metabolic and hormonal responses to
- during exercise, 245-253
 - during exercise by starved subjects, 1332-1339
- Adrenocorticotropin hormone (ACTH; corticotropin), low-dose CRH stimulation test effects on levels of, in IDDM with and without neuropathy, 541
- Adrenomedullin (AM) stimulating cAMP formation in mesangial cells, 10-12
- Adult hepatocytes, GLUT1 mRNA and GLUT2 mRNA in, glucose regulation of, 1553-1558

Adult subjects

insulin resistance in GH-deficient, 1126-1129

see also Age; Men; Normal adult subjects; Older subjects; Women; Young subjects *entries beginning with terms: Middle-aged and specific conditions*

Adverse effects of fluoxetine, 1572

Aerobic exercise

and effects of age on response of aerobic power to physical conditioning and deconditioning, 161-165

long-term, effects of energy restriction and, on protein synthesis, 188-192

African Americans, *see* Race and ethnicity

Age

of acromegalic subjects, 380

of acute trauma patients, 1206

of AIDS patients, 1161, 1566

arginine and proline synthesis and, 467

of beta-thalassemia subjects, 282

of bezafibrate therapy patients, 1403, 1406

body composition and, *see* Body composition, age and

of burn patients, 660

of CF subjects, 14

changes in pancreatic islet cell gene expression related to, 320-324

of cirrhotic subjects, 255, 826, 900

dietary fat intake, RBC phospholipid FA composition and, 1141

and estimates of visceral and subcutaneous abdominal AT, 1619

of exercising men, *see* Men, exercising, age and

of exercising women, *see* Age of exercising women

and hemolysis in primary LPL deficiency, 654

and heparin effects on release, oxidation, and reesterification of FAs from TGs, 1591

of hepatic steatosis subjects, 700

of hypercholesterolemic subjects, 399

of hyperinsulinemic subjects, *see* Age of hyperinsulinemic subjects

of hypertensive subjects, *see* Age of hypertensive subjects

of hyperthyroidic subjects, *see* Age of hyperthyroidic patients

of hypertriglyceridemic subjects, *see* Age of hypertriglyceridemic subjects

of hypothyroidic patients, 1284

of IDDM subjects, *see* Age of IDDM subjects

of IGT patients, *see* Age of IGT subjects

and insulin resistance in GH-deficient adults, 1127

and insulin sensitivity, 1122

LBM and, 1445

and levels of erythrocyte sugar nucleotide, 599

and LPL and HL activity, protective profile of Lps and, 492

and malnutrition due to nonneoplastic gastrointestinal diseases, 1112

of microvascular angina patients, 877

milk consumption effects on serum ALP, 1191, 1192

of NIDDM subjects, *see* Age of NIDDM subjects

of non-obese men, and effects of moderate calorie restriction on fibrinolytic factors, 1549

of normolipidemic subjects, 1053

of normotensive smokers, HbA_{1c} levels and insulin sensitivity and, 558

of obese subjects, *see* Age of obese subjects

of pituitary deficiency subjects, 68

of postmenopausal women, *see* Age of postmenopausal women

and postprandial glucose, insulin, and Lp responses to high- and low-fiber diets, 849

and n-3 PUFA ethyl ester effects on platelet phospholipid composition and platelet functions, 563

Age (Continued)

and RBC IGF-I receptor in normal, GH-deficient, and acromegalic subjects, 924

and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1060

of SCI subjects, *see* Age of SCI subjects

of TS patients, 1034

weight loss effects on AT distribution and, 1414; *see also* Age of obese men, effects of weight loss and

worksites ETS effects and, 1537

see also Adolescent males; Adult subjects; Aging; Children; Neonatal subjects

Age of exercising women

and effects of exercise on plasma Lps and apos, 702

energy expenditure and, 1047

Age of hyperinsulinemic subjects

of hyperinsulinemic first-degree relatives of NIDDM patients, 1279

of nondiabetic hyperinsulinemic subjects, 918

Age of hypertensive subjects

and effects of vasodilators on LPL activity, 715

of essential hypertension subjects, 316

of hypertensive pregnant subjects, erythrocyte insulin and IGF-I receptor tyrosine kinase activity and, 1309

of hypertensive smokers, HbA_{1c} levels and insulin sensitivity in, 558

Age of hyperthyroidic patients

hyperuricemia and, 210

plasma ET-1 levels and, 1240

Age of hypertriglyceridemic subjects, 590

of borderline hypertriglyceridemics, 1294

and mononuclear cell adhesion to endothelial cells in combined hypercholesterolemia-hypertriglyceridemia and in isolated hypercholesterolemia subjects, 376

and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086

Age of IDDM subjects

and abundance of Na⁺/H⁺ exchanger isoform-1 in skin fibroblasts, 792

of early IDDM subjects, natural course of insulin sensitivity in, 618

with or without neuropathy, low-dose CRH stimulation test and, 539

and RBC IGF-I receptor in IDDM, 924

Age of IGT subjects

of persistent IGT subjects, 1101

serum insulin level and, 1373

weight loss and, 1504, 1505

Age of NIDDM subjects

and changes in SM LPL activity, 787

of early NIDDM subjects, 758

and effects of hyperglycemia on urinary excretion of C-peptide, 1195

GHb levels and, 1476

of hypertensive NIDDM subjects, 86

with hypertriglyceridemia, 692

insulin binding, glycemic control and, 507

with obesity or glucose intolerance, fluoxetine effects and, 1571

and role of basal insulin in maintenance of intracellular glucose metabolic pathways, 42

serum insulin level and, 1373

Age of obese men

and beta-adrenergic stimulation of abdominal subcutaneous AT BF, 184

- Age of obese men (*Continued*)
effects of weight loss and, *see* Age of obese men, effects of weight loss and
and pulsatile GH secretion during fasting, 606
and testosterone and adrenal C₁₉ steroid levels, 514
- Age of obese men, effects of weight loss and
on β -adrenergically mediated thermogenic and HR responses, 521
on norepinephrine and insulin levels, 440
- Age of obese subjects
of centrally obese subjects, hemostatic function in, 1418
insulin sensitivity, insulin secretion, glucose effectiveness and, 1399
with NIDDM, fluoxetine effects and, 1571
of obese children, fasting plasma insulin level and, as risk factors for development of complications, 479, 481, 482
see also Age of obese men; Age of obese women
- Age of obese women
insulin resistance in adipocytes and, 988
of obese NIDDM women, 1476
- Age of postmenopausal women
and changes in musculoskeletal mass, race and, 30-34
on HRT, 411
- Age of SCI subjects
insulin sensitivity and AT metabolism and, 53
vitamin C deficiency in chronic SCI subjects, 1613
- Aging
free radicals and, 365
intraabdominal AT contribution to insulin resistance of, 954-959
see also Older subjects
- AIDS (acquired immunodeficiency syndrome)
soluble receptors for TNF as markers for clinical course of, but not for metabolic changes in, 1564-1569
testicular dysfunction in, 946-953
with weight loss, effects of increased dietary protein intake and nutritional status on whole-body protein metabolism in, 1159-1165
- Alanine
effects of, on SM protein synthesis during sepsis, 1131
effects of, on muscle proteolysis, 426
following total hip replacement, 1217-1219
glucose and glutamine metabolism in enterocytes and, 327, 328
interorgan flow of, between muscle and small intestine, 721
plasma, *see* Plasma alanine
in soy protein, 1147, 1148
T₃ effects on, 1382
in TPN of burn patients, 660, 661
- Alanine aminotransferase (ALT)
in cirrhosis, 826
in hepatic steatosis, 700
- Albumin
in AIDS patients, 1566
in chronic SCI subjects, 1613, 1614
in cirrhosis, *see* Albumin in cirrhosis
in elderly subjects with femoral neck fracture, 61
in hepatic steatosis, 700
serum, *see* Serum albumin
transendothelial permeation of, by high glucose concentration, 739-744
urinary excretion of, *see* Urinary excretion, albumin
- Albumin in cirrhosis
and altered lipid composition and changes in activities of RBC membrane-bound enzymes, 826
in diabetic and nondiabetic cirrhosis, 255
- Albumin in cirrhosis (*Continued*)
and hepatic conversion of AA nitrogen, 900
with severe malnutrition, 767
- ALC, *see* Acetyl-L-carnitine, effects of, on peripheral nerve function
- Alcohol consumption and alcoholism
by borderline hypertriglyceridemic subjects, 1294
as cardiovascular risk factor in fasting hyperinsulinemia, 918
dietary fat intake, RBC phospholipid FA composition and, 1141
GH response to sumatriptan suppressed by, 1577-1580
see also Ethanol
- Alkaline phosphatase (ALP)
in chronic SCI subjects, 1613
in hepatic steatosis, 700
and long-term ethanol exposure, 892
serum, milk consumption effects on, 1190-1193
- ALLN (*N*-Ac-Leu-Leu-norleucinal), effects of, on PTH-induced retraction of MC3T3-E1 osteoblastic cells, 141-144
- ALP, *see* Alkaline phosphatase
- Alpha-*N*-acetylarginine, *see* α -*N*-Acetylarginine in cirrhosis
- Alpha-adrenoceptor antagonists, *see* α - and β -Adrenoceptor antagonists, metabolic and hormonal responses to
- 3Alpha (α)-androstanediol glucuronide, flutamide effects on, in PCOS, 527
- Alpha-ketoglutarate, *see* α -Ketoglutarate
- Alpha-keto- δ -guanidinovaleic acid, *see* α -Keto- δ -guanidinovaleic acid in cirrhosis
- Alpha-lipoproteins, *see* High-density lipoprotein(s)
- ALT, *see* Alanine aminotransferase
- Altitude, exhaustive exercise at high, with acute hypoxia, ET-1 responses to, 8-9
- AM (adrenomedullin) stimulating cAMP formation in mesangial cells, 10-12
- Amilyn-like activity of salmon calcitonin responsible for its diabetogenic effects, 1581-1589
- Amino acid(s) (AAs)
effects of, on synthesis of SM proteins during sepsis, 1130-1138
interorgan flow of, between muscle and small intestine, role of membrane transport in, 719-724
plasma, *see* Plasma amino acids
see also Amino acid nitrogen; Branched-chain amino acids and specific amino acids
- Amino acid (AA) nitrogen, effects of β -adrenergic blockers on hepatic conversion of, in cirrhosis, 899-905
- Aminotransferase, *see* Alanine aminotransferase
- Amlopipine, effects of, on insulin sensitivity for glucose metabolism in essential hypertension, 315-319
- Ammonia, *see* NH₃
- Amylin, reduction in insulin sensitivity mediated by, and reduced IR kinase activity, 705-711
- Amylin mRNA (messenger ribonucleic acid), age-related changes in, 322
- Anabolic steroids (ASs), effects of, on tumor growth and cancer cachexia, 445-451
- 3 α (alpha)-Androstanediol glucuronide, flutamide effects on, in PCOS, 527
- Androst-5-ene-3 β ,17 β -diol (Δ^5 -DIOL), levels of, and abdominal AT in obese men, 513-519
- Androstenedione (Δ^4 -DIONE)
in AIDS, 950
flutamide effects on, in PCOS, 527
levels of, and abdominal AT in obese men, 513-519
salivary T and, in middle-aged men, relationship of smoking cessation and nicotine gum use to, 90-95

- Androstenedione (Δ^4 -DIONE) (*Continued*)
 serum, effects of low-fat, high-fiber diet on, in premenopausal women, 752-753
- Anesthesia, lipolysis during, NE and, 1516
- ANF (atrial natriuretic factor), plasma, angiotensin II and phenylephrine effects on, 117
- Angina, microvascular, insulin resistance in, 876-882
- Angiotensin II (ANGII), effects of phenylephrine and, on urinary excretion of ET in women, 115-118
- Anorexia, influence of zinc deficiency-induced, on distribution of serum IGFs, 1495-1501
- ANPs (atrial natriuretic peptides), effects of, on ET-1 secretion after stimulation with CSA, 405
- Anterior pituitary cells, effects of NSAIDs and loop diuretics on TSH release by, 1008-1012
- Antiandrogenic therapy of PCOS in non-obese women, insulin sensitivity and, 525-531
- Antibody(ies), islet cell, in parents of IDDM patients, 869-875
- Antigen, human leukocyte, in parents of IDDM patients, 872, 873
- Antihypertensive therapy
 of borderline hypertriglyceridemia, 1294
see also specific antihypertensive agents
- Antiinflammatory drugs, nonsteroidal, effects of loop diuretics and, on TSH release by anterior pituitary cells, 1008-1012
- Antilipolytic effects
 of PIA, 991, 992
see also Antilipolytic effects of insulin and specific substances
- Antilipolytic effects of insulin
 in insulin resistance of obesity, 989-991
 in nondiabetic subjects, gemfibrozil decreasing TG level in mild hypertriglyceridemia without affecting, 589-596
- Antithrombin III (AT III), levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919
- Aorta, thoracic, arachidonate distribution in LDLs and, in hyperinsulinemia, 806-811
- Apheresis of LDLs by dextran sulfate adsorption in pregnancy with HFH, 929-933
- Apo(s), *see* Apolipoprotein(s)
- Apolipoprotein(s) (apos)
 n-3 PUFA effects on, 1225
see also Plasma apolipoproteins; Serum apolipoproteins and specific apolipoproteins
- Apolipoprotein A-I (apo A-I)
 in centrally obese subjects, hemostatic function and, 1418
 CME and fluvastatin effects on, 1451
 in congenital hypothyroidism, effects of L-T₄ on, 1284-1286
 effects of exercise by fertile women on, 703
 effects of nibbling versus gorging on, 551, 552
 high- and low-fiber diet effects on, 851
 in hypertension, effects of vasodilators on, 715
 in hypertriglyceridemia, *see* Apolipoprotein A-I in hypertriglyceridemia
 levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919
 LPL and HL activity and levels of, sex differences in, 493, 494
 in nonsmoking women, effects of worksite ETS on, 1537
 in obese normoinsulinemic men, 1386
 and persistent IGT, 1101
 plasma volume effects on, during menstrual cycle, 967, 968
 in pregnancy with HFH treated by dextran sulfate LDL apheresis, 931
 n-3 PUFA effects on, 1225-1226
 short-term GH therapy effects on, 726-728
 L-thyroxine effects on, in hypothyroidism, 1561
- Apolipoprotein A-I (apo A-I) in hypertriglyceridemia
 with and without CV disease, PP Lp responses and, 1086, 1088
 in NIDDM with hypertriglyceridemia, 692
- Apolipoprotein A-II (apo A-II)
 plasma volume effects on, during menstrual cycle, 967, 968
 and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086
- Apolipoprotein B (apo B)
 in centrally obese subjects, hemostatic function and, 1418
 CME and fluvastatin effects on, 1451
 in congenital hypothyroidism, effects of L-T₄ on, 1284-1286
 effects of exercise by fertile women on, 703
 effects of nibbling versus gorging on, 551
 in fasting hyperinsulinemia, level of, as CV risk factor, 917, 919
 HRT effects on, 412-414
 in hyperthyroidism before and after subtotal thyroidectomy, 5, 6
 in hypertriglyceridemia, *see* Apolipoprotein B in hypertriglyceridemia
 and LPL activity, *see* Apolipoprotein B, LPL activity and
 in nonsmoking women, effects of worksite ETS on, 1537
 in obese normoinsulinemic men, 1386, 1387
 and persistent IGT, 1101
 plasma LDL, relationship of hepatic mRNA level with metabolism of, low- and high-fat diets and, 1058-1066
 plasma volume effects on, during menstrual cycle, 967, 968
 in pregnancy with HFH treated by dextran sulfate LDL apheresis, 930
 n-3 PUFA effects on, 1225-1226
 relationship of insulin and insulin propeptides to, 1484-1485
 short-term GH therapy effects on, 726-728
 L-thyroxine effects on, in hypothyroidism, 1561
 of VLDL, [¹⁵N]glycine in measurement of synthetic rate of, serine and hippurate as precursor equivalents of, compared, 1253-1258
- Apolipoprotein B (apo B), LPL activity and
 in hypertension, 714, 715
 LPL and HL activity and levels of, sex differences in, 493, 494
- Apolipoprotein B (apo B) in hypertriglyceridemia
 with and without CV disease, PP Lp responses and, 1086, 1087
 with NIDDM, 692
- Apolipoprotein B:AI (apo B:AI), effects of nibbling versus gorging on, 551, 552
- Apolipoprotein B-100 (apo B-100)
 hepatic, correlation between cholesterol synthesis and secretion of, in normolipidemia, 1052-1057
 high- and low-fiber diet effects on, 851
- Apolipoprotein C-I (apo C-I), and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086-1088
- Apolipoprotein C-II (apo C-II), and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086-1088
- Apolipoprotein C-III (apo C-III)
 CME and fluvastatin effects on, 1451
 and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086-1088
- Apolipoprotein E (apo E)
 CME and fluvastatin effects on, 1451
 and long-term ethanol exposure, 892, 893
- Apolipoprotein E (apo E) phenotype
 and effects of brisk walking on insulinemia in sedentary middle-aged women, 392
 in normolipidemic subjects, 1053
- Arachidonate, distribution of, in LDLs and thoracic aorta in hyperinsulinemia, 806-811

- Arginine (ARG)**
 beta cell response to, in early IDDM, 619, 620
 in cirrhosis, *see* Arginine in cirrhosis
 effects of, on SM protein synthesis during sepsis, 1131
 following total hip replacement, 1217-1219
 and glucagon secretion, 359
 insulinotropic action of glicentin and, 48-50
 NMLA and somatostatin decreasing blood glucose and plasma insulin and blocking ET-1-induced insulin release but not ET-1-induced hypoglycemia, 1532-1535
 plasma, *see* Plasma arginine
 and proline synthesis, isotopic evidence for differential regulation of, 466-473
 in soy protein, 1147, 1148
Arginine (ARG) in cirrhosis
 serum levels of, 585
 urinary excretion of, 586
AS(s) (anabolic steroids), effects of, on tumor growth and cancer cachexia, 445-451
Asparagine
 effects of, on SM protein synthesis during sepsis, 1131
 effects of overnight infusion of, on muscle proteolysis, 426
 following total hip replacement, 1217-1219
 plasma, in AIDS patients, 1162
 in soy protein, 1147, 1148
Aspartate
 following total hip replacement, 1217-1219
 and glucose and glutamine metabolism in enterocytes, 327, 328
Aspartic acid
 effects of, on SM protein synthesis during sepsis, 1131
 in soy protein, 1147, 1148
 in TPN of burn patients, 660, 661
Asthmatic children, prepubertal, short- and long-term effects of oral salbutamol on GH secretion in, 149-151
AT, *see* Adipose tissue
AT III (antithrombin III), levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919
Atherogenic lipoprotein (Lp) phenotype, association of insulin and insulin propeptides with, 1481-1488
Atherosclerosis
 prevention of, and bezafibrate therapy in patients with isolated low LDL-C levels, 1401-1408
 sex and development of hyperlipidemia and, 1326-1331
Athletes, *see* Exercise
Athymic subjects injected with PBMNCs from IDDM subjects, insulin secretion by pancreas of, 1435-1441
ATP (adenosine triphosphate)
 from glucose and glutamine, *see* ATP production from glucose and glutamine
 LPS effects on, 1171
 myocardial, from glucose and palmitate, 503
ATP (adenosine triphosphate) production from glucose and glutamine
 in enterocytes, 328
 HCO₃⁻ effects on, 1251
ATPase (adenosine triphosphatase)
 RBC Ca²⁺-, D-myo-inositol 1,4,5-triphosphate modulating activity of, guanine nucleotide regulatory protein mediating, 865-868
 and T₃ effects on AdNT activity, 197
Atrial natriuretic factor (ANF), plasma, angiotensin II and phenylephrine effects on, 117
Atrial natriuretic peptides (ANPs), effects of, on ET-1 secretion after stimulation with CSA, 405
A23187 (Ca²⁺ ionophore), NO response to, in STZ-DM, 695-698
Autophosphorylation
 insulin receptor, *see* Autophosphorylation, IR
 tyrosine kinase, dexamethasone and PSL effects on activity of, 304
Autophosphorylation, IR
 site of, insulin resistance associated with abnormal dephosphorylation of phosphopeptide corresponding to, 1074-1081
 starvation- and STZ-DM-induced changes in, 291-297
B cells, changes in insulin sensitivity, glucose effectiveness, and function of, in regularly exercising men, 1259-1263
Basal insulin, role of, in maintenance of intracellular glucose metabolic pathways in NIDDM, 41-46
Basal metabolic rate (BMR), GH therapy effects on, in pituitary deficiency, 67-74
Basal thyrotropin (TSH), SP effects on release of, 474-477
BCAAs, *see* Branched-chain amino acids
BCKA (branched-chain keto-acid) dehydrogenase, hepatic, effects of chronic ethanol intake on flux of, 1243-1246
Beef tallow diet
 β-adrenergic receptor binding and lipolytic activities decreased by, in AT, 1271-1277
 effects of, on NE, *see* Norepinephrine, beef tallow diet effects on
 effects of, on sympathetic activity, 934-939
Beta (β)-adrenergic blockers, effects of, on hepatic conversion of AA nitrogen and urea synthesis in cirrhosis, 899-905
Beta (β)-adrenergic mediation of thermogenic and HR responses in obese men, effects of weight loss on, 520-524
Beta (β)-adrenergic receptor, binding and lipolytic activities of, in AT, decreased by beef tallow diet, 1271-1277
Beta (β)-adrenergic responsiveness of adenylate cyclase in adipocyte plasma membrane in obesity and after weight loss, 1288-1292
Beta (β)-adrenergic stimulation, and abdominal subcutaneous fat BF in lean, obese, and reduced-obese subjects, 183-187
Beta₂-adrenoceptor agonists, *see* Clenbuterol; Salbutamol
Beta-adrenoceptor antagonists, *see* α- and β-Adrenoceptor antagonists, metabolic and hormonal responses to
Beta (β) cells
 in early IDDM, 619
 in parents of IDDM patients, 869-875
 secretion of, in beta-thalassemia, 283, 284
 in spontaneous hypertension, function and replication of, 1360-1364
 at transition to early NIDDM, 757-764
Beta (β)-cyclodextrin (β-CD), effects of, on plasma lipids and C metabolism, 200-206
3-Beta (β)-hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone
Beta-hydroxybutyrate, *see* β-Hydroxybutyrate
Beta-lipoproteins, *see* Low-density lipoprotein(s)
Beta (β)-oxidation, effects of troglitazone and bezafibrate on, in fructose-fed subjects, 1626-1630
Beta (β)-thalassemia, homozygous, hyperinsulinemia and insulin resistance in, 281-286
Bezafibrate
 effects of troglitazone and, on glucose tolerance, liver glycogen synthase activity, and β-oxidation, in fructose-fed subjects, 1626-1630
 in patients with isolated low HDL-C levels, prevention of atherosclerosis and, 1401-1408
BF, *see* Blood flow
Bicarbonate (HCO₃⁻), effects of, on glucose and glutamine metabolism in lymphocytes, 1247-1252

Bile acids

- low-dose pravastatin effects on biliary lipids and composition of, in nonfamilial hyperlipoproteinemia, 1410-1412
- and relationship of hepatic mRNA level to metabolism of plasma LDL apo B, 1060

Biliary lipids, low-dose pravastatin effects on bile acid composition and, in nonfamilial hyperlipoproteinemia, 1410-1412**Bilirubin in cirrhosis, 826**

- serum, 255
- in severely malnourished cirrhotic patients, 767
- total, 900

Binding protein, *see* Acyl-CoA binding protein; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s)**Biphosphatase, fructose-1,6-, effects of troglitazone on, in DM, 488, 489****Biphosphate, *see* Fructose-1,6-biphosphate; Fructose-2,6-biphosphate****Blood cytokines, levels of, in brain-dead patients, and their relationship with circulating hormones and acute-phase reactants, 812-816****Blood flow (BF)**

- abdominal subcutaneous AT, β -adrenergic stimulation of, in lean, obese, and reduced-obese men, 183-187
- NE and changes in regional, 1516
- in pituitary deficiency subjects, 68
- portal, in cirrhosis, effects of β -adrenergic blockers on, 903

Blood gases

- maternal and fetal, chronic maternal hypoxia and, 533
- venous, adrenoceptor antagonists and, 248

Blood glucose

- adrenoceptor antagonists and, 248
- effects of nibbling versus gorging on, 552
- of hypertriglyceridemic subjects, gemfibrozil effects on, 590-592
- in IDDM with or without neuropathy, low-dose CRH stimulation test effects on, 539, 540
- in NIDDM, oral (-)-BM 13.0913.Na improving, 571-573
- NMLA and somatostatin decreasing plasma insulin and, and blocking ET-1-induced insulin release but not ET-1-induced hypoglycemia, 1532-1535
- sodium pivalate effects on, 501
- in starved exercising subjects, 1334

Blood insulin in NIDDM, oral (-)-BM 13.0913.Na improving, 571-573**Blood lipids**

- dietary fat effects on, 1492
- effects of age on response of, to physical conditioning and deconditioning, 161-165
- effects of nibbling versus gorging on, 549-555
- sodium pivalate effects on, 501

Blood pressure (BP)

- of borderline hypertriglyceridemic subjects, 1294
- in cirrhosis, effects of β -adrenergic blockers on, 903
- dietary fat effects on, 1491-1492
- effects of fructose and glucose ingestion with and without caffeine on, 634, 636
- in elderly subjects with femoral neck fracture, 61
- and fasting serum insulin in metabolic syndrome, 36-38
- following CABG, 1017, 1018, 1023
- in hyperinsulinemia, *see* Blood pressure in hyperinsulinemia
- of hyperthyroidic patients, 1240
- of hypertriglyceridemic subjects, *see* Blood pressure in hypertriglyceridemia

Blood pressure (BP) (Continued)

- in IDDM, and abundance of Na^+/H^+ exchanger isoform-1 in skin fibroblasts, 792
- in IGT, serum insulin level and, 1373
- of microvascular angina patients, 877
- of middle-aged men, training status and, 343
- in NIDDM, *see* Blood pressure in NIDDM
- of obese children, as risk factor for development of complications, 479, 482
- and n-3 PUFA ethyl ester effects on platelet phospholipid composition and platelet functions, 563
- of SCI subjects, 53
- weight loss and response of, to upright posture, 441
- see also* Hypertension

Blood pressure (BP) in hyperinsulinemia

- arachidonate distribution in LDLs and thoracic aorta and, 807
- in fasting hyperinsulinemia, 917, 919

Blood pressure (BP) in hypertriglyceridemia

- gemfibrozil effects on, 590
- in NIDDM, 692

Blood pressure (BP) in NIDDM

- with obesity or glucose intolerance, fluoxetine effects on, 1571
- serum level insulin level and, 1373

(-)-BM 13.0913.Na, *see* Oral (-)-BM 13.0913.Na**BMI, *see* Body mass and body mass index****BMR (basal metabolic rate), GH therapy effects on, in pituitary deficiency, 67-74****BNPs (brain natriuretic peptides), effects of, on ET-1 secretion after stimulation with CSA, 405****Body composition**

- age and, *see* Body composition, age and
- and beta-adrenergic stimulation of abdominal subcutaneous AT BF, 185

- effects of dietary fat types on, 274-276

- of pituitary deficiency subjects, 71

- see also* Adipose tissue; Fat-free mass; Lean body mass; Muscle

Body composition, age and

- age-related changes in musculoskeletal mass of postmenopausal women, 31-33

- effects of age on response of body composition to physical conditioning and deconditioning, 161-165

- of older obese men, effects of weight loss on, 439-440

- variations in AT distribution and body composition associated with age and menopause in healthy women, DEXA in measurement of, 369-373

Body fat, *see* Adipose tissue**Body mass and body mass index (BMI)**

- of acromegalic subjects, 380
- of acute trauma patients, 1206
- of adolescent males with constitutional delay of growth, 1014
- age and, *see* Body mass and body mass index, age and
- of AIDS patients, 1161, 1566
- arginine and proline synthesis and, 467
- and beta-adrenergic stimulation of abdominal subcutaneous AT BF, 184
- of cirrhotic subjects, 255
- dietary fat intake, RBC phospholipid FA composition and, 1141
- and estimates of visceral and subcutaneous abdominal AT, 1619
- exercise and, *see* Body mass and body mass index, exercise and
- and fasting serum insulin in metabolic syndrome, 36, 37
- following CABG, 1018
- GH deficiency and, *see* Body mass and body mass index, GH deficiency and

- Body mass and body mass index (BMI) (Continued)**
- and heparin effects on release, oxidation, and reesterification of FAs from TGs, 1591
 - of hypercholesterolemic subjects, 399
 - of hyperinsulinemic subjects, *see* Body mass and body mass index of hyperinsulinemic subjects
 - of hypertensive subjects, *see* Body mass and body mass index of hypertensive subjects
 - of hypertriglyceridemic subjects, *see* Body mass and body mass index of hypertriglyceridemic subjects
 - of IDDM subjects, *see* Body mass and body mass index of IDDM subjects
 - of IGT subjects, *see* Body mass and body mass index, IGT and
 - and insulin sensitivity, 1122, 1123
 - lipase activity and protective profile of Lps and, 492
 - and malnutrition due to nonneoplastic gastrointestinal diseases, 1112
 - of men with CAD, 108
 - of microvascular angina patients, 877
 - milk consumption effects on serum ALP, 1191, 1192
 - of NIDDM subjects, *see* Body mass and body mass index of NIDDM subjects
 - of non-obese men, and effects of moderate calorie restriction on fibrinolytic factors, 1549, 1550
 - of normolipidemic subjects, 1053
 - of normotensive smokers, HbA_{1c} and insulin sensitivity in, 558
 - of obese subjects, *see* Body mass and body mass index of obese subjects
 - of patients on bezafibrate therapy, 1403, 1406
 - of pituitary deficiency subjects, 68
 - and postprandial glucose, insulin, and Lp responses to HF and LF diet, 849
 - and n-3 PUFA ethyl ester effects on platelet phospholipid composition and platelet functions, 563
 - of SCI subjects, *see* Body mass and body mass index of SCI subjects
 - testosterone and adrenal C₁₉ steroid levels and, 514, 517
 - weight loss and, *see* Body mass and body mass index, and weight loss effects
 - see also* Adipose tissue; Body weight; Fat-free mass; Height; Lean body mass; Waist-to-hip ratio; Waist-to-thigh ratio
- Body mass and body mass index (BMI), age and**
- age- and menopause-associated variations in BMI of healthy women, 370
 - of beta-thalassemia patients, 282
 - of elderly women, *see* Body mass and body mass index of elderly women
 - of middle-aged men, *see* Body mass and body mass index of middle-aged men
 - and response to physical conditioning and deconditioning, 162
- Body mass and body mass index (BMI), exercise and**
- age and response to physical conditioning and deconditioning, 162
 - changes in insulin sensitivity, B-cell function, and glucose effectiveness and, 1260
 - effects of brisk walking, 393
 - and energy expenditure by elderly exercising women, 1047
 - in fertile women, 702
 - and influence of submaximal exercise on glucose assimilation, 834
 - and training status, 342
- Body mass and body mass index (BMI), GH deficiency and**
- in adults, insulin resistance and, 1127
 - in normal, NIDDM, and acromegalic children, RBC IGF-1 receptor in, 924
- Body mass and body mass index (BMI), IGT and**
- and persistent IGT, 1101
 - serum level insulin level and, 1373
 - weight loss and, 1504, 1505
- Body mass and body mass index (BMI), and weight loss effects**
- on β -adrenergically mediated thermogenic and HR responses, 521
 - on norepinephrine and insulin levels, 440
- Body mass and body mass index (BMI) of elderly women**
- of exercising elderly women, energy expenditure of, 1047
 - with femoral neck fracture, 61
- Body mass and body mass index (BMI) of hyperinsulinemic subjects**
- arachidonate distribution in LDLs and thoracic aorta and, 807
 - as CV risk factor in fasting hyperinsulinemic subjects, 917
 - of hyperinsulinemic first-degree relatives of NIDDM patients, 1279
- Body mass and body mass index (BMI) of hypertensive subjects**
- and effects of vasodilators on LPL activity, 715
 - of essential hypertension subjects, 316
 - of hypertensive pregnant patients, 1309
 - of hypertensive smokers, HbA_{1c} levels and insulin sensitivity in, 558
 - with NIDDM, 86
- Body mass and body mass index (BMI) of hypertriglyceridemic subjects**
- of borderline hypertriglyceridemic subjects, 1294
 - with and without CV disease, 1086
 - with NIDDM, 692
- Body mass and body mass index (BMI) of IDDM subjects**
- and abundance of Na⁺/H⁺ exchanger isoform-1 in skin fibroblasts in IDDM, 792
 - of early IDDM subjects, natural course of insulin sensitivity in, 618
- Body mass and body mass index (BMI) of middle-aged men**
- of smoking middle-aged men, 92
 - training status and, 342
- Body mass and body mass index (BMI) of NIDDM subjects**
- and changes in SM LPL activity, 787
 - of early NIDDM subjects, 758
 - and effects of hyperglycemia on urinary excretion of C-peptide, 1195
 - of GH-deficient NIDDM children, RBC IGF-1 receptor in, 924
 - of hypertensive NIDDM subjects, 86
 - hypertriglyceridemia and, 692
 - in obese NIDDM women, 1476
 - and role of basal insulin in maintenance of intracellular glucose metabolic pathways, 42
 - serum level insulin level and, 1373
- Body mass and body mass index (BMI) of obese subjects**
- of centrally obese subjects, hemostatic function and, 1418
 - insulin resistance, insulin secretion, and glucose effectiveness and, 1399
 - of obese children, and fasting plasma insulin as risk factor for development of complications, 479, 482
 - of obese men, and pulsatile GH secretion during fasting, 606
 - of obese women, *see* Body mass and body mass index of obese women
- Body mass and body mass index (BMI) of obese women**
- insulin resistance in adipocytes and, 988
 - of obese NIDDM women, 1476
 - with PCOS, effects of VLCD on, 613, 614
- Body mass and body mass index (BMI) of SCI subjects**
- insulin sensitivity and AT metabolism in, 53
 - vitamin C deficiency in chronic SCI subjects, 1613

- Body temperature, short-term effects of clenbuterol and salbutamol on, 121, 122
- Body weight (BW)
- of acute trauma patients, 1206
 - of adolescent males with constitutional delay of growth, 1014
 - age and, *see* Body weight, age and
 - of AIDS patients, 1566
 - and ALC and PLC effects on peripheral nerve function and vascular supply in DM, 1210; *see also* Body weight of IDDM subjects; Body weight of NIDDM subjects
 - of anorexic subjects, 1496-1497
 - arginine and proline synthesis and, 467
 - of CF subjects, 14
 - of cirrhotic subjects, 255
 - dietary fat effects on, 1490-1491; *see also* Body weight, beef tallow diet and
 - effects of fructose and glucose ingestion with and without caffeine on, 631
 - and estimates of visceral and subcutaneous abdominal AT, 1619
 - exercise and, *see* Body weight, exercise effects on
 - fetal, and maternal chronic hypoxia, maternal food intake and, 534
 - following CABG, 1017
 - gain in, *see* Weight gain
 - and GH-secreting tumors, 77
 - and heparin effects on release, oxidation, and reesterification of FAs from TGs, 1591
 - of hepatic steatosis subjects, 700
 - high-calorie TPN effects on, 154
 - of hyperinsulinemic subjects, 229
 - of hypertensive subjects, and effects of vasodilators on LPL activity, 715
 - of hyperthyroidic subjects before and after subtotal thyroidectomy, 5
 - of hypertriglyceridemic subjects, 590
 - of hypothyroidic patients, 1284
 - and impact of chemotherapy on protein metabolism, 1341-1342
 - and insulin resistance in GH-deficient adults, 1127
 - long-term effects on, *see* Body weight, long-term effects on
 - loss in, *see* Weight loss
 - and malnutrition due to non-neoplastic gastrointestinal diseases, 1112
 - of microvascular angina patients, 877
 - of non-obese men, and effects of moderate calorie restriction on fibrinolytic factors, 1549
 - pioglitazone effects on, 1106
 - of pituitary deficiency subjects, 68
 - plasma volume effects on, during menstrual cycle, 967, 968
 - of postmenopausal women on HRT, 411
 - and n-3 PUFA ethyl ester effects on platelet phospholipid composition and platelet functions, 563
 - and RBC IGF-I receptor in normal, GH-deficient, and acromegalic children, 924
 - and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1060
 - of SCI subjects, *see* Body weight of SCI subjects
 - simvastatin and gemfibrozil effects on, 215
 - and soy protein diet, 1148
 - testosterone and adrenal C₁₉ steroid levels and, 514
 - troglitazone and bezafibrate effects on, 1627
 - worksite ETS effects on, 1537
 - and zinc deficiency, 129
 - see also* Body mass and body mass index; Non-obese subjects; Obesity
- Body weight (BW), age and
- age- and menopause-associated variations in, in healthy women, 370
 - and age-related changes in musculoskeletal mass of postmenopausal women, 31
 - of elderly subjects with femoral neck fracture, 61
 - and insulin resistance of aging, 956
- Body weight (BW), beef tallow diet and
- beef tallow and safflower oil effects on, 936, 937
 - effects on, 1273
- Body weight (BW), exercise effects on
- by fertile women, 702
 - of submaximal exercise, 834
- Body weight (BW), long-term effects on
- of captopril, 270
 - of lipectomy and dexamethasone, 1632
 - of ethanol, 892
 - of long-term overfeeding in identical twins, 98, 104
- Body weight (BW) of IDDM subjects
- of IDDM children, 924
 - with and without neuropathy, 539
- Body weight (BW) of NIDDM subjects, 941
- and changes in SM LPL activity, 787
 - of early NIDDM subjects, 758
 - with glucose intolerance, fluoxetine effects and, 1571
 - insulin binding and glycemic control and, 507
 - and role of basal insulin in maintenance of intracellular glucose metabolic pathways, 42
- Body weight (BW) of SCI subjects
- insulin sensitivity and AT metabolism and, 53
 - vitamin C deficiency in chronic SCI, 1613
- Bone density
- and metabolism, effects of testosterone on, in adolescent male hypogonadism, 419-423
 - total, and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- Bone minerals, total, and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- Borderline hypertriglyceridemia in NIDDM, Lp(a) in, 1293-1297
- BP, *see* Blood pressure
- Bradykinin antagonism, and captopril effects on insulin-stimulated glucose transport in SM of obese subjects, 269
- Brain
- beef tallow diet effects on NE turnover rate in, 1377-1379
 - see also* entries beginning with term: Brain
- Brain-dead patients, levels of blood cytokines in, and their relationship with circulating hormones and acute-phase reactants, 812-816
- Brain natriuretic peptides (BNPs), effects of, on ET-1 secretion after stimulation with CSA, 405
- Branched-chain amino acids (BCAAs)
- sustained suppression of muscle proteolysis due to overnight infusions of, 424-429
 - see also* specific branched-chain amino acids
- Branched-chain keto-acid (BCKA) dehydrogenase, hepatic, effects of chronic ethanol intake on flux of, 1243-1246
- Brisk walking, effects of, on insulinemia in sedentary middle-aged women, 390-397
- Bromocriptine, FFA oxidation and hepatic glucose production inhibited by, in obesity, 1349-1355
- Burn patients, plasma arginine and leucine kinetics, and urea production rates in, 659-666

- γ (gamma)-Butyrobetaine, carnitine synthesis from, vitamin C deficiency and, 624-629
 BW, *see* Body weight
- C, *see* Cholesterol
- C₁₉ steroids, levels of testosterone and, and abdominal AT in obese men, 513-519
- Ca (calcium)
 increase in SM, of STZ-DM subjects, 1455-1461
 plasma, in elderly subjects with femoral neck fracture, 61
 in SCI subjects, 1613, 1614
 serum, amylin effects on, 709
see also Ca²⁺; Ca²⁺-ATPase; Ca channel blockers; Ca²⁺ ionophore
- Ca (calcium) channel blockers, increase of, in SM of STZ-DM subjects, 1455-1461
- Ca²⁺ (calcium), effects of, on enzymatic activity of PKC, 304
- Ca²⁺-ATPase (calcium-adenosine triphosphatase), RBC, D-myoinositol 1,4,5-triphosphate modulating activity of, guanine nucleotide regulatory protein mediating, 865-868
- Ca²⁺ (calcium) ionophore, A23187, NO response to, in STZ-DM, 695-698
- CABG (coronary artery bypass graft), risk of IGT and DM during first postoperative year following, 1016-1027
- Cachexia, cancer, anabolic steroid effects on, 445-451
- CAD, *see* Coronary heart disease
- Caffeine, acute effects of fructose and glucose ingestion with and without, in young and old subjects, 630-638
- Calcitonin, salmon, diabetogenic effects of, due to its amylin-like activity, 1581-1589
- Calcium, *see* Ca
- Calorie(s)
 TPN high in, effects of, on hepatic IGF-I mRNA and serum IGF-BPs, 152-160
see also Calorie restriction; Thermogenesis and entries beginning with term: Energy
- Calorie restriction
 changes in insulin action and insulin secretion following restricted dietary protein and, 1519-1526
 differential effects of HF diet varying in FAs on efficiency of lean and AT deposition following, 273-279
 effects of long-term aerobic exercise and, on protein synthesis, 188-192
 effects of moderate, on fibrinolytic factors in non-obese men, 1548-1552
 in obesity, *see* Calorie restriction in obesity
 pulsatile GH secretion in non-obese men during, 605-610
- Calorie restriction in obesity
 with PCOS, effects of VLCD on insulin sensitivity and fibrinolytic capacity in, 611-616
 pulsatile GH secretion in obese men during, 605-610
- cAMP (cyclic adenosine monophosphate)
 AM stimulating formation of, in mesangial cells, 10-12
 effects of, on CSA-induced ET-1 secretion, 405
 phosphodiesterase dependent on, Cr effects on, 1317
- Cancer, *see* Tumor(s)
- Captopril, effects of, on glucose transport, in skeletal muscle of obese subjects, 267-272
- Carbamylcholine (CCh), NO response to, in STZ-DM, 695-698
- Carbohydrates (CHOs)
 effects of LCD on intracellular glucose in exercising men, 1264-1270
 exchange between dietary fat and, and regulation of hepatic cholesterol and plasma Lp metabolism, 855-864
- Carbohydrates (CHOs) (*Continued*)
 hypertriglyceridemia and insulin resistance and diet high in, 1540-1547
 middle-aged men intake of, training status and, 342
 oxidation of, during fasting and after TPN of elderly subjects with femoral neck fracture, 63
- ¹⁴Carbon dioxide (¹⁴CO₂), rate of production of, by enterocytes, 327
- Carboxylase, pyruvate, T₃ effects on substrate cycling between malic enzyme and, in liver, 1380-1383
- Cardiac function, fatty acid oxidation and, in sodium pivalate model of secondary carnitine deficiency, 499-505
- Cardiac natriuretic peptides, CSA-induced ET production in mesangial cells inhibited by, 404-409
- Cardiologic syndrome X (microvascular angina), insulin resistance in, 876-882
- Cardiovascular (CV) adaptation to brisk walking by sedentary middle-aged women, 393
- Cardiovascular (CV) disease
 and mononuclear cell adhesion to endothelial cells in combined hypercholesterolemia-hypertriglyceridemia and in isolated hypercholesterolemia, 376
 postprandial Lp responses in hypertriglyceridemia with and without, 1082-1098
 role of oxidative stress in diabetes mellitus, hypertension and, 363-368
see also Cardiovascular risk factors; Coronary heart disease
- Cardiovascular (CV) risk factors
 effects of nibbling versus gorging on, 549-555
 fasting hyperinsulinemia and, in nondiabetic lean and obese adult subjects, 914-922
 in middle-aged men, training status, RMR and, 340-347
- Cardiovascular (CV) system
 responsiveness of, to mental stress, glucose uptake during hyperinsulinemia and, 1303-1307
see also entries beginning with terms: Heart, Myocardial, Venous and element: Card-
- Carnitine
 sodium pivalate model of secondary carnitine deficiency, fatty acid oxidation and cardiac function in, 499-505
 vitamin C deficiency and, *see* Vitamin C deficiency, carnitine and
see also Acetyl-L-carnitine, effects of, on peripheral nerve function; Propionyl-L-carnitine
- Catecholamines
 serum, response of, to amlopidine in essential hypertension, 316, 318
see also Dopamine; Epinephrine; Norepinephrine
- CCh (carbamylcholine), NO response to, in STZ-DM, 695-698
- β (beta)-CD (β -cyclodextrin), effects of, on plasma lipids and C metabolism, 200-206
- cDNA (complementary deoxyribonucleic acid) amplification, promoter region of IR gene analyzed with, in leprechaunism with severe insulin resistance, 430-437
- Cecal short-chain fatty acids (SCFAs), beta-CD effects on, 201-202
- Cecal steroids, beta-CD effects on, 202-203
- Cellular cGMP (cyclic guanosine monophosphate), ANP and BNP effects on, after stimulation with CSA, 405
- Cellular ribose-5-phosphate (R5P), role of, in regulation of PRPP and de novo purine synthesis in hepatoma cell line, 1469-1474
- Central obesity in young men and women, hemostatic function in, 1417-1421

- Cephalic-phase insulin, and glucagon release in normal subjects and in recipients of pancreas transplantation, 1153-1158
- Cerebral cortex, beef tallow diet effects on NE turnover rate in hypothalamus and, 1377-1379
- Ceruloplasmin (Cp), plasma, in IDDM, oxidative stress and, 996-999
- CF (cystic fibrosis), impaired glucose tolerance with, tolbutamide effects on insulin secretion in, 13-18
- cGMP (cyclic guanosine monophosphate), cellular, ANP and BNP effects on, after stimulation with CSA, 405
- Chemotherapy, impact of, in healthy and tumor-bearing subjects, 1340-1348
- Children
- acromegalic, normal, and IDDM, RBC IGF-I receptor in, 923-928
 - GH-deficient, *see* Growth hormone, deficiency in, in children
 - Japanese obese, fasting plasma insulin level as risk factor for complications development in, 478-485
 - prepubertal asthmatic, short- and long-term effects of oral salbutamol on GH secretion in, 149-151
- Chloride (Cl), plasma, in elderly subjects with femoral neck fracture, 61
- 4-[2-(5-chloro-2-methoxybenzamide)ethyl]-benzoic acid (meglitinide), effects of, on glycogen phosphorylase and F-2,6-P₂ activity in hepatocytes, 1000-1007
- CHO(s), *see* Carbohydrates
- Cholesterol (C)
- age and response of, to physical conditioning and deconditioning, 163
 - beta-CD effects on metabolism of, 200-206
 - in centrally obese subjects, hemostatic function and, 1418
 - in cirrhosis, 827, 900
 - correlation between synthesis of, and hepatic secretion of apo B-100 in normolipidemia, 1052-1057
 - effects of dietary fat types on, 276
 - hepatic, *see* Hepatic cholesterol
 - in hepatic steatosis, 700
 - in hypertension, effects of vasodilators on, 715
 - low-dose pravastatin effects on, 1411
 - and low-fat, high-fiber diet, 750-754
 - in middle-aged men, training status and, 342, 343
 - in NIDDM, *see* Cholesterol in NIDDM
 - oral (-)-BM 13,0913.Na effects on, in lean and obese subjects, 580, 581
 - oral vanadyl effects on, 334
 - and persistent IGT, 1101
 - plasma, *see* Plasma cholesterol
 - in postmenopausal women on HRT, 411
 - postprandial response of, to high- and low-fiber diets, 849-850
 - and pulsatile GH secretion during fasting, 606
 - in SCI, 54
 - short-term GH therapy effects on, 726-728
 - simvastatin and gemfibrozil effects on, 215
 - total, *see* Total cholesterol
 - see also* High-density lipoprotein-cholesterol; Hypercholesterolemia; Lecithin-cholesterol acyltransferase; Low-density lipoprotein-cholesterol; Very-low-density lipoprotein-cholesterol
- Cholesterol (C) in NIDDM
- with hypertriglyceridemia, 692
 - in obese NIDDM women, 1476
 - with obesity or glucose intolerance, 1571
- Cholesteryl esters, hyperinsulinemia effects on, 807-809
- Cholestyramine (CME), effects of fluvastatin and, on Lp particles, compared, 1447-1454
- Choline, insulin effects on SM content of, 352
- Cholinesterase, serum, in β -thalassemia, 282
- Chromium (Cr), effects of, on insulin response to glucose, 1314-1320
- Chronic ethanol intake, effects of, on hepatic BCKA dehydrogenase flux, 1243-1246
- Chronic hypoinsulinemia (and hyperinsulinemia), IGF-I and IGF-I receptor gene expression in kidney, 982-986
- Chronic malnutrition, adaptation in glucose homeostasis during, 817-824
- Chronic maternal hypoxia, effects of, on fetal growth and glucose utilization by fetal tissues, 532-537
- Chronic spinal cord injury (SCI), vitamin D deficiency in, 1612-1618
- Chylomicrons, and hemolysis in primary LPL deficiency, 654, 655
- Cigarette smoking, *see* Smoking
- Circulating hormones
- blood cytokine levels in brain-dead patients and their relationship with acute-phase reactants and, 812-816
 - meal frequency influence on levels of, 218-223
 - see also specific hormones*
- Circulating insulin, effects of ethanol on, 1356-1359
- Circulating insulin-like growth factor-binding protein-1 (IGFBP-1), effects of ethanol on, 1356-1359
- Cirrhosis
- altered lipid composition and differential changes in activities of RBC membrane-bound enzymes in, 825-832
 - diabetic and nondiabetic, proinsulin and des-31,32-proinsulin contribution to hyperinsulinemia in, 254-260
 - effects of β -adrenergic blockers on hepatic conversion of AA nitrogen and urea synthesis in, 899-905
 - serum and urine guanidino compounds in, 584-588
 - severe malnutrition in, and short-term changes in EE after 1 month of regular oral diet, 765-770
- Citrulline in TPN of burn patients, 661
- Cl (chloride), plasma, in elderly subjects with femoral neck fracture, 61
- Classic galactosemia, levels of erythrocyte uridine sugar nucleotide in normal subjects, subjects with other metabolic disorders, and in, compared, 597-604
- Clenbuterol, effects of, on tissue Rb uptake, 119-125
- Clinical course of AIDS, soluble receptors for TNF as markers for, but not for metabolic changes in, 1564-1569
- Clinical significance of changes in sex hormone levels in AIDS, 951
- Clofibrate, pyruvate inhibiting hepatic peroxisome proliferation and free radical production induced by, 166-171
- CME (cholestyramine), effects of fluvastatin and, on Lp particles, compared, 1447-1454
- ¹⁴CO₂ (¹⁴carbon dioxide), rate of production of, by enterocytes, 327
- Coenzyme A, *see* Acyl-CoA binding protein; Hepatic HMG-CoA reductase; HMG-CoA synthase
- Collagen, n-3 PUFA ethyl ester effects on aggregation of, 566
- Combined hypercholesterolemia-hypertriglyceridemia, mononuclear cell adhesion to endothelial cells in, 374-378
- Complementary deoxyribonucleic acid (cDNA) amplification, promoter region of IR gene analyzed with, in leprechaunism with severe insulin resistance, 430-437
- Congenital hypothyroidism, L-T₄ therapy effects on plasma apos and Lps in, 1283-1287
- Connecting peptides, *see* C-peptides
- Conscious subjects, glucagon kinetics in, 452-459
- Constitutional delay of growth in adolescent males, testosterone therapy of, 1013-1015

- Continuous hormonal replacement therapy (HRT), low-dosage, effects of, on Lp metabolism in postmenopausal women, 410-417
- Copper (Cu), plasma, in IDDM, plasma Cp and, 998
- Coronary artery bypass graft (CABG), risk of IGT and DM during first postoperative year following, 1016-1027
- Coronary heart disease (CAD)
men with, HDL subclasses associated with insulin and glucose levels, physical activity, resting HR, and regional adiposity in, 106-114
serum sialic acid as indicator of change in, 147-148
- Corticosterone
high-calorie TPN effects on, 155
serum, effects of high-CHO diet on, 1544
- Corticotropin (ACTH; adrenocorticotropin hormone), low-dose CRH stimulation test effects on levels of, in IDDM with and without neuropathy, 541
- Corticotropin-releasing hormone (CRH) stimulation test, low-dose, in IDDM with or without neuropathy, 538-542
- Cortisol
in AIDS patients, 1567
in cirrhosis, effects of β -adrenergic blockers on, 901
CRH stimulation test effects on urinary levels of, in IDDM with or without neuropathy, 541
following total hip replacement, 1217, 1221
plasma, *see* Plasma cortisol
in SCI, 54, 1117
- Cp (ceruloplasmin), plasma, in IDDM, oxidative stress and, 996-999
- C-peptides (connecting peptides)
in CF, 16
fasting plasma, *see* Fasting plasma C-peptides
following total hip replacement, 1217, 1221
in hyperinsulinemic first-degree relatives of NIDDM patients, 1279
in IGT, serum level insulin level and, 1373
in NIDDM, *see* C-peptides in NIDDM
in PCOS with obesity, effects of VLCD on, 613, 614
in SCI, 54
serum, *see* Serum C-peptides
- C-peptides (connecting peptides) in NIDDM
hyperglycemia facilitating urinary excretion of C-peptides by increasing glomerular filtration rate, 1194-1198
with hypertriglyceridemia, 692
serum insulin levels and, 1373
- Cr (chromium), effects of, on insulin response to glucose, 1314-1320
- C-reactive protein (CRP)
in AIDS patients, 1162
and malnutrition in nonneoplastic gastrointestinal diseases, 1112
- Creatine in cirrhosis
serum levels of, 585
urinary excretion of, 586
- Creatinine
and abundance of Na^+/H^+ exchanger isoform-1 in skin fibroblasts in IDDM, 792
in cirrhosis, *see* Creatinine in cirrhosis
effects of nibbling versus gorging on clearance of, 551-552
serum, *see* Serum creatinine
vitamin C deficiency and clearance of, 1641
- Creatinine in cirrhosis
with severe malnutrition, 767
urinary excretion of, 586
- CRH (corticotropin-releasing hormone) stimulation test, low-dose, in IDDM with or without neuropathy, 538-542
- CRP, *see* C-reactive protein
- CS-045, *see* Troglitazone
- CSA (cyclosporine), cardiac natriuretic peptides inhibiting ET production induced by, in mesangial cells, 404-409
- Cu (copper), plasma, in IDDM, plasma Cp and, 998
- CV system, *see* Cardiovascular system
- Cyclase
adenylate, β -adrenergic responsiveness of, in adipocyte plasma membrane in obesity and after weight loss, 1288-1292
adenylate, sensitivity of, to inhibitory and stimulatory agonists, increased concentrations of proteins G_i1 and G_i2 in elderly subjects altering, 239-244
- Cyclic adenosine monophosphate, *see* cAMP
- Cyclic guanosine monophosphate (cGMP), cellular, ANP and BNP effects on, after stimulation with CSA, 405
- β (beta)-Cyclodextrin (β -CD), effects of, on plasma lipids and C metabolism, 200-206
- Cycloheximide, effects of, on high-affinity HDL binding in hepatocytes, 734-735
- Cyclosporine (CSA), cardiac natriuretic peptides inhibiting ET production induced by, in mesangial cells, 404-409
- Cysteine
effects of, on SM protein synthesis during sepsis, 1131
effects of overnight infusion of, on muscle proteolysis, 426
following total hip replacement, 1217-1219
plasma, in AIDS patients, 1162
in soy protein, 1147, 1148
- Cystic fibrosis (CF), impaired glucose tolerance with, tolbutamide effects on insulin secretion in, 13-18
- Cytokines
levels of blood, in brain-dead patients, and their relationship with circulating hormones and acute-phase reactants, 812-816
see also specific cytokines
- Cytophotometry, flow, of mononuclear cells, 376-377
- Cytosolic phosphorylation, LPS effects on hepatic free-NADP(P) $^{+}$ -linked redox states, during fasting, 1170-1174
- DA (dopamine), urinary excretion of, in hyperinsulinemia, arachidonate distribution in LDLs and thoracic aorta and, 807
- DAG (SN-1,2-diacylglycerol), skeletal muscle, insulin effects on, 348-357
- DBP (diastolic blood pressure), *see* Blood pressure
- Decarboxylation, mitochondrial KIC, in hepatic macrovesicular hepatic steatosis, 699-700
- Dehydroepiandrosterone (DHEA; 3- β -hydroxy-5-androsten-17-one)
in AIDS, 950
effects of, on glucose uptake by fibroblasts, 543-548
levels of, and abdominal AT in obese men, 513-519
- Dehydrogenase
glucose-6-phosphate, insulin effects on, 1464-1465
hepatic branched-chain keto-acid, effects of chronic ethanol intake on flux of, 1243-1246
pyruvate, *see* Pyruvate dehydrogenase, muscle
succinate, and long-term ethanol exposure, 892
xanthine, ethanol as inhibitor, 779-785
- Demographics, *see* Age; Race and ethnicity; Sex
- Density, bone, *see* Bone density
- [^3H]2-Deoxyglucose (DOG), effects of dexamethasone and PSL on, in adipocytes and soleus muscles, 298-306

- Deoxyribonucleic acid (DNA) amplification, complementary, in analysis of promoter region of IR gene in leprechaunism with severe insulin resistance, 430-437
- Dephosphorylation, abnormal phosphopeptide, corresponding to autophosphorylation site of IR, insulin resistance associated with, 1074-1081
- Des-31-32 proinsulin, contribution of, to hyperinsulinemia in diabetic and nondiabetic cirrhosis, 254-260
- Detoxification, hydroperoxide, in intestine of STZ-DM subjects, effects of insulin and fasting on GSH redox cycle and, 1462-1468
- DEX, *see* Dexamethasone
- DEXA (dual-energy x-ray absorptiometry), age- and menopause-associated variations in AT distribution and body composition in healthy women measured with, 369-373
- Dexamethasone (DEX)
effects of, on high-affinity HDL binding sites in hepatocytes, 730-738
effects of prednisolone and, on insulin-induced activation of PKC in adipocytes and SM, 298-306
long-term effects of lipectomy and, on visceral AT and metabolic variables, 1631-1638
- Dextran sulfate
fluorescein-labeled, transendothelial permeation of, by high glucose concentration, 739-744
LDL apheresis by adsorption of, in pregnancy with HFH, 929-933
- DHEA, *see* Dehydroepiandrosterone
- Diabetes mellitus (DM)
ALC and PLC effects on peripheral nerve function and vascular supply in, 1209-1214
with cirrhosis, proinsulin and des-31,32-proinsulin contribution to hyperinsulinemia in, 254-250
gestational, insulin secretion in insulin resistance in patient with history of, 1067-1073
high-fat, high-sucrose diet effects on development of obesity and, 645-651
hypertension, *see* Diabetes mellitus with hypertension
increased abundance of SM PTPases in, 1175-1184
long-term troglitazone therapy suppressing hepatic gluconeogenesis in, 487-490
regulation of GF mRNA in eyes of subjects with, 1038-1045
risk of IGT and, during first postoperative year following CABG, 1016-1027
see also Diabetic ketoacidosis; Diabetogenic effects; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
- Diabetes mellitus (DM) with hypertension
and cardiovascular disease, role of oxidative stress in, 363-368
doxazosin improving peripheral insulin sensitivity in, 673-676
NIDDM with hypertension, glucose storage and insulin sensitivity improved with enalapril in, 85-88
- Diabetic ketoacidosis, increased serum D-lactate associated with, 287-290
- Diabetogenic effects of salmon calcitonin due to its amylin-like activity, 1581-1589
- SN-1,2-Diacylglycerol (DAG), skeletal muscle, insulin effects on, 348-357
- Diastolic blood pressure, *see* Blood pressure
- Diet
effects of weight loss and, on lipoprotein levels in obese men with silent myocardial ischemia and reduced HDL-C, 307-314
influence of, on mononuclear cell adhesion to endothelial cells in combined hypercholesterolemia-hypertriglyceridemia and in isolated hypercholesterolemia, 374-378
- Diet (*Continued*)
pioglitazone effects on hypertension induced by, 1105-1109
tissue-specific alterations in G protein expression in model of NIDDM induced by, 771-778
see also Calorie(s); Fasting; Fed state; Food intake; Malnutrition; Meals; Overfeeding; Parenteral nutrition; Postprandial responses; Starvation; Supplementation *entries beginning with term:* Dietary specific food groups, diets, and substances
- Dietary fats
assessing intake of, by comparing 3-day food record and phospholipid fatty acid composition of RBCs, 1139-1145
exchange between CHOs and, and regulation of hepatic cholesterol and plasma Lp metabolism, 855-864
middle-aged men intake of, training status and, 342
troglitazone effects on insulin resistance induced by, 1489-1494
see also High-fat diet; Low-fat, high-fiber diet; Low-fat diet and specific types of dietary fats
- Dietary protein
effects of nutritional status and increased intake of, on whole-body protein metabolism of AIDS patients with weight loss, 1159-1165
middle-aged men intake of, training status and, 342
soy, hypercholesterolemia induced by, and Lp susceptibility to peroxidation potentiated by methionine deficiency in subjects fed, 1146-1152
see also High-protein diet; Restricted dietary protein
- 1,25-Dihydroxyvitamin D [$1,25(\text{OH})_2\text{D}$]
chronic SCI and deficiency in, 1612-1618
testosterone effects on, in adolescent male hypogonadism, 420-421
- D-Dimer, serum, in PCOS with obesity, effects of VLCD on, 613, 614
- Δ^5 -DIOL (androst-5-ene-3 β ,17 β -diol) levels of, and abdominal AT in obese men, 513-519
- Δ^4 -DIONE, *see* Androstenedione
- Diphosphate, uridine, in normal adult subjects, in galactosemia, and other metabolic disorders, 513-519
- Diphosphogalactose, uridine, in normal subjects and in galactosemia, 599, 600
- Diphosphoglucose, hepatic uridine, rate of entry of glucose into, in fasted and fed states in normal subjects, 172-182
- Diphosphohexoses, uridine, in normal subjects and in galactosemia, 600-602
- Diuretics, effects of NSAIDs and loop, on TSH release by anterior pituitary cells, 1008-1012
- DM, *see* Diabetes mellitus
- DNA (deoxyribonucleic acid) amplification, complementary, in analysis of promoter region of IR gene in leprechaunism with severe insulin resistance, 430-437
- Docosapentaenoic acid (DPA), effects of, on platelet phospholipid composition and platelet function, 562-569
- [^3H]-2-DOG (deoxyglucose), effects of dexamethasone and PSL on, in adipocytes and soleus muscles, 298-306
- Dopamine (DA), urinary excretion of, in hyperinsulinemia, arachidonate distribution in LDLs and thoracic aorta and, 807
- Dose
and response to GLP-1(7-37) in hyperglycemia, 1232
see also entries beginning with terms: Low-dose
- Doubly labeled water, determination of, by gas-phase FTIR spectroscopy, 1-3
- Doxazosin, peripheral insulin sensitivity improved with, in diabetic hypertensive patients, 673-676
- DPA (docosapentaenoic acid), effects of, on platelet phospholipid composition and platelet function, 562-569

- Drinking, *see* Alcohol consumption and alcoholism
- Dual-energy x-ray absorptiometry (DEXA), age- and menopause-associated variations in AT distribution and body composition in healthy women measured with, 369-373
- E, *see* Epinephrine
- Early insulin-dependent diabetes mellitus (IDDM), natural course of insulin sensitivity in, 617-623
- Early non-insulin-dependent diabetes mellitus (NIDDM), beta cell function at transition to, 757-764
- EE, *see* Energy expenditure
- Effectiveness of chemotherapy, and its impact on protein metabolism, 1341
- Eicosapentaenoic acid (EPA), effects of, on platelet phospholipid composition and platelet function, 562-569
- Elderly subjects, *see* Older subjects
- Enalapril, glucose storage and insulin sensitivity improved with, in hypertensive NIDDM, 85-88
- Endothelial cells, mononuclear cell adhesion to, in combined hypercholesterolemia-hypertriglyceridemia and in isolated hypercholesterolemia, 374-378
- Endothelin (ET)
cardiac natriuretic peptides inhibiting CSA-induced production of, in mesangial cells, 404-409
urinary excretion of, angiotensin II and phenylephrine effects on, in women, 115-118
- Endothelin-1 (ET-1)
CSA effects on production of, 405
effects of, on glucose and glucagon, 1321-1325
hypoglycemia induced by, NMLA and somatostatin effects on, 1532-1535
and insulin release, *see* Endothelin-1, insulin release and plasma, in hyperthyroidism, 1239-1242
responses of, to exhaustive exercise at high altitude with acute hypoxia, 8-9
- Endothelin-1 (ET-1), insulin release and
ET-1 effects on insulin release, 1321-1325
NMLA and somatostatin blocking ET-1-induced release, 1532-1535
- Endurance exercise, *see* Exercise
- Energy balance, protein and, following femoral neck fracture in elderly subjects, 59-66
- Energy expenditure (EE)
and adrenoceptor antagonists, 247
changes in, in response to fructose and glucose with and without caffeine, 633
by exercising healthy elderly women, 1046-1051
protein metabolism and, and malnutrition in nonneoplastic gastrointestinal diseases, 1110-1115
resting, *see* Resting energy expenditure
short-term changes in, after 1 month of regular oral diet in severely malnourished cirrhotic patients, 765-770
by starved exercising subjects, 1334
- Energy intake
pioglitazone effects on, 1106
see also Food intake
- Energy restriction, *see* Calorie restriction
- Enterocytes, influence of lactation stage on glucose and glutamine metabolism in, 325-331
- Environmental tobacco smoke (ETS), worksite, effects of, on serum Lps in nonsmoking women, 1536-1539
- Enzymes, *see specific enzymes*
- EPA (eicosapentaenoic acid), effects of, on platelet phospholipid composition and platelet function, 562-569
- Epididymal adipose tissue (AT)
beef tallow diet effects on, 1273-1274
lipolytic response of, to NE, 1515-1516
- Epinephrine (E; adrenaline; EPI)
adrenoceptor antagonists and, 248
in AIDS patients, 1567
changes in insulin sensitivity, B-cell function, and glucose effectiveness and, 1261
in cirrhosis, effects of β -adrenergic blockers on, 903
plasma, *see* Plasma epinephrine
response of, to amlopidine in essential hypertension, 316, 318
in SCI, 54
urinary excretion of, in hyperinsulinemic subjects, arachidonate distribution in LDLs and thoracic aorta and, 807
- Epsilon (ϵ)-N-trimethyllysine, carnitine synthesis from, vitamin C deficiency and, 624-629
- Erythrocyte (red blood cells; RBCs) Ca^{2+} -ATPase (calcium-adenosine triphosphatase), D-myo-inositol 1,4,5-triphosphate modulating activity of, guanine nucleotide regulatory protein mediating, 865-868
- Erythrocyte (red blood cells; RBCs) insulin-like growth factor-I (IGF-I) receptor in normal, acromegalic, GH-deficient, and IDDM children, 923-928
- Erythrocyte (red blood cells; RBCs) insulin-like growth factor-I (IGF-I) receptor tyrosine kinase, activity of, in hypertensive pregnancy, 1308-1313
- Erythrocyte (red blood cells; RBCs) insulin receptor (IR), activity of, in hypertensive pregnancy, 1308-1313
- Erythrocyte (red blood cells; RBCs) membranes, differential changes of enzymes bound to, in hepatic cirrhosis, 825-832
- Erythrocyte (red blood cells; RBCs) phospholipid fatty acids (FAs), dietary fat intake assessed by comparing 3-day food record and composition of, 1139-1145
- Erythrocyte (red blood cells; RBCs) protein, and hemolysis in primary LPL deficiency, 654, 656-657
- Erythrocyte (red blood cells; RBCs) uridine sugar nucleotide, levels of, in normal subjects, in classic galactosemia, and subjects with other metabolic disorders, 597-604
- Essential hypertension, amlopidine effects on insulin sensitivity for glucose metabolism in, 315-319
- Estradiol, serum, effects of low-fat, high-fiber diet on, in premenopausal women, 752-753
- Estrogen
in AIDS, 950
serum, changes in concentrations of plasma Lps in response to low-fat, high-fiber diet associated with changes in, in premenopausal women, 749-756
- Estrone, serum, effects of low-fat, high-fiber diet on, in premenopausal women, 752, 753
- ET, *see* Endothelin; Endothelin-1
- Ethanol
effects of, on circulating IGFBP-1 and insulin, 1356-1359
effects of chronic intake of, on hepatic BCKA dehydrogenase flux, 1243-1246
effects of long-term exposure to, on glycosylation of N- and O-glycosylated proteins, 890-897
as xanthine dehydrogenase inhibitor, 779-785
see also Alcohol consumption and alcoholism
- Ethnicity, *see* Race and ethnicity
- Etiology
primary NIDDM, impaired insulin secretion or insulin resistance as, 940-945
see also specific conditions
- ETS (environmental tobacco smoke), worksite, effects of, on serum Lps in nonsmoking women, 1536-1539

Exercise

- effects of, on AT, *see* Adipose tissue, exercise and
- effects of fed state and, on LPL gene expression in heart and skeletal muscle, 1596-1605
- exhaustive, at high altitude with acute hypoxia, ET-1 responses to, 8-9
- and persistent IGT, 1101
- submaximal, influence of, on glucose assimilation analyzed with minimal model, 833-840
- see also* α - and β -Adrenoceptor antagonists, metabolic and hormonal responses to; Men, exercising; Women, exercising and specific types of exercise
- Exhaustive exercise at high altitude with acute hypoxia, ET-1 responses to, 8-9
- Eyes of diabetic subjects, regulation of GF mRNA in, 1038-1045

F, *see* FructoseFA(s), *see* Fatty acids

Factor VII

- in central obesity, hemostatic function and, 1419
- levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919

Factor VIII, levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919

Familial hypercholesterolemia (FH)

- homozygous, pregnancy with, in patient undergoing LDL apheresis by dextran sulfate adsorption, 929-933
- type III hyperlipoproteinemia with, 460-465

Familial (type III) hyperlipoproteinemia with FH, 460-465

Familial non-insulin-dependent diabetes mellitus (NIDDM)

- hyperinsulinemia in first-degree relatives of NIDDM patients, 1278-1282
- metabolic defects in persistent IGT related to, 1099-1104

Fasting

- arginine and proline synthesis during, 470, 471
- by centrally obese subjects, hemostatic function and, 1418
- effects of, on GSH redox cycle, hydroperoxide detoxification in intestine of STZ-DM subjects and, 1462-1468
- effects of, on serum lipids, 1329
- effects of exercise and, on LPL gene expression in AT, heart, and skeletal muscle, 1596-1605
- effects of high-fat diet and, on levels of acyl-CoA binding protein in liver, kidney, and heart, 1185-1189
- HRT effects on apo B levels in, 412
- LPS effects on hepatic free-NAD(P)⁺-linked redox states and cytosolic phosphorylation during, 1170-1174
- N balance and substrate oxidation during, by elderly subjects with femoral neck fracture, 63, 64
- NT effects during, on ventromedian nucleus of obese subjects, 972-975
- pulsatile GH secretion in non-obese and obese men during, 605-610
- rate of entry of glucose into hepatic UDP-glucose during, in normal adult subjects, 172-182
- response to GLP-1(7-37) in, 1233
- short-term effects of, on changes in GHBP concentrations in normal and acromegalic subjects, 667-672
- see also* entries beginning with term: Fasting

Fasting free fatty acids (FFAs)

- and persistent IGT, 1102
- and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086

Fasting glucose

- in borderline hypertriglyceridemic subjects, 1294, 1295

Fasting glucose (*Continued*)

- effects of fructose and glucose ingestion with and without caffeine on, 631
- of hypertensive and normotensive smokers, HbA_{1c} levels and insulin sensitivity in, 558
- in men with CAD, 108
- in NIDDM, 42
- in obesity, 1399
- plasma, *see* Fasting plasma glucose
- and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086
- and pulsatile GH secretion, 606
- Fasting hyperinsulinemia, cardiovascular risk factors and, in non-diabetic lean and obese subjects, 914-922
- Fasting insulin
 - effects of fructose and glucose ingestion with and without caffeine on, 631
 - following CABG, 1018
 - GH therapy effects on, in pituitary deficiency subjects, 71
 - of hypertensive and normotensive smokers, HbA_{1c} levels and insulin sensitivity and, 558
 - and insulin sensitivity, 1122
 - in men with CAD, 108
 - in NIDDM, 42
 - in obesity, 1399
 - plasma, *see* Fasting plasma insulin
 - and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086
 - serum, *see* Fasting serum insulin
- Fasting lipids, bezafibrate therapy effects on, 1403-1405, 1407
- Fasting lipoproteins (Lps), bezafibrate therapy effects on, 1403-1405, 1407
- Fasting plasma cholesterol (C) in middle-aged men, training status and, 343
- Fasting plasma C-peptides (connecting peptides)
 - in beta-thalassemia subjects, 282
 - and persistent IGT, 1102
- Fasting plasma glucose (FPG)
 - of beta-thalassemia subjects, 282
 - effects of dietary fat types on, 276
 - following CABG, 1022, 1023
 - of IGT and NIDDM patients, serum insulin level and, 1373
 - and insulin sensitivity, 1122
 - in microvascular angina, 877
 - in middle-aged men, training status and, 343
 - and persistent IGT, 1102
 - in STZ-DM, 1423-1424
- Fasting plasma high-density lipoprotein-cholesterol (HDL-C) in middle-aged men, training status and, 343
- Fasting plasma insulin
 - of beta-thalassemia subjects, 282
 - effects of dietary fat types on, 276
 - following CABG, 1022
 - level of, as risk factor for development of complications in obese Japanese children, 478-485
 - in middle-aged men, training status and, 343
 - and persistent IGT, 1102
 - in STZ-DM, 1423-1424
- Fasting plasma low-density lipoprotein-cholesterol (LDL-C) in microvascular angina, 877
- Fasting plasma nonesterified fatty acids (NEFAs) in microvascular angina, 877
- Fasting plasma thyroxine (T₄) in middle-aged men, training status and, 343
- Fasting plasma total cholesterol (TC) in microvascular angina, 877

- Fasting plasma triglycerides (TGs)
in microvascular angina, 877
in middle-aged men, training status and, 343
- Fasting plasma triiodothyronine (T₃) in middle-aged men, training status and, 343
- Fasting serum C-peptides (connecting peptides) in microvascular angina, 877
- Fasting serum insulin
in healthy men with metabolic syndrome, 35-40
of IGT and NIDDM subjects, serum level insulin level and, 1373
in microvascular angina, 877
- Fat, *see* Adipose tissue; Dietary fats; Fat-free mass *entries beginning with terms:* Fatty element: Lip- and specific types of fats
- Fat-free mass (FFM)
age and, *see* Fat-free mass, age and
in AIDS patients, 1566
and beta-adrenergic stimulation of abdominal subcutaneous AT BF, 184
effects of fructose and glucose ingestion with and without caffeine on, 631
and effects of weight loss on β -adrenergically mediated thermogenic and HR responses, 521, 522
in IGT subjects, 1504
of microvascular angina patients, 877
in NIDDM subjects, and role of basal insulin in maintenance of intracellular glucose metabolic pathways, 42
in obese women, insulin resistance in adipocytes and, 988
of pituitary deficiency subjects, 68, 70, 71
- Fat-free mass (FFM), age and
in elderly women, *see* Fat-free mass in elderly women
in middle-aged men, training status and, 342
and response to physical conditioning and deconditioning, 162
- Fat-free mass (FFM) in elderly women
in elderly exercising women, energy expenditure and, 1047
with femoral neck fracture, 61
and malnutrition due to non-neoplastic gastrointestinal diseases, 1112
- Fatty acids (FAs)
beef tallow diet effects on, 1273, 1274
cecal short-chain, beta-CD effects on, 201-202
in cirrhosis, 828
differential effects of HF diet varying in, on efficiency of lean and fat tissue deposition during weight recovery following low food intake, 273-279
fish oil effects on, 1369
free, *see* Free fatty acids
HP diet effects on synthesis of, in obesity, 23-24
low-dose pravastatin effects on, 1411
monounsaturated, in low-fat, high-fiber diet, 750
nonesterified, *see* Nonesterified fatty acids
oxidation of, and cardiac function in sodium pivalate model of secondary carnitine deficiency, 499-505
polyunsaturated, *see* Polyunsaturated fatty acid(s); n-3 Polyunsaturated fatty acid(s); n-3 Polyunsaturated fatty acid ethyl esters
RBC phospholipid, dietary fat intake assessed by comparing 3-day food record and composition of, 1139-1145
regulation of LDL receptor interactions by, 1428-1434
saturated, *see* Saturated fatty acids
from TGs, heparin effects on release, oxidation, and reesterification of, 1590-1595
- FD (fluorescein-labeled dextran), transendothelial permeation of, by high glucose concentration, 739-744
- Fe (iron) in β -thalassemia patients, 282
- Fecal steroids, beta-CD effects on, 202-203
- Fed state
arginine and proline synthesis in, 470, 471
effects of exercise and, on LPL gene expression in AT, heart, and skeletal muscle, 1596-1605
rate of entry of glucose into hepatic UDP-glucose during, in normal adult subjects, 172-182
response to GLP-1(7-37) in, 1233
see also Diet
- Femoral neck fracture in elderly subjects, protein and energy balance in, 59-66
- Fertile women, exercising, effects of, on plasma Lps and apos in, 701-704
- Fetal blood gases, chronic maternal hypoxia and, 533
- Fetal growth retardation, chronic maternal hypoxia and, 532-537
- Fetal hepatocytes, GLUT1 mRNA and GLUT2 mRNA in, glucose regulation of, 1553-1558
- Fetal tissues, effects of chronic maternal hypoxia on glucose utilization by, 532-537
- Fetal weight, and maternal chronic hypoxia, maternal food intake and, 534
- FFAs, *see* Free fatty acids
- FFM, *see* Fat-free mass
- FH, *see* Familial hypercholesterolemia
- Fiber, *see* High-fiber diet; Low-fiber diet
- Fibrinogen (Fn)
age and response of, to physical conditioning and deconditioning, 163
in centrally obese subjects, hemostatic function and, 1418
levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 919
in PCOS with obesity, effects of VLCD on, 613, 614
plasma, *see* Plasma fibrinogen
- Fibrinolytic capacity, insulin sensitivity and, with VLCD in obese women with PCOS, 611-616
- Fibrinolytic factors, effects of moderate calorie restriction on, in non-obese men, 1548-1552
- Fibroblasts
DHEA effects on glucose uptake by, 543-548
skin, abundance of Na⁺/H⁺ exchanger isoform-1 in, in IDDM with nephropathy, 791-795
- Fibrosis, cystic, impaired glucose tolerance with, tolbutamide effects on insulin secretion in, 13-18
- First-degree relatives of patients with NIDDM, hyperinsulinemia in, 1278-1282
- Fish oil
macrophage TNF- α mRNA expression enhanced by, at transcriptional level, 800-805
muscle glucose uptake in TNF-treated subjects improved with, 1365-1370
- Flow cytophotometry of mononuclear cell, 376-377
- Fluorescein-labeled dextran (FD), transendothelial permeation of, by high glucose concentration, 739-744
- Fluoxetine, long-term effects of, on glycemic control in NIDDM with obesity or glucose intolerance, 1570-1576
- Flutamide in treatment of PCOS, 525-531
- Fluvastatin, effects of cholestyramine and, on Lp particles, compared, 1447-1454
- Fn, *see* Fibrinogen
- Follicle-stimulating hormone (FSH) in men with SCI, 1117
- Food intake
clenbuterol and salbutamol effects on, 121
effects of nibbling versus gorging on cardiovascular risk factors, 549-555
and impact of chemotherapy on protein metabolism 1341-1342
low, *see* Calorie restriction; Restricted dietary protein

Food intake (*Continued*)

- maternal, in chronic hypoxia, fetal body and tissue weight and, 534
- of middle-aged men, training status, 342
- obesity and, *see* Food intake in obesity
- and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086
- see also* Diet
- Food intake in obesity
 - effects of weight loss on, in obese men, 439-440
 - and NT effects during fasting on ventromedian nucleus of obese subjects, 973
- Fourier infrared (FTIR) spectroscopy, gas-phase, doubly labeled water determination by, 1-3
- F-6-P (fructose-6-phosphate), effects of troglitazone on, in DM, 489
- F-1,6-P₂ (fructose-1,6-biphosphate), effects of troglitazone on, in DM, 489
- F-2,6-P₂ (fructose-2,6-biphosphate), glibenclamide and meglinide effects of activity of, in hepatocytes, 1000-1007
- F-1,6-P₂ase (fructose-1,6-biphosphatase), effects of troglitazone on, in DM, 488, 489
- FPG, *see* Fasting plasma glucose
- Fracture, femoral neck, in elderly subjects, protein and energy balance in, 59-66
- Free fatty acids (FFAs)
 - adrenoceptor antagonists and, 248
 - beef tallow diet effects on, 1273
 - bromocriptine inhibiting hepatic glucose production and oxidation of, in obesity, 1349-1355
 - fasting, *see* Fasting free fatty acids
 - high- and low-fiber diet effects on, 851
 - in hyperinsulinemia, 229
 - in hypertensive and normotensive smokers, 559
 - in hypertriglyceridemia, gemfibrozil effects on, 593
 - and insulin resistance in GH-deficient adults, 1127
 - LCD effects on, in exercising men, 1267
 - in NIDDM, *see* Free fatty acids in NIDDM
 - in pituitary deficiency subjects, 71
 - plasma, *see* Plasma free fatty acids
 - and pulsatile GH secretion during fasting, 606
 - in SCI, 54
 - serum, *see* Serum free fatty acids
 - in STZ-DM, 1392
- Free fatty acids (FFAs) in NIDDM
 - and changes in SM LPL activity, 787
 - in obese NIDDM women, 1476
- Free glutamine, α -ketoglutarate and glutamine preventing decrease in concentration of muscle, and influencing protein synthesis after total hip replacement, 1215-1222
- Free-NADP(P)⁺-linked redox states, hepatic, LPS effects on cytosolic phosphorylation potential and, during fasting, 1170-1174
- Free radicals
 - aging and, 365
 - clofibrate-induced production of, pyruvate inhibiting, 166-171
 - DM and, 364-365
 - hypertension and, 365
- Frequency of meals, influence of, on circulating hormone level and lipogenesis, 218-223
- Frequently sampled intravenous glucose tolerance test (FSIGTT) of beta-thalassemia subjects, 283
- in insulin resistance with history of GDM, 1071
- measuring influence of submaximal exercise on glucose assimilation with, 833-840

Fructose (F)

- and effects of troglitazone and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β -oxidation, 1626-1630
- galactose and concentration of, in lens, 1528
- glucose and, *see* Glucose, fructose and
- and insulin sensitivity and hepatic VLDL secretion, 841-847
- sorbitol effects on sorbitol and myo-inositol in eyes of diabetic subjects, 1042
- Fructose-1,6-biphosphatase (F-1,6-P₂ase), effects of troglitazone on, in DM, 488, 489
- Fructose-1,6-biphosphate (F-1,6-P₂), effects of troglitazone on, in DM, 489
- Fructose-2,6-biphosphate (F-2,6-P₂), glibenclamide and meglinide effects of activity of, in hepatocytes, 1000-1007
- Fructose-6-phosphate (F-6-P), effects of troglitazone on, in DM, 489
- FSH (follicle-stimulating hormone) in men with SCI, 1117
- FSIGTT, *see* Frequently sampled intravenous glucose tolerance test
- FTIR (Fourier infrared) spectroscopy, gas-phase, doubly labeled water determination by, 1-3
- G, *see* Glucagon
- G protein, tissue-specific alterations in expression of, in genetic versus diet-induced models of NIDDM, 771-778
- G₁l (and G₁2) protein, increased concentrations of, in adipocytes of elderly subjects altering sensitivity of adenylyl cyclase to inhibitory and stimulatory agonists, 239-244
- Galactitol 2-phosphate (and galactitol 3-phosphate) in lens, galactose and, 1527-1531
- Galactose
 - galactitol 2-phosphate and galactitol 3-phosphate in lens and, 1527-1531
 - UDP-, in normal subjects, in galactosemia, and in subjects with other metabolic disorders, 599, 600
- Galactosemia, classic, levels of erythrocyte uridine sugar nucleotide in normal subjects, subjects with other metabolic disorders and, compared, 597-604
- Galactosyl transferase, and long-term ethanol exposure, 892, 894
- Galanin
 - effects of, on inhibitory effects of glucocorticoids on GH secretion, 224-227
 - role of, in regulation of somatotrope and gonadotrope function in young ovulatory women, 1028-1032
- Gamma (γ)-butyrobetaine, carnitine synthesis from, vitamin C deficiency and, 624-629
- Gamma (γ)-glutamyl transpeptidase (γ -GTP), serum levels of, as risk factor for development of complications in obese children, 479, 481, 482
- Gamma-guanidinobutyric acid, *see* γ -Guanidinobutyric acid in cirrhosis
- Gas-phase Fourier infrared (FTIR) spectroscopy, doubly labeled water determination by, 1-3
- Gastrointestinal diseases, nonneoplastic, protein metabolism and energy expenditure in malnutrition due to, 1110-1115
- GCK (glucokinase) mRNA (messenger ribonucleic acid), age-related changes in, 322
- GDM (gestational diabetes mellitus), insulin secretion in insulin resistance in patient with history of, 1067-1073
- Gemfibrozil
 - decreasing TG levels in mild hypertriglyceridemia in nondiabetic subjects without affecting glucoregulatory or antilipolytic effects of insulin, 589-596

Gemfibrozil (*Continued*)

- effects of, on insulin sensitivity in NIDDM and hyperlipoproteinemia, 212-217

Gene

- expression of IGF-I receptor, in kidney in chronic hypoinsulinemia and hyperinsulinemia, 982-986
- expression of pancreatic islet cell, age-related changes in, 320-324
- IR, cDNA amplification in analysis of promoter region of, in leprechaunism with severe insulin resistance, 430-437
- LPL, effects of exercise and fed state on expression of, in AT, heart, and skeletal muscle, 1596-1605

Genetic model of NIDDM, tissue-specific alterations in expression of G protein in, 771-778

Genotype, galactosemia and, 601

Gestational diabetes mellitus (GDM), insulin secretion in insulin resistance in patient with history of, 1067-1073

GFs, *see* Growth factor mRNA and entries beginning with terms: Insulin-like growth factorGH, *see* Growth hormoneGHB, *see* Glycohemoglobin in NIDDM, LPL and

GHBP (growth hormone-binding protein), changes in concentrations of, in normal and acromegalic subjects, effects of short-term fasting on, 667-672

GHRH, *see* Growth hormone-releasing hormone, GH and; Growth hormone-releasing hormone 1-29NH₂GHRP, *see* entries beginning with terms: Growth hormone-releasing peptideGL(s), *see* GlucocorticoidsGlibenclamide, effects of, on glycogen phosphorylase and F-2,6-P₂ activity in hepatocytes, 1000-1007

Glicentin (GLI), insulinotropic action of, 47-51

Globulin, *see* Sex hormone-binding globulin

Glomerular filtration rate in NIDDM, hyperglycemia facilitating urinary excretion of C-peptide by increasing, 1194-1198

Glomeruli in STZ-DM, impaired NO release by, 695-698

GLP-1 (7-37) [glucagon-like peptide-1 (7-37)], glucose-dependent action of, effects of, during long-or short-term administration, 1231-1237

Glucagon (G; hyperglycemic factor; hyperglycemic-glycogenolytic factor)

in AIDS patients, 1567

beta cell response to, in early IDDM, 619

in cirrhosis, effects of β -adrenergic blockers on, 901

ET-1 effects on release of, 1321-1325

following total hip replacement, 1217, 1221

glucopenia-induced secretion of, insulin effects on, 358-362

hepatic resistance to, during chronic malnutrition, 817-824

insulin and, *see* Insulin, glucagon and

kinetics of, in conscious subjects, 452-459

plasma, *see* Plasma glucagon

response to, and insulinotropic action of glicentin, 48-50

in SCI, 54

Glucagon-like peptide-1 (7-37) [GLP-1(7-37)], glucose-dependent action of, effects of, during long-or short-term administration, 1231-1237

Glucagon mRNA (messenger ribonucleic acid), age-related changes in, 322

Glucocorticoids (GLs)

GH and, *see* Glucocorticoids, GH and

high-affinity HDL binding sites in hepatocytes upregulated by, 730-738

see also specific glucocorticoids

Glucocorticoids (GLs), GH and

galanin effects on inhibition of GH secretion by, 224-227

Glucocorticoids (GLs), GH and (*Continued*)

GL effects on GH response to TRH in acromegaly, 379-383

Glucokinase (GCK) mRNA (messenger ribonucleic acid), age-related changes in, 322

Gluconeogenesis, *see* Hepatic gluconeogenesis

Glucopenia, glucagon secretion induced by, insulin effects on, 358-362

Glucose

adaptations in homeostasis of, during chronic malnutrition, 817-824

in AIDS patients, 1566

amlodipine effects on insulin sensitivity for metabolism of, in essential hypertension, 315-319

beta cell response to, in early IDDM, 619, 620

blood, *see* Blood glucose

chromium effects on insulin response to, 1314-1320

concentration-dependent lowering effects of oral vanadyl on, in STZ-DM, are maintained after treatment withdrawal, 332-339

DHEA effects on fibroblast uptake of, 543-548

in diabetic ketoacidosis, 288

effects of acute increase of plasma TGs on metabolism of, 883-889

effects of nibbling versus gorging on, 551

ET-1 effects on, 1321-1325

exercise effects on, *see* Glucose, exercise effects onfasting, *see* Fasting glucose

fetal tissue utilization of, effects of chronic maternal hypoxia on, 532-537

fish oil effects on muscle uptake of, in TNF-treated subjects, 1365-1370

following total hip replacement, 1217-1218, 1221

fructose and, *see* Glucose, fructose and

GLP-1(7-37) action dependent on, effects of, during long- or short-term administration, 1231-1237

glucagon and, *see* Glucose, glucagon and

HDL subclasses in men with CAD associated with physical activity, resting HR, regional adiposity, levels of insulin and, 106-114

hepatic production of, *see* Hepatic glucose production

in hypertension, effects of vasodilators on, 715

in hypertriglyceridemia, gemfibrozil effects on metabolism of, 592-593

influence of lactation stage on metabolism of, in enterocytes, 325-331

insulin propeptides and, 1483, 1485

insulin-resistant metabolism of, in microvascular angina, 876-882

insulin sensitivity and acute insulin response to, 1121-1125

insulinotropic action of glicentin and, 48-50

intracellular, *see* Intracellular glucose

in lipid-induced insulin resistance, 642-643

in lymphocytes, bicarbonate effects on metabolism of, 1247-1252

mental stress effects on uptake of, during hyperinsulinemia, 1303-1307

in NIDDM, *see* Glucose in NIDDM

in non-obese men, effects of moderate calorie restriction on, 1549, 1550

in obesity, *see* Glucose in obesityoxidation of, *see* Oxidation, glucoseplasma, *see* Plasma glucose

rate of entry of, into hepatic UDP-, in normal adult subjects, 172-182

serum, *see* Serum glucose

sorbitol effects on sorbitol and myo-inositol in eyes of diabetic subjects, 1042

Glucose (*Continued*)

- T₃ effects on, 1382
- transendothelial permeation of albumin by high concentration of, 739-744
- and troglitazone effects on insulin action in normal subjects, 1167
- see also* [³H]2-Deoxyglucose; Glucose intolerance; Glucose-6-phosphate; Glucose tolerance; Glucose transport; GLUT1 mRNA; GLUT2 mRNA; GLUT4; GLUT4 mRNA; Hyperglycemia; Uridine diphosphoglucose and entries beginning with elements: Gluc-, Glyc-
- Glucose, exercise effects on
 - changes in glucose effectiveness in regularly exercising men, 1259-1263
 - effects of brisk walking by sedentary middle-aged women on, 393
 - submaximal exercise effects on assimilation of, 833-840
- Glucose, fructose and
 - effects of ingestion of, with and without caffeine in young and old men and women, 630-638
 - sorbinil effects on, in eyes of diabetic subjects, 1042
- Glucose, glucagon and
 - and glucagon kinetics in conscious subjects, 454
 - and glucagon secretion, 359
- Glucose intolerance
 - with NIDDM, long-term effects of fluoxetine on glycemic control in, 1570-1576
 - see also* Glucose tolerance
- Glucose in NIDDM
 - changes in SM LPL activity in response to insulin and, 786-790
 - gemfibrozil and simvastatin effects on, 212-213
 - with hypertriglyceridemia, 692
 - intracellular, metabolic pathways of, role of basal insulin in, 41-46
 - oral (-)-BM 13.0913.Na effects on uptake of, 573-574
 - relation between ATLPL response to insulin and, with GHb levels in obese women with NIDDM, 1475-1480
 - storage of, improved with enalapril in hypertensive NIDDM, 85-88
- Glucose in obesity
 - bromocriptine inhibiting HGP in obesity, 1349-1355
 - effectiveness of, insulin sensitivity, insulin secretion and, 1397-1400
 - see also* Glucose in obese men; Glucose in obese women; Glucose transport in obesity
- Glucose in obese men
 - normoinsulinemic, 1386
 - weight loss effects on, 440
- Glucose in obese women
 - with PCOS, VLCD effects on, 613, 614
 - relationship between AT LPL response to insulin and, with GHb levels in obese NIDDM women, 1475-1480
- Glucose-6-phosphate (G-6-P)
 - effects of troglitazone on, in DM, 489
 - partitioning of hepatic, and hepatic UDP-glucose synthesis, 179
- Glucose-6-phosphate dehydrogenase (G-6-PD), insulin effects on, 1464-1465
- Glucose tolerance
 - effects of troglitazone and bezafibrate on liver glycogen synthase activity, β -oxidation and, in fructose-fed subjects, 1626-1630
 - gemfibrozil and simvastatin effects on, in NIDDM, 212-213
 - and insulin secretion following calorie and dietary protein restriction, 1521
 - see also* Impaired glucose tolerance; Intravenous glucose tolerance test; Oral glucose tolerance test
- Glucose transport
 - glucose phosphorylation and utilization and, in pancreatic islets, 261-266
 - in muscle cells, troglitazone and M3 regulating, 976-981
 - in obesity, *see* Glucose transport in obesity
 - see also* entries beginning with acronym: GLUT
- Glucose transport in obesity
 - effects of insulin on, in obese women, 989
 - in skeletal muscle, captopril effects on, 267-272
- GLUT1 mRNA (messenger ribonucleic acid) in adult and fetal hepatocytes, glucose regulation of, 1553-1558
- GLUT2 mRNA (messenger ribonucleic acid)
 - in adult and fetal hepatocytes, glucose regulation of, 1553-1558
 - age-related changes in, 322
- GLUT4, dexamethasone and PSL effects on immunoreactivity of, 304
- GLUT4 mRNA (messenger ribonucleic acid), liver and AT, hyperinsulinemia effects on expression of, 228-233
- Glutamate
 - effects of overnight infusion of, on muscle proteolysis, 426
 - following total hip replacement, 1217-1219
 - glucose and glutamine metabolism in enterocytes and, 327, 328
 - plasma, in AIDS patients, 1162
- Glutamic acid
 - effects of, on SM protein synthesis during sepsis, 1131
 - in TPN of burn patients, 660
- Glutamic pyruvate transaminase (GPT), serum levels of, in obese children, as risk factor for development of complications, 479, 481, 482
- Glutamine
 - effects of, on SM protein synthesis during sepsis, 1131
 - effects of overnight infusion of, on muscle proteolysis, 426
 - following total hip replacement, 1217-1219
 - HCO₃⁻ effects on metabolism of, in lymphocytes, 1247-1252
 - influence of lactation stage on metabolism of, in enterocytes, 325-331
 - α -ketoglutarate and, preventing decrease in muscle free glutamine synthesis and influencing protein synthesis after total hip replacement, 1215-1222
 - oxidation, nonoxidative disposal, and kinetics of, and malnutrition due to nonneoplastic gastrointestinal diseases, 1114
 - plasma, in AIDS patients, 1162
- γ (gamma)-Glutamyl transpeptidase (γ -GTP), serum levels of, in obese children, as risk factor for development of complications, 479, 481, 482
- Glutathione (GSH) redox cycle, effects of insulin and fasting on, hydroperoxide detoxification in intestine of STZ-DM subjects and, 1462-1468
- Glycemic control, *see specific substances*
- Glycerol
 - interstitial, NE and recovery of, 1516
 - in lipid-induced insulin resistance, 641
 - plasma, exercise effects on, 682
 - serum, beef tallow diet effects on, 1273
- Glycerolipids, hepatocyte, effects of HP diet on, 21-22
- Glycine
 - effects of, on SM protein synthesis during sepsis, 1131
 - effects of overnight infusion of, on muscle proteolysis, 426
 - following total hip replacement, 1217-1219
 - plasma, *see* Plasma glycine
 - in soy protein, 1147, 1148
 - in TPN of burn patients, 660
- [¹⁵N]Glycine, measurement of VLDL apo B rates of synthesis with, serine and hippurate as precursor equivalents in, compared, 1253-1258

- Glycogen
 effects of chronic malnutrition on, 820-821
 hepatic and muscle, defective metabolism of, in neonatal and obese subjects, 1298-1302
- Glycogen phosphorylase, glibenclamide and meglitinide effects of activity of, in hepatocytes, 1000-1007
- Glycogen synthase (GS) activity
 effects of troglitazone and bezafibrate on liver, in fructose-fed subjects, 1626-1630
see also Glycogen synthase activity, muscle
- Glycogen synthase (GS) activity, muscle
 effects of fluoxetine on, in NIDDM with obesity or glucose intolerance, 1570-1576
 LCD effects on, in exercising men, 1267
 in microvascular angina, 878-879
 in NIDDM, 44-45
- Glycohemoglobin (GHb) in NIDDM, LPL and
 and changes in SM LPL activity, 787
 relation between levels of, with response of ATLPL to glucose and insulin in obese NIDDM women, 1475-1480
- N- and O-Glycosylated proteins, effects of long-term exposure to ethanol on glycosylation of, 890-897
- GMP (guanosine monophosphate), cellular cyclic, ANP and BNP effects on, after stimulation with CSA, 405
- Gonadotrope, galanin role in regulating function of somatotrope and, in young ovulatory women, 1028-1032
- Gorging, effects of nibbling versus, on cardiovascular risk factors, 549-555
- G-6-P, *see* Glucose-6-phosphate
- G-6-PD (glucose-6-phosphate dehydrogenase), insulin effects on, 1464-1465
- GPT (glutamic pyruvate transaminase), levels of serum, in obese children, as risk factor for development of complications, 479, 481, 482
- Graves' disease, hyperuricemia in hyperthyroidism due to, 207-211
- Growth
 constitutional delay of, in adolescent males, testosterone therapy of, 1013-1015
 fetal, effects of chronic maternal hypoxia on, 532-537
 tumor, anabolic steroid effects on, 445-451
see also Acromegaly; Short stature
- Growth factor(s), *see* Growth factor mRNA and entries beginning with terms: Insulin-like growth factor
- Growth factor (GF) mRNA (messenger ribonucleic acid), regulation of, in eyes of diabetic subjects, 1038-1045
- Growth hormone (GH)
 in adolescent males with constitutional delay of growth, 1014
 alcoholism suppressing response of, to sumatriptan, 1577-1580
 deficiency in, *see* Growth hormone, deficiency in
 GH-releasing activity of hexarelin, 136-138
 GHRH and, *see* Growth hormone-releasing hormone, GH and glucocorticoids and, *see* Glucocorticoids, GH and high-calorie TPN effects on, 155
 recombinant, *see* Growth hormone, therapy with
 in SCI, 55, 1117
 secretion of, *see* Growth hormone, secretion of
- Growth hormone (GH), deficiency in
 in adults, insulin resistance in, 1126-1129
see also Growth hormone, deficiency in, in children
- Growth hormone (GH), deficiency in, in children
 GH-releasing effects of GHRP-2 and GHRH in, 1199-1204
 RBC IGF-I receptor in, 923-928
- Growth hormone (GH), secretion of
 galanin effects on glucocorticoid inhibition of, 224-227
 in obesity, *see* Growth hormone, secretion of, in obesity
- Growth hormone (GH), secretion of (*Continued*)
 in prepubertal asthmatic children, short- and long-term effects of oral salbutamol on, 149-151
 by tumors, insulin resistance with, 75-84
- Growth hormone (GH), secretion of, in obesity
 effects of combined administration of GHRH, GHRP-6, and pyridostigmine on, in non-obese and obese women, 745-748
 obesity-related insulin status and blunted, in Turner's syndrome, 1033-1037
 of pulsatile GH in non-obese and obese men during energy restriction, 605-610
- Growth hormone (GH), therapy with
 effects of, on BMR in pituitary deficiency, 67-74
 effects of short-term, on lipids and Lps in men and women without GH disturbances, 725-729
- Growth hormone-binding protein (GHRP), changes in concentrations of, in normal and acromegalic subjects, effects of short-term fasting on, 667-672
- Growth hormone-releasing hormone (GHRH), GH and
 acipimox potentiating GH response to GHRH by decreasing serum FFA levels in hyperthyroidism, 1509-1512
 effects of combined administration of GHRP-6, pyridostigmine, and GHRH on GH secretion in normal and obese subjects, 745-748
- Growth hormone-releasing hormone (GHRH) 1-29NH₂, GHRP-2 and, in children with GH deficiency and idiopathic short stature, 1199-1204
- Growth hormone-releasing peptide-2 (GHRP-2), GH-releasing effects of, in GH-deficient children, 1199-1204
- Growth hormone-releasing peptide-6 (GHRP-6), effects of combined administration of GHRH, pyridostigmine and, on GH secretion in normal and obese subjects, 745-748
- GS, *see* Glycogen synthase activity
- GSA, *see* Guanidosuccinic acid in cirrhosis
- GSH (glutathione) redox cycle, effects of insulin and fasting on, hydroperoxide detoxification in intestine of STZ-DM subjects and, 1462-1468
- γ -GTP (γ -glutamyl transpeptidase), serum levels of, in obese children, as risk factor for development of complications, 479, 481, 482
- Guanidine in cirrhosis
 serum levels of, 585
 urinary excretion of, 586
- Guanidino compounds in serum and urine of cirrhotic subjects, 584-588
- Guanidinoacetic acid in cirrhosis
 serum levels of, 585
 urinary excretion of, 586
- γ (gamma)-Guanidinobutyric acid in cirrhosis
 serum levels of, 585
 urinary excretion of, 586
- Guanidosuccinic acid (GSA) in cirrhosis
 serum levels of, 585, 586
 urinary excretion of, 586
- Guanine nucleotide regulatory protein mediating D-myo-inositol 1,4,5-triphosphate modulation of RBC Ca²⁺-ATPase activity, 865-868
- Guanosine monophosphate (GMP), cellular cyclic, ANP and BNP effects on, after stimulation with CSA, 405
- Haptoglobin phenotype in parents of IDDM patients, 869-875
- Hb (hemoglobin), and hemolysis in primary LPL deficiency, 654, 655

- HbA₁** (hemoglobin A₁)
 and abundance of Na⁺/H⁺ exchanger isoform-1 in skin fibroblasts in IDDM, 792
 in CF subjects, 14
 following CABG, 1018
- HbA_{1c}** (hemoglobin A_{1c})
 fluoxetine effects on, in NIDDM subjects with obesity or glucose intolerance, 1571
 in hypertriglyceridemic subjects, 590
 in IDDM, *see* HbA_{1c} in IDDM
 and insulin sensitivity, *see* HbA_{1c}, insulin sensitivity and
 and Lp(a) in IDDM during pregnancy, 1607
 in microvascular angina, 877
 in NIDDM, *see* HbA_{1c} in NIDDM
 in normal, GH-deficient, and acromegalic children, 925
- HbA_{1c}** (hemoglobin A_{1c}), insulin sensitivity and
 impaired insulin sensitivity and HbA_{1c} levels in hypertensive and normotensive smokers, 557-561
 natural course of insulin sensitivity in early IDDM, 618
- HbA_{1c}** (hemoglobin A_{1c}) in IDDM
 in early IDDM, natural course of insulin sensitivity and, 618
 in IDDM children, 925
 with or without neuropathy, low-dose CRH stimulation test effects on, 539
- HbA_{1c}** (hemoglobin A_{1c}) in NIDDM
 in hypertensive NIDDM, 86
 with hypertriglyceridemia, 692
- HCO₃⁻** (bicarbonate), effects of, on glucose and glutamine metabolism in lymphocytes, 1247-1252
- HDL(s)**, *see* High-density lipoprotein(s)
- HDL-C**, *see* entries beginning with terms: High-density lipoprotein-cholesterol
- Healthy subjects**, *see* Normal adult subjects
- Heart**
 carnitine in, in vitamin C deficiency, 1641
 exercise and fed state effects on LPL gene expression in, 1596-1605
 high-fat diet and fasting effects on levels of acyl-CoA binding protein levels in, 1185-1189
see also Heart rate and entries beginning with term: Myocardial and element: Card-
- Heart disease**, *see* Cardiovascular disease
- Heart rate (HR)**
 in cirrhosis, effects of β -adrenergic blockers on, 903
 in elderly subjects with femoral neck fracture, 61
 exercise effects on, 1260
 of hyperinsulinemic subjects, arachidonate distribution in LDLs and thoracic aorta and, 807
 of hyperthyroidic patients, 1240
 in NIDDM with obesity or glucose intolerance, fluoxetine effects on, 1571
 resting, associated with HDL subclasses in men with CAD, 106-114
 weight loss effects on, *see* Heart rate, weight loss effects on
- Heart rate (HR)**, weight loss effects on
 on β -adrenergically mediated HR responses in obese men, 520-524
 on HR response to upright posture, 441
- Height**
 of adolescent males with constitutional delay of growth, 1014
 age and, *see* Height, age and
 arginine and proline synthesis and, 467
 and effects of fructose and glucose ingestion with and without caffeine, 631
- Height (Continued)**
 and exercise, *see* Height of exercising men; Height of exercising women
 and heparin effects on release, oxidation, and reesterification of FAs from TGs, 1591
 and insulin resistance in GH-deficient adults, 1127
 LBM and, 1443
 of obese subjects, *see* Height of obese subjects
 of pituitary deficiency subjects, 68
 of postmenopausal women on HRT, 411
 and RBC IGF-I receptor in normal, GH-deficient, acromegalic, and IDDM children, 924
 of SCI subjects, *see* Height of SCI subjects
 of TS patients, 1034
 and weight loss effects on AT distribution, 1414
 worksite ETS effects and, 1537
see also Acromegaly; Short stature
- Height, age and**
 age- and menopause-associated variations in body composition and AT distribution in healthy women and, 370
 and age-related changes in musculoskeletal mass of postmenopausal women, 31
 of middle-aged men, training status and, 342
see also Height of elderly exercising women
- Height of elderly exercising women**
 energy expenditure and, 1047
 with femoral neck fracture, 61
- Height of exercising men**
 and influence of submaximal exercise on glucose assimilation, 834
 of middle-aged men, training status, age and, 342
- Height of exercising women**
 and effects of exercise on plasma Lps and apos, 702
 and influence of submaximal exercise on glucose assimilation, 834
see also Height of elderly exercising women
- Height of obese subjects**
 of centrally obese subjects, hemostatic function and, 1418
 fasting plasma insulin level as risk factor for development of complications in obese children, 479, 482
 with NIDDM, fluoxetine effects and, 1571
 pulsatile GH secretion during fasting in obese men, 606
- Height of SCI subjects**
 insulin sensitivity and AT metabolism and, 53
 vitamin C deficiency in chronic SCI, 1613
- Hematocrit** of hypertensive and normotensive smokers, HbA_{1c} levels and insulin sensitivity in, 558
- Hemodynamics**
 hemodynamic responses to upright posture, effects of weight loss on, in obese men, 440-441
see also Blood flow; Blood pressure; Heart rate
- Hemoglobin**, *see* entries beginning with acronym: Hb
- Hemolysis** in primary LPL deficiency, 652-658
- Hemostatic function** in centrally obese young men and women, 1417-1421
- Heparin**
 effects of, on release, oxidation, and reesterification of FAs from TGs, 1590-1595
 effects of diet and weight loss on postheparin hepatic lipase in obese men with silent myocardial ischemia and reduced HDL-C, 310
- Hepatic apolipoprotein B-100 (apo B-100)**, correlation between cholesterol synthesis and secretion of, in normolipidemia, 1052-1057

- Hepatic artery, plasma glucagon concentrations in, during glucagon infusions, 455
- Hepatic branched-chain keto-acid (BCKA) dehydrogenase, effects of chronic ethanol intake on flux of, 1243-1246
- Hepatic cholesterol (C)
beta-CD effects on, 203
CHO-dietary fat exchange and regulation of metabolism of, 855-864
- Hepatic cirrhosis, *see* Cirrhosis
- Hepatic clearance of glucagon in conscious subjects, 455
- Hepatic conversion of AA nitrogen and urea synthesis in cirrhosis, β -adrenergic blocker effects on, 899-905
- Hepatic free-NAD(P)⁺-linked redox states, LPS effects on cytosolic phosphorylation potential and, during fasting, 1170-1174
- Hepatic gluconeogenesis
in DM, long-term troglitazone therapy suppressing, 487-490
IL-6 stimulating, 145-146
- Hepatic glucose-6-phosphate (G-6-P), partitioning of, and hepatic UDP-glucose synthesis, 179
- Hepatic glucose production (HGP)
and acute increase in plasma TGs, 886, 887
bromocriptine inhibiting FFA oxidation and, in obesity, 1349-1355
in early NIDDM, 759, 760
and glucagon kinetics in conscious subjects, 455-456
and persistent IGT, 1102
- Hepatic glycogen, defective metabolism of, in neonatal and obese subjects, 1298-1302
- Hepatic HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase)
beta-CD effects on, 203
dietary fat effects on, 860
- Hepatic insulin-like growth factor-I (IGF-I) mRNA, high-calorie TPN effects on, 152-160
- Hepatic insulin receptors (IRs), insulin resistance and decreased number of, with GH-secreting tumors, 75-84
- Hepatic kinase, activity of, and insulin resistance with GH-secreting tumors, 75-84
- Hepatic lipase (HL)
activity of, and protective Lp profile in premenopausal women, 491-498
in hypertension, effects of vasodilators on, 715
postheparin, effects of diet and weight loss on, in obese men with silent myocardial ischemia and reduced HDL-C, 310
- Hepatic lipids, high-calorie TPN effects on, 154
- Hepatic macrovesicular steatosis, mitochondrial KIC decarboxylation in, 699-700
- Hepatic mRNA, *see* mRNA, hepatic
- Hepatic peroxisome, clofibrate-induced proliferation of, pyruvate inhibiting, 166-171
- Hepatic resistance to insulin and glucagon during chronic malnutrition, 817-824
- Hepatic uridine diphosphoglucose (UDP-glucose), rate of entry of glucose into, in fasted and fed normal adult subjects, 172-182
- Hepatic vein, plasma glucagon concentrations in, during glucagon infusions, 455
- Hepatic very-low-density lipoproteins (VLDLs)
HP diet effects on, in obesity, 19-29
insulin sensitivity and secretion of, in fructose-fed subjects, 841-847
- Hepatocytes
fetal and adult, glucose regulation of GLUT1 mRNA and GLUT2 mRNA in, 1553-1558
- Hepatocytes (*Continued*)
glucocorticoids upregulating high-affinity HDL binding sites in, 730-738
HP diet effects on lipids of, in obesity, 20
IL-6 stimulating gluconeogenesis in, 145-146
meglitinide and glibenclamide effects on glycogen phosphorylase and F-2,6-P₂ activity in, 1000-1007
- Hepatoma cell line, role of cellular RSP in regulation of PRPP and de novo purine synthesis in, 1469-1474
- Hexarelin (his-D-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂), GH-releasing activity of, 136-138
- Hexoses, UDP, in normal subjects, in galactosemia, and in other metabolic disorders, 600-602
- HF diet, *see* High-fat diet
- HFH (homozygous familial hypercholesterolemia), pregnancy with, in patient undergoing LDL apheresis by dextran sulfate adsorption, 929-933
- HGP, *see* Hepatic glucose production
- High-affinity high-density lipoproteins (HDLs), glucocorticoids upregulating binding sites of, in hepatocytes, 730-738
- High altitude, exhaustive exercise with acute hypoxia at, ET-1 responses to, 8-9
- High-calorie total parenteral nutrition (TPN), effects of, on hepatic IGF-I mRNA and serum IGF-BPs, 152-160
- High-carbohydrate (CHO) diet, hypertriglyceridemia and insulin resistance and, 1540-1547
- High-density lipoprotein(s) (HDLs; alpha-lipoproteins)
dietary fat effects on levels of, 859
in DM with hypertension, doxazocin effects on, 674
effects of nibbling versus gorging on, 551
and hemolysis in primary LPL deficiency, 653
high-affinity, glucocorticoids upregulating binding sites of, in hepatocytes, 730-738
insulin and glucose levels, physical activity, resting HR, and regional adiposity in men with CAD associated with subclasses of, 106-114
in obesity, *see* High-density lipoprotein(s) in obesity
and persistent IGT, 1101
plasma volume effects on, during menstrual cycle, 967, 968
in postmenopausal women on HRT, 412
and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1088
n-3 PUFA effects on, 1226, 1227
in SCI, 54
serum, *see* Serum high-density lipoproteins
short-term GH therapy effects on, 726, 727
see also High-density lipoprotein-cholesterol
- High-density lipoprotein(s) (HDL) in obesity
in NIDDM with obesity or glucose intolerance, fluoxetine effects on, 1571
in obese normoinsulinemic men, 1386
with PCOS, effects of VLCD on, 613, 614
- High-density lipoprotein-cholesterol (HDL-C)
bezafibrate therapy and, 1403, 1406
cholestyramine and fluvastatin effects on, 1449, 1450
in congenital hypothyroidism, effects of L-T₄ on, 1284-1286
effects of nibbling versus gorging on, 551, 552
exercise effects on, *see* High-density lipoprotein-cholesterol, effects of exercise on
and fasting serum insulin in metabolic syndrome, 36-38
following CABG, 1018
in hypercholesterolemic subjects, 399, 400
in hypertension, effects of vasodilators on, 715
of hyperthyroidic subjects before and after subtotal thyroidectomy, 5

High-density lipoprotein-cholesterol (HDL-C) (*Continued*)

- in hypertriglyceridemia, *see* High-density lipoprotein-cholesterol in hypertriglyceridemia
- insulin propeptides and, 1483
- levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919
- low-dose pravastatin effects on, 1411
- low-fat, high-fiber diet effects on, 750-754
- LPL and HL activity and levels of, sex differences in, 493, 494
- in men with CAD, 108
- in nonsmoking women, effects of worksite ETS on, 1537
- in normolipidemic subjects, 1053
- in obesity, *see* High-density lipoprotein-cholesterol in obesity
- plasma, *see* Plasma high-density lipoprotein-cholesterol
- postprandial response of, to high- and low-fiber diets, 849-851
- in pregnancy with HFH treated by dextran sulfate LDL apheresis, 931
- n-3 PUFA effects on, 1225
- L-thyroxine effects on, in hypothyroidism, 1561
- see also* High-density lipoprotein₂-cholesterol; High-density lipoprotein₃-cholesterol
- High-density lipoprotein-cholesterol (HDL-C), effects of exercise on
 - effects of brisk walking by sedentary middle-aged women on, 394
 - by fertile women, 703
- High-density lipoprotein-cholesterol (HDL-C) in hypertriglyceridemia
 - in borderline hypertriglyceridemia, 1294, 1295
 - with and without CV disease, postprandial responses of, 1086
 - with NIDDM, 692
- High-density lipoprotein-cholesterol (HDL-C) in obesity
 - in centrally obese subjects, hemostatic function and, 1418
 - in obese children, as risk factor for development of complications, 479, 482
 - in obese men with silent myocardial ischemia and reduced levels of, effects of diet and weight loss on Lp levels in, 307-314
- High-density lipoprotein₂-cholesterol (HDL₂-C)
 - effects of exercise by fertile women on, 703
 - effects of plasma volume on, during menstrual cycle, 967, 968
 - in hypertension, effects of vasodilators on, 715
 - LPL and HL activity and levels of, sex differences in, 493, 494
 - postprandial response of, to high-fiber and low-fiber diets, 849-851
 - in pregnancy with HFH treated by dextran sulfate LDL apheresis, 931
- High-density lipoprotein₃-cholesterol (HDL₃-C)
 - effects of exercise by fertile women on, 703
 - effects of plasma volume on, during menstrual cycle, 967, 968
 - LPL and HL activity and levels of, sex differences in, 493, 494
 - postprandial response of, to high-fiber and low-fiber diets, 849-851
 - in pregnancy with HFH treated by dextran sulfate LDL apheresis, 931
- High-fat (HF) diet
 - effects of fasting and, on levels of acyl-CoA binding protein in liver, kidney, and heart, 1185-1189
 - high-sucrose, effects of, on development of obesity and diabetes mellitus, 645-651
 - hypertriglyceridemia and insulin resistance and, 1540-1547
 - and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1058-1066
 - varying in FA composition, differential effects of, on efficiency of lean and fat tissue deposition during weight recovery following low food intake, 273-279

High-fiber diet

- low-fat, changes in plasma Lp concentrations in response to, associated with changes in serum estrogen in premenopausal women, 749-756
- postprandial serum glucose, insulin, and Lp responses to, 848-854
- High-protein (HP) diet, effects of, on hepatic VLDLs in obese subjects, 19-29
- High-sucrose, high-fat diet, effects of, on development of obesity and DM, 646-651
- Hip replacement, total, α -ketoglutarate and glutamine preventing decrease in concentration of muscle free glutamine and influencing protein synthesis after, 1215-1222
- Hippurate, serine and, compared as precursor equivalents during [¹⁵N]glycine measurement of VLDL apo B rates of synthesis, 1253-1258
- His-D-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ (hexarelin), GH-releasing activity of, 136-138
- Histidine
 - effects of, on SM protein synthesis during sepsis, 1131
 - following total hip replacement, 1217-1219
 - plasma, *see* Plasma histidine
 - in soy protein, 1147, 1148
 - in TPN of burn patients, 660
- HIV (human immunodeficiency virus) infection, *see* AIDS
- HL, *see* Hepatic lipase
- HLA (human leukocyte antigen) in parents of IDDM patients, 872, 873
- HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A), *see* Hepatic HMG-CoA reductase; HMG-CoA synthase
- HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, *see* Fluvastatin; Lovastatin; Pravastatin; Simvastatin
- HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) synthase, relationship of hepatic mRNA level with metabolism of plasma LDL apo B and, 1060, 1061, 1065
- Homeostasis, adaptation in glucose, during chronic malnutrition, 817-824
- Homoarginine in cirrhosis
 - serum levels of, 585
 - urinary excretion of, 586
- Homozygous familial hypercholesterolemia (HFH), pregnancy with, in patient undergoing LDL apheresis by dextran sulfate adsorption, 929-933
- Homozygous β (beta)-thalassemia, hyperinsulinemia and insulin resistance in, 281-286
- Hormonal replacement therapy (HRT), continuous low-dosage, effects of, on Lp metabolism in postmenopausal women, 410-417
- Hormone(s), *see* Circulating hormones; Hormonal replacement therapy and specific hormones
- Hormone-sensitive lipase (HSL), regulation of, in STZ-DM, 1391-1396
- HP (high-protein) diet, effects of, on hepatic VLDLs in obese subjects, 19-29
- HR, *see* Heart rate
- HRT (hormonal replacement therapy), continuous low-dosage, effects of, on Lp metabolism in postmenopausal women, 410-417
- HSL (hormone-sensitive lipase), regulation of, in STZ-DM, 1391-1396
- Human immunodeficiency virus infection, *see* AIDS
- Human leukocyte antigen (HLA) in parents of IDDM patients, 872, 873

- Hydroperoxide detoxification in intestine of STZ-DM subjects, effects of insulin and fasting on GSH redox cycle and, 1462-1468
- 3- β (beta)-Hydroxy-5-androsten-17-one, *see* Dehydroepiandrosterone
- β (beta)-Hydroxybutyrate (OHB)
in diabetic ketoacidosis, 288
LPS effects on, 1171
plasma, in elderly subjects with femoral neck fracture, 61
- 3-Hydroxy-methylglutaryl-coenzyme A, *see* Hepatic HMG-CoA reductase; HMG-CoA synthase
- 3-Hydroxy-methylglutaryl-coenzyme A reductase inhibitors, *see* Fluvastatin; Lovastatin; Pravastatin; Simvastatin
- 25-hydroxyvitamin D [25(OH)D]
in chronic SCI, 1612-1618
testosterone effects on, in adolescent male hypogonadism, 420-421
- Hypercholesterolemia**
familial, *see* Familial hypercholesterolemia
induced by methionine deficiency in subjects fed soy protein, 1146-1152
isolated and combined with hypertriglyceridemia, mononuclear cell adhesion to endothelial cells in, 374-378
primary, serum retinol in, with 2 years of cholesterol-lowering therapy, 398-403
- Hyperglycemia**
response to GLP-1(7-37) in, 1232-1234
urinary excretion of C-peptide facilitated by, by increasing glomerular filtration rate in NIDDM, 1194-1198
young obese subjects with, insulin secretion in, 906-913
- Hyperglycemic factor**, *see* Glucagon
- Hyperinsulinemia**
arachidonate distribution in LDLs and thoracic aorta in, 806-811
chronic, IGF-I and IGF-I receptor gene expression in kidney, 982-986
in diabetic cirrhosis, proinsulin and des-31,32-proinsulin contribution to, 254-260
effects of, on lipogenic enzymes and GLUT4 mRNA expression in liver and AT, 218-233
in first-degree relatives of NIDDM patients, 1278-1282
insulin resistance and, in homozygous β -thalassemia, 281-286
mental stress effects on glucose uptake during, 1303-1307
in nondiabetic subjects, *see* Nondiabetic subjects, hyperinsulinemia in
- Hyperlipidemia**
sex and development of atherosclerosis and, 1326-1331
see also specific hyperlipidemic conditions
- Hyperlipoproteinemia**
nonfamilial, low-dose pravastatin effects on bile acid composition and biliary lipids in, 1410-1412
simvastatin and gemfibrozil effects on, 212-217
type III, with FH, 460-465
- Hypertension**
diet-induced, pioglitazone effects on, 1105-1109
factors affecting LPL activity in, 712-718
and persistent IGT, 1101
in pregnancy, erythrocyte insulin and IGF-I receptor tyrosine kinase activity in, 1308-1313
spontaneous, beta cell function and replication in, 1360-1364
see also Diabetes mellitus with hypertension; Hypertension, insulin sensitivity and
- Hypertension, insulin sensitivity and**
amlodipine effects on insulin sensitivity for glucose metabolism in essential hypertension, 315-319
- Hypertension, insulin sensitivity and (Continued)**
doxazosin improving peripheral insulin sensitivity in DM with hypertension, 673-676
glucose storage and insulin sensitivity improved with enalapril in NIDDM with hypertension, 85-88
HbA_{1c} levels and impaired insulin sensitivity in hypertensive smokers, 557-561
- Hyperthyroidism**
acipimox potentiating GH response to GHRH by decreasing serum FFA levels in, 1509-1512
due to Graves' disease, hyperuricemia in, 207-211
plasma ET-1 in, 1239-1242
serum Lp(a) levels before and after subtotal thyroidectomy for, 4-7
- Hypertriglyceridemia**
with and without CV disease, postprandial Lp responses in, 1082-1098
hypercholesterolemia combined with, mononuclear cell adhesion to endothelial cells in, 374-378
and insulin resistance, high-CHO diet and, 1540-1547
insulin sensitivity and, 883-889
mild, gemfibrozil decreasing TG levels in, without affecting glucoregulatory or antilipolytic effects of insulin in nondiabetic subjects with, 589-596
in NIDDM, *see* Hypertriglyceridemia in NIDDM
- Hypertriglyceridemia in NIDDM**
Lp(a) in, *see* Lipoprotein(a), NIDDM with hypertriglyceridemia and
TNF- β polymorphism associated with, 691-694
- Hyperuricemia in hyperthyroidism due to Graves' disease**, 207-211
- Hypocaloric diet**, *see* Calorie restriction
- Hypoglycemia**, ET-1-induced, NMLA and somatostatin effects on, 1532-1535
- Hypoglycemic agents**, *see specific substances*
- Hypogonadism**
in AIDS, 947-948
in male adolescents, testosterone effects on bone density and bone metabolism in, 419-423
- Hypoinsulinemia, chronic**, IGF-I and IGF-I receptor gene expression in kidney in, 982-986
- Hypothalamus**, beef tallow diet effects on NE turnover rate in cerebral cortex and, 1377-1379
- Hypothalamus-pituitary axis**, suppression of, in men with SCI, 1116-1120
- Hypothyroidism**
renal and thyroid function in, 208, 209
L-thyroxine effects on, *see* L-Thyroxine effects in hypothyroidism
- Hypoxia**
acute, exhaustive exercise at high altitude with, ET-1 responses to, 8-9
chronic maternal, effects of, on fetal growth and glucose utilization by fetal tissues, 532-537
- ICA (islet cell antibody) in parents of IDDM patients**, 869-875
- IDDM**, *see* Insulin-dependent diabetes mellitus
- Ideal body weight**, effects of weight loss to, on AT distribution, 1413-1416
- Identical twins**, long-term overfeeding of, plasma glucose, insulin, and glucagon in, 96-105
- Idiopathic short stature**, GHRP-2 and GHRH in children with GH deficiency and, 1199-1204
- IGF**, *see* Insulin-like growth factor-I; Insulin-like growth factor-II
- IGF-BC (insulin-like growth factor-binding capacity)**, and pulsatile GH secretion in non-obese and obese women during fasting, 607, 608

- IGFBPs, *see* Insulin-like growth factor-binding protein(s)
- IGT, *see* Impaired glucose tolerance
- IL-6 (interleukin-6), gluconeogenesis in hepatocytes stimulated by, 145-146
- Immune function, sex hormones and, in AIDS, 950-951
- Immunoreactivity, GLUT4, dexamethasone and PSL effects on, 304
- Impaired glucose tolerance (IGT)
- CF with, tolbutamide effects on insulin secretion in, 13-18
 - in NIDDM, *see* Impaired glucose tolerance in NIDDM
 - risk of DM and, in first postoperative year following CABG, 1016-1027
 - weight loss by middle-aged and older men with, reduces abdominal AT and improves insulin action, 1502-1508
 - see also* Intravenous glucose tolerance test; Oral glucose tolerance test and specific conditions
- Impaired glucose tolerance (IGT) in NIDDM
- metabolic defects in persistent, related to familial NIDDM, 1099-1104
 - serum insulin level and, 1371-1376
- Infrared spectroscopy, Fourier gas-phase, doubly labeled water determination by, 1-3
- Injury, *see* Trauma and injury
- Inosine, plasma, effects of ethanol on, 781-782
- Inositol, galactose and concentration of, in lens, 1528
- Ins(1,2,5)P₃ (D-myo-inositol 1,4,5-triphosphate), modulation of Ca²⁺-ATPase activity in, guanine nucleotide regulatory protein mediating, 865-868
- Insulin
- adrenoceptor antagonists and, 248
 - in AIDS patients, 1567
 - antilipolytic effects of, *see* Antilipolytic effects of insulin
 - association of insulin propeptides and, with atherogenic Lp phenotype, 1481-1488
 - in cirrhosis, effects of β -adrenergic blockers on, 901
 - effects of nibbling versus gorging on, 551
 - exercise and, *see* Insulin, exercise and
 - fasting, *see* Fasting insulin
 - following total hip replacement, 1217, 1221
 - glucagon and, *see* Insulin, glucagon and
 - hepatic resistance to, during chronic malnutrition, 817-824
 - in hypertension, effects of vasodilators on, 715
 - NE and, in regulation of lipolysis, microdialysis in study of, 1513-1518
 - in non-obese men, effects of moderate calorie restriction on, 1549, 1550
 - in obesity, *see* Insulin, obesity and
 - oral vanadyl effects on, 334
 - pioglitazone effects on, 1106
 - plasma, *see* Plasma insulin
 - and pulsatile GH secretion during fasting, 606
 - serum, *see* Serum insulin
 - SM and, *see* Insulin, SM and
 - troglitazone effects on action of, in normal subjects, 1166-1169
 - weight loss by middle-aged and older men with IGT reducing abdominal AT and improving action of, 1502-1508
 - see also* Diabetes mellitus; Insulin mRNA; Insulin receptor(s); Insulin release and secretion; Insulin resistance; Insulin sensitivity; Insulinemia; Normoinsulinemic men; Proinsulin and entries beginning with terms: Insulin-like growth factor, Insulinotropic
- Insulin, exercise and
- effects of brisk walking by sedentary middle-aged women on, 393
 - HDL subclasses in men with CAD associated with physical
- Insulin, exercise and (*Continued*)
- activity, resting HR, regional adiposity, and levels of, 106-114
 - in starved exercising subjects, 1334
- Insulin, glucagon and
- cephalic-phase insulin and glucagon release in normal subjects and in recipients of pancreas transplantation, 1153-1158
 - and glucagon kinetics in conscious subjects, 454
 - insulin effects on glucopenia-induced glucagon secretion, 358-362
- Insulin, obesity and
- and blunted GH secretion in Turner's syndrome, 1033-1037
 - captopril effects on insulin-stimulated glucose transport in SM in obesity, 268-270
 - fasting plasma insulin level as risk factor for development of complications in obese children, 478-485
 - insulin secretion in young obese hyperglycemic subjects, 906-913
 - weight loss effects on insulin in older obese men, 438-444
 - see also* Insulin in obese women; Insulin resistance in obesity
- Insulin, SM and
- captopril effects on insulin-stimulated glucose transport in SM of obese subjects, 268-270
 - changes in LPL activity in SM in response to insulin and glucose in NIDDM, 786-790
 - insulin effects on skeletal muscle DAG, 348-357
 - prednisolone and dexamethasone effects on PKC activation in SM induced by insulin, 298-306
 - see also* Insulin, SM protein and
- Insulin, SM protein and
- increased abundance of SM PTPases and, in insulin-resistant obesity and in DM, 1175-1184
 - modulation of SM protein synthesis by AAs and insulin during sepsis, 1130-1138
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
- athymic subjects injected with PBMCs from subjects with, insulin secretion by pancreas of, 1435-1441
 - children with, RBC IGF-I receptor in, 923-928
 - early, natural course of insulin sensitivity in, 617-623
 - Lp(a) in, during pregnancy, 1606-1611
 - with nephropathy, abundance of Na⁺/H⁺ exchanger isoform-1 in skin fibroblasts in, 791-795
 - with or without neuropathy, low-dose CRH stimulation test in, 538-542
 - plasma Cp in, and oxidative stress, 996-999
 - relationship between NIDDM and, 869-875
- Insulin-like growth factor-I (IGF-I)
- in acromegalic subjects, 380
 - in adolescent males with constitutional delay of growth, 1014
 - chromium effects on response of, to glucose, 1314-1320
 - circulating, effects of ethanol on, 1356-1359
 - expression of, in kidney in chronic hypoinsulinemia and hyperinsulinemia, 982-986
 - in men with SCI, 1117
 - in pituitary deficiency subjects, 70, 71
 - and pulsatile GH secretion in non-obese and obese men during fasting, 607, 608
 - testosterone effects on, in adolescent male hypogonadism, 420-421
 - in TS, 1034
 - see also* entries beginning with terms: Insulin-like growth factor-I
- Insulin-like growth factor-I (IGF-I) mRNA (messenger ribonucleic acid), hepatic, high-calorie TPN effects on, 152-160
- Insulin-like growth factor-I (IGF-I) receptor, RBC, in normal, acromegalic, GH-deficient, and IDDM children, 923-928

- Insulin-like growth factor-I (IGF-I) receptor gene, expression of, in kidney in chronic hypoinsulinemia and hyperinsulinemia, 982-986
- Insulin-like growth factor-I (IGF-I) receptor tyrosine kinase, activity of, in hypertensive pregnancy, 1308-1313
- Insulin-like growth factor-II (IGF-II), and pulsatile GH secretion in non-obese and obese men during fasting, 607, 608
- Insulin-like growth factor-binding capacity (IGF-BC), and pulsatile GH secretion in non-obese and obese men during fasting, 607, 608
- Insulin-like growth factor-binding protein(s) [IGFBP(s)] and pulsatile GH secretion in non-obese and obese men during fasting, 607, 608
- serum, *see* Serum insulin-like growth factor-binding proteins
- see also* Insulin-like growth factor-binding protein-1; Insulin-like growth factor-binding protein-3
- Insulin-like growth factor-binding protein-1 (IGFBP-1), effects of ethanol on circulating, 1356-1359
- Insulin-like growth factor-binding protein-3 (IGFBP-3), plasma, in acute trauma, 1205-1208
- Insulin mRNA (messenger ribonucleic acid), age-related changes in, 322
- Insulin in obese women
- with NIDDM, relationship between GHb levels and response of AT LPL to glucose and, 1475-1480
- with PCOS, effects of VLCD on, 613, 614
- Insulin propeptides, relationship of insulin and, to atherogenic Lp phenotype, 1481-1488
- Insulin receptor(s) (IRs)
- activity of RBC, in hypertensive pregnancy, 1308-1313
- autophosphorylation of, *see* Autophosphorylation, IR
- hepatic, insulin resistance and decreased number of, with GH-secreting tumors, 75-84
- see also* Insulin receptor gene; Insulin receptor kinase activity
- Insulin receptor (IR) gene, cDNA amplification in analysis of promoter region of, in leprechaunism with severe insulin resistance, 430-437
- Insulin receptor (IR) kinase activity
- fluoxetine effects on, in NIDDM with obesity or glucose intolerance, 1570-1576
- reduced, and amylin-mediated reduction in insulin sensitivity, 705-711
- Insulin release and secretion, changes in insulin action and, following protein and calorie restriction, 1519-1526
- ET-1 effects on, *see* Endothelin-1, insulin release and
- and glucose transport in pancreatic islets, 262-263
- impaired, as primary etiology in NIDDM, 940-945
- in insulin resistance in patient with history of GDM, 1067-1073
- in obesity, *see* Insulin release and secretion in obesity
- by pancreas of athymic subjects injected with PBMNCs from IDDM subjects, 1435-1441
- salmon calcitonin and, 1586
- tolbutamide effects on, in CF patients with impaired glucose tolerance, 13-18
- Insulin release and secretion in obesity, 1397-1400
- in young obese hyperglycemic subjects, 906-913
- Insulin resistance
- of aging, intraabdominal AT contribution to, 954-959
- associated with abnormal dephosphorylation of phosphopeptide corresponding to autophosphorylation site of IR, 1074-1081
- dietary fat-induced, effects of troglitazone on, 1489-1494
- in GH-deficient adults, 1126-1129
- GH-secreting tumors and, hepatic kinase activity and, 75-84
- hepatic, during chronic malnutrition, 817-824
- Insulin resistance (*Continued*)
- and history of GDM, insulin secretion and, 1067-1073
- hyperinsulinemia and, in homozygous B-thalassemia, 281-286
- and hypertriglyceridemia, high-CHO diet and, 1540-1547
- leprechaunism with severe, cDNA amplification in analysis of promoter region of IR gene in, 430-437
- lipid-induced, role of plasma NEFA oxidation and total lipid oxidation in, 639-644
- in microvascular angina, 876-882
- in obesity, *see* Insulin resistance in obesity
- oral (-)-BM 13.0913.Na effects on, in lean subjects, 577-584
- as primary etiology in NIDDM, 940-945
- PTPases and, *see* Protein-tyrosine phosphatases, insulin resistance and
- in STZ-DM with malnutrition, 1422-1427
- see also* Insulin sensitivity
- Insulin resistance in obesity
- in adipocytes of obese women, effects of AT distribution and race on, 987-995
- increased abundance of SM PTPases in, 1175-1184
- oral (-)-BM 13.0913.Na effects on, 577-584
- Insulin sensitivity
- and acute insulin response to glucose, measurement of, 1121-1125
- amylin-mediated reduction in, and reduced IR kinase activity, 705-711
- AT and, *see* Adipose tissue, insulin sensitivity and
- changes in glucose effectiveness, B-cell function and, in regularly exercising men, 1259-1263
- in early IDDM, natural course of, 617-623
- effects of weight loss by IGT subjects on, 1504-1505
- gemfibrozil and simvastatin effects on, in hyperlipoproteinemia, 212-217
- HbA_{1c} and, *see* HbA_{1c}, insulin sensitivity and
- and hepatic VLDL secretion in fructose-fed subjects, 841-847
- hypertension and, *see* Hypertension, insulin sensitivity and
- hypertriglyceridemia and, 883-889
- in NIDDM, *see* Non-insulin-dependent diabetes mellitus, insulin sensitivity in
- in obesity, 1397-1400
- in PCOS, *see* Polycystic ovary syndrome, insulin sensitivity in
- peripheral, *see* Peripheral insulin sensitivity
- see also* Insulin resistance
- Insulinemia
- adiposity and, 111
- brisk walking effects on, in sedentary middle-aged women, 390-397
- see also* Hyperinsulinemia; Hypoinsulinemia
- Insulinotropic action of glicentin, 47-51
- Interleukin-6 (IL-6), hepatic gluconeogenesis stimulated by, 145-146
- Interorgan amino acid (AA) flow between muscle and small intestine, role of membrane transport in, 719-724
- Interstitial glycerol, NE and recovery of, 1516
- Intestine
- hydroperoxide detoxification in, of STZ-DM subject, effects of insulin and fasting on GSH redox cycle and, 1462-1468
- small, interorgan AA flow between muscle and, role of membrane transport in, 719-724
- Intra-abdominal adipose tissue (AT), contribution of, to insulin resistance of aging, 954-959
- Intracellular glucose
- LCD effects on, in exercising men, 1264-1270
- role of basal insulin in maintenance of metabolic pathways of, in NIDDM, 41-46

- Intrauterine growth retardation (IUGR), chronic maternal hypoxia and, 532-537
- Intravascular lipolysis of VLDLs, n-3 PUFA effects on, 1223-1230
- Intravenous glucose tolerance test (IVGTT)
in CF, 13-18
chromium effects on, 1314-1320
frequently sampled, *see* Frequently sampled intravenous glucose tolerance test
- IR(s), *see* Insulin receptor(s)
- Iron (Fe) in beta-thalassemia patients, 282
- Ischemia, silent myocardial, obese men with reduced HDL-C and, effects of diet and weight loss on Lp levels in, 307-314
- Islet cell antibody (ICA) in parents of IDDM patients, 869-875
- Isoleucine
effects of, on SM protein synthesis during sepsis, 1131
effects of overnight infusion of, on muscle proteolysis, 426
following total hip replacement, 1217-1219
plasma, *see* Plasma isoleucine
in soy protein, 1147, 1148
in TPN of burn patients, 660, 661
- Isoprenaline (ISO), thermogenic and heart rate responses mediated by, obesity and weight loss effects on, 520-524
- Isoproterenol, adenylate cyclase response to, in obesity and after weight loss, 1291
- IUGR (intrauterine growth retardation), chronic maternal hypoxia and, 532-537
- IVGTT, *see* Intravenous glucose tolerance test
- Japanese children, obese, fasting plasma insulin level as risk factor for development of complications in, 478-485
- K (potassium)
plasma, in elderly subjects with femoral neck fracture, 61
serum, *see* Serum K
total body, and age-related changes in musculoskeletal mass, 31-33
- KBs, *see* Ketone bodies
- Keto-acid dehydrogenase, hepatic branched-chain, effects of chronic ethanol intake on flux of, 1243-1246
- Ketoacidosis, diabetic, increased serum D-lactate associated with, 287-290
- α (alpha)-Ketoglutarate
glutamine and, preventing decrease in muscle free glutamine synthesis and influencing protein synthesis after total hip replacement, 1215-1222
LPS effects on, 1171
- α (alpha)-Keto- δ -guanidinovaleic acid in cirrhosis
serum levels of, 585
urinary excretion of, 586
- Ketoisocaproic acid (KIC), mitochondrial, decarboxylation of, in hepatic macrovesicular hepatic steatosis, 699-700
- Ketone(s), plasma, in elderly subjects with femoral neck fracture, 61
- Ketone bodies (KBs)
in lipid-induced insulin resistance, 641
response of, to amlopidine in essential hypertension, 316
- KIC (ketoisocaproic acid), mitochondrial, decarboxylation of, in hepatic macrovesicular hepatic steatosis, 699-700
- Kidney
effects of high-fat diet and fasting on levels of acyl-CoA binding protein levels in, 1185-1189
expression of IGF-I and IGF-I receptor gene in, in chronic hypoinsulinemia and hyperinsulinemia, 982-986
see also Nephropathy and entries beginning with term: Renal
- Kinase
activity of hepatic, and insulin resistance with GH-secreting tumors, 75-84
6-phosphofructo-1-, effects of troglitazone on, in DM, 488, 489
reduced activity of IR, and amylin-mediated reduction in insulin sensitivity, 705-711
tyrosine, *see* Tyrosine kinase
see also Glucokinase mRNA; Protein kinase C
- Kinetics
apo B, HRT effects on, 413, 414
glucagon, in conscious subjects, 452-459
glucose, *see* Kinetics, glucose
glutamine, and malnutrition due to non-neoplastic gastrointestinal diseases, 1114
leucine, *see* Kinetics, leucine
phenylalanine, during BCAA infusion, 427
- Kinetics, glucose
fish oil effects on, 1368
following calorie and dietary protein restriction, 1523
- Kinetics, leucine
during BCAA infusion, 427
during fasting and after TPN of elderly subjects with femoral neck fracture, 64
plasma arginine and, and urea production rates in burn patients, 659-666
- Lactate
adrenoceptor antagonists and, 248
exercise and, *see* Lactate, exercise and
and glucose and glutamine metabolism in enterocytes, 327, 328
LPS effects on, 1171
plasma, *see* Plasma lactate
serum, *see* Serum lactate; Serum D-lactate
- Lactate, exercise and
LCD effects on, in exercising men, 1267
in starved exercising subjects, 1334
- D-Lactate, serum, in diabetic ketoacidosis, 287-290
- Lactation stage, influence of, on glucose and glutamine metabolism in enterocytes, 325-331
- Lactic acid
ethanol effects on, 782, 783
fetal and maternal, maternal chronic hypoxia and, 534
- Lactose, effects of diet low in, on UDP-hexose levels, 601-602
- LBM, *see* Lean body mass
- LCAT, *see* Lecithin-cholesterol acyltransferase
- LCD (low-carbohydrate diet), effects of, on intracellular glucose, in exercising men, 1264-1270
- LDL(s), *see* Low-density lipoprotein(s)
- LDL-C, *see* Low-density lipoprotein-cholesterol
- Lean body mass (LBM)
and insulin resistance in GH-deficient adults, 1127
in NIDDM with obesity or glucose intolerance, fluoxetine effects on, 1571
in twins, 1442-1446
and weight loss effects on AT distribution, 1414, 1415
- Lean subjects, *see* Non-obese subjects
- Lean tissue
differential effects of HF diet varying in FAs on efficiency of deposition of, during weight recovery following low food intake, 273-279
see also Fat-free mass; Lean body mass
- Lecithin-cholesterol acyltransferase (LCAT)
in cirrhosis, 825-829
plasma, dietary fat effects on, 860

- Lecithin-cholesterol acyltransferase (LCAT) (*Continued*)
and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086
- Lens, galactitol 2-phosphate and galactitol 3-phosphate in, galactose and, 1527-1531
- Leprechaunism with severe insulin resistance, cDNA amplification in analysis of promoter region of IR gene in, 430-437
- Leucine
effects of, on SM protein synthesis during sepsis, 1131
effects of long-term ethanol exposure on, 893
effects of overnight infusion of, on muscle proteolysis, 426, 427
flux of, and malnutrition due to non-neoplastic gastrointestinal diseases, 1114
following total hip replacement, 1217-1219
interorgan flow of, between muscle and small intestine, 721, 722
kinetics of, *see* Kinetics, leucine
plasma, and effects of fructose and glucose ingestion with and without caffeine, 635
in soy protein, 1147, 1148
- Leukocytes, *see* White blood cell count and specific types of leukocytes
- Leydig cells, steroidogenesis in, NO as interstitial regulator of, 234-238
- LF (low-fat) diet, and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1058-1066
- LH (luteinizing hormone) in men with SCI, 1117
- Lipase, *see* Hepatic lipase; Hormone-sensitive lipase; Lipoprotein lipase
- Lipectomy, long-term effects of dexamethasone and, on visceral AT and metabolic variables, 1631-1638
- Lipids
altered composition of, and differential changes in activities of RBC membrane-bound enzymes in hepatic cirrhosis, 825-832
biliary, low-dose pravastatin effects on bile acid composition and, in nonfamilial hyperlipoproteinemia, 1410-1412
blood, *see* Blood lipids
in congenital hypothyroidism, effects of L-T₄ on, 1284-1286
effects of brisk walking by sedentary middle-aged women on, 393
effects of short-term GH therapy on, in men and women without GH disturbances, 725-729
fasting, bezafibrate therapy effects on, 1403-1405, 1407
hepatic, high-calorie TPN effects on, 154
hepatocyte, HP diet effects on, in obesity, 20
levels of, following CABG, 1017
metabolism of, in microvascular angina, 878
oxidation, *see* Oxidation, lipid
plasma, *see* Plasma lipids
role of plasma NEFA oxidation and total oxidation of, in lipid-induced insulin resistance, 639-644
serum, *see* Serum lipids
in STZ-DM, 1392
see also Antilipolytic effects; Dietary fats; Fatty acids; Glycerolipids; Hyperlipidemia; Normolipidemia; Phospholipid(s); Steroid(s) entries beginning with element: Lip- and specific lipids
- Lipogenesis, meal frequency influence on, 218-223
- Lipogenic enzymes, hyperinsulinemia effects on, 218-223
- Lipolysis
insulin and NE in regulation of, microdialysis in study of, 1513-1518
intravascular, of VLDLs, n-3 PUFA effects on, 1223-1230
see also Antilipolytic effects; Lipolytic activities
- Lipolytic activities
of β -adrenergic receptor in AT, beef tallow decreasing, 1271-1277
- Lipolytic activities (*Continued*)
see also specific substances
- Lipopolysaccharide (LPS), effects of, on hepatic free-NAD(P)⁺-linked redox states and cytosolic phosphorylation potential during fasting, 1170-1174
- Lipoprotein (Lp)
effects of brisk walking by sedentary middle-aged women on, 393
cholestyramine and fluvastatin effects on particles of, compared, 1447-1454
continuous low-dosage HRT effects on metabolism of, in postmenopausal women, 410-417
diet and weight loss effects on levels of, in obese men with silent myocardial ischemia and reduced HDL-C, 307-314
fasting, bezafibrate therapy effects on, 1403-1405, 1407
HL activity and protective profile of, in premenopausal women, 491-498
LPL activity and, *see* Lipoprotein lipase activity, Lps and plasma, *see* Plasma lipoproteins
PP responses of, *see* Lipoprotein, PP responses of
n-3 PUFA effects on, 1226
serum, *see* Serum lipoprotein(s)
short-term GH therapy effects on, in men and women without GH disturbances, 725-729
susceptibility of, to peroxidation potentiated by methionine deficiency in subjects fed soy protein, 1146-1152
L-thyroxine effects on fractions of, in hypothyroidism, 1559-1563
see also Chylomicrons; High-density lipoprotein(s); Hyperlipoproteinemia; Lipoprotein(a); Lipoprotein lipase; Lipoprotein phenotype; Low-density lipoprotein(s); Very-low-density lipoprotein(s) and specific apolipoproteins
- Lipoprotein (Lp), PP responses of
to bezafibrate therapy, 1403-1405
in hypertriglyceridemia with and without CV disease, 1082-1098
of serum Lps to high- and low-fiber diets, 848-854
- Lipoprotein(a) [Lp(a)]
in centrally obese subjects, hemostatic function and, 1418
in hypothyroidism, *see* Lipoprotein(a) in hypothyroidism, L-T₄ effects on
in IDDM during pregnancy, 1606-1611
in NIDDM with hypertriglyceridemia, *see* Lipoprotein(a), NIDDM with hypertriglyceridemia and
in postmenopausal women on HRT, 411
serum levels of, before and after subtotal thyroidectomy for hyperthyroidism, 4-7
short-term GH therapy effects on, 726-729
- Lipoprotein(a) [Lp(a)], NIDDM with hypertriglyceridemia and with borderline hypertriglyceridemia, 1293-1297
TNF- β polymorphism and, 692
- Lipoprotein(a) ([Lp(a)]) in hypothyroidism, L-T₄ effects on, 1559-1563
in congenital hypothyroidism, 1284-1286
- Lipoprotein lipase (LPL)
activity of, *see* Lipoprotein lipase activity
effects of exercise and fed state on expression of gene of, in AT, heart, and skeletal muscle, 1596-1605
hemolysis in primary LPL deficiency, 652-658
n-3 PUFA effects on, 1227-1228
see also Glycohemoglobin in NIDDM, LPL and
- Lipoprotein lipase (LPL) activity
changes in SM, in response to insulin and glucose in NIDDM, 786-790
factors affecting, in hypertension, 712-718
Lps and, *see* Lipoprotein lipase activity, Lps and
postheparin, effects of diet and weight loss on, in obese men with silent myocardial ischemia and reduced HDL-C, 310

- Lipoprotein lipase (LPL) activity (*Continued*)
 simvastatin and gemfibrozil effects on, 215
- Lipoprotein lipase (LPL) activity, Lps and
 and postprandial Lp responses in hypertriglyceridemia with and
 without CV disease, 1086
 and protective Lp profile in premenopausal women, 491-498
- Lipoprotein (Lp) phenotype, atherogenic, association of insulin
 and insulin propeptides with, 1481-1488
- Liver
 carnitine in, in vitamin C deficiency, 1641
 effects of high-fat diet and fasting on levels of acyl-CoA binding
 protein levels in, 1185-1189
 effects of troglitazone and bezafibrate on GS activity in, in
 fructose-fed subjects, 1626-1630
 hyperinsulinemia effects on GLUT4 mRNA expression and
 lipogenic enzymes in, 228-233
 of NIDDM subjects, pioglitazone and insulin sensitization in,
 384-389
 T₃ effects on, *see* Liver, T₃ effects on
 weight of, *see* Liver weight
see also entries beginning with element: Hepat-
- Liver, T₃ effects on
 on liver mitochondrial AdNT activity, 197
 on substrate cycling between malic enzyme and pyruvate carbox-
 ylase, 1380-1383
- Liver weight
 effects of long-term ethanol exposure on, 892
 in GH-secreting tumors, 77
 high-calorie TPN effects on, 154
 and soy protein diet, 1148
 troglitazone and bezafibrate effects on, in fructose-fed subjects,
 1627
 zinc deficiency and, 129
- Long-term effects
 of aerobic exercise and energy restriction on protein synthesis,
 188-192
 of captopril on insulin-stimulated glucose transport in SM of
 obese subjects, 269-270
 of ethanol exposure on glycosylation of N- and O-glycosylated
 proteins, 890-897
 of fluoxetine on glycemic control in NIDDM with obesity or
 glucose intolerance, 1570-1576
 GLP-1(7-37) glucagon-dependent, 1231-1237
 of lipectomy and dexamethasone on visceral AT and metabolic
 variables, 1631-1638
 of oral salbutamol on GH secretion in prepubertal asthmatic
 children, 149-151
 of overfeeding on plasma glucose, insulin, and glucagon in
 identical twins, 96-105
- Long-term therapy
 cholesterol-lowering, effects of, on serum retinol, 398-403
 with low-dose pravastatin, effects of, on biliary lipids and bile
 acid composition in nonfamilial hyperlipoproteinemia, 1410-
 1412
 with troglitazone, hepatic gluconeogenesis in DM suppressed by,
 487-490
- Loop diuretics, effects of NSAIDs and, on TSH release by anterior
 pituitary cells, 1008-1012
- Lovastatin, effects of, on high-affinity HDL binding in hepatocytes,
 735
- Low-calorie diet, very-, effects of, on insulin sensitivity and
 fibrinolytic capacity in PCOS with obesity, 611-616
- Low-carbohydrate diet (LCD), effects of, on intracellular glucose,
 in exercising men, 1264-1270
- Low-density lipoprotein(s) (LDLs; β -lipoproteins)
 apheresis of, by dextran sulfate adsorption in pregnancy with
 HFH, 929-933
 arachidonate distribution in thoracic aorta and, in hyperinsulin-
 emia, 806-811
 dietary fats and, *see* Low-density lipoprotein(s), dietary fats and
 in DM with hypertension, doxazosin effects on, 674
 effects of nibbling versus gorging on, 551
 and hemolysis in primary LPL deficiency, 654
 and persistent IGT, 1101
 in postmenopausal women on HRT, 412
 relationship between obesity and concentration and composition
 of subfractions of, in normoinsulinemic obese men, 1384-
 1390
 in SCI, 54
 serum, *see* Serum low-density lipoproteins
 short-term GH therapy effects on, 726, 727
 in nonsmoking women, effects of worksite ETS on, 1537
see also Low-density lipoprotein-cholesterol; Low-density lipopro-
 tein receptors; Very-low-density lipoprotein(s)
- Low-density lipoprotein(s) (LDLs; β -lipoproteins), dietary fats
 and
 dietary fat effects on LDL level, 859
 low- and high-fat diets and relationship of hepatic mRNA level
 with metabolism of plasma LDL apo B, 1058-1066
 n-3 PUFA effects on, 1226, 1227
- Low-density lipoprotein-cholesterol (LDL-C)
 cholestyramine and fluvastatin effects on, 1449, 1450
 in congenital hypothyroidism, effects of L-T₄ on, 1284-1286
 diet and weight loss effects on, in obese men with silent
 myocardial ischemia and reduced HDL-C, 309
 effects of exercise by fertile women on, 703
 effects of nibbling versus gorging on, 551, 552
 and fasting serum insulin in metabolic syndrome, 36-38
 following CABG, 1018
 in hypercholesterolemic subjects, 399, 400
 of hyperthyroid subjects before and after subtotal thyroidec-
 tomy, 5
 in hypertriglyceridemia, *see* Low-density lipoprotein-cholesterol
 in hypertriglyceridemia
 insulin propeptides and, 1483
 isolated low levels of, bezafibrate therapy in prevention of
 atherosclerosis in, 1401-1408
 levels of, as cardiovascular risk factor in fasting hyperinsulin-
 emia, 917, 919
 low-dose pravastatin effects on, 1411
 low-fat, high-fiber diet effects on, in premenopausal women,
 750-754
 in normolipidemic subjects, 1053
 plasma, *see* Plasma low-density lipoprotein-cholesterol
 plasma volume effects on, during menstrual cycle, 965-971
 postprandial response of, to high- and low-fiber diets, 849-851
 in pregnancy with HFH treated by dextran sulfate LDL apher-
 esis, 930
 L-thyroxine effects on, in hypothyroidism, 1561
- Low-density lipoprotein-cholesterol (LDL-C) in hypertriglyceri-
 demia
 in borderline hypertriglyceridemia, 1294, 1295
 with and without CV disease, postprandial Lp responses and,
 1086
 with NIDDM, 692
- Low-density lipoprotein (LDL; β -lipoproteins) receptors, regula-
 tion of interactions of, by FAs, 1428-1434
- Low-dose corticotropin-releasing hormone (CRH) stimulation test
 in IDDM with or without neuropathy, 538-542

- Low-dose hormonal replacement therapy (HRT), continuous, effects of, on Lp metabolism in postmenopausal women, 410-417
- Low-dose pravastatin, effects of, on biliary lipids and bile acid composition in nonfamilial hyperlipoproteinemia, 1410-1412
- Low-fat, high-fiber diet, changes in plasma Lp concentrations in response to, associated with changes in serum estrogen in premenopausal women, 749-756
- Low-fat (LF) diet, and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1058-1066
- Low-fiber diet, postprandial serum glucose, insulin, and Lp responses to, 848-854
- Lp, *see* Lipoprotein
- Lp(a), *see* Lipoprotein(a)
- LPL, *see* Lipoprotein lipase
- LPS (lipopolysaccharide), effects of, on hepatic free-NADP(P)⁺-linked redox states and cytosolic phosphorylation potential during fasting, 1170-1174
- Luteinizing hormone (LH) in men with SCI, 1117
- Lymphocytes
- changes in B-cell function in regularly exercising men, 1259-1263
 - HCO₃⁻ effects on glutamine and glucose metabolism in, 1247-1252
- Lysine
- effects of, on SM protein synthesis during sepsis, 1131
 - following total hip replacement, 1217-1219
 - interorgan flow of, between muscle and small intestine, 721, 722
 - plasma, *see* Plasma lysine
 - in soy protein, 1147, 1148
 - in TPN of burn patients, 660
- Lysophosphatidylcholine, role of, in hemolysis of primary LPL deficiency, 657
- M3, troglitazone and, regulating glucose transport in muscle cells, 976-981
- Macrophage tumor necrosis factor- α (TNF- α) mRNA (messenger ribonucleic acid), expression of, enhanced by fish oil at transcriptional level, 800-805
- Macrovesicular steatosis, hepatic, mitochondrial KIC decarboxylation in, 699-700
- Males, *see* Adolescent males; Men
- Malic enzyme, T₃ effects on substrate cycling between pyruvate carboxylase and, in liver, 1380-1383
- Malnutrition
- chronic, adaptation in glucose homeostasis during, 817-824
 - due to non-neoplastic gastrointestinal diseases, energy expenditure and protein metabolism in, 1110-1115
 - effects of increased dietary protein intake and, on whole-body protein metabolism of AIDS patients with weight loss, 1159-1165
 - severe, in cirrhosis, short-term changes in EE after 1 month of regular diet in patients with, 765-770
 - in STZ-DM, insulin resistance and, 1422-1427
 - see also* Diet
- Mannitol, effects of, on albumin and FD permeation by high glucose concentration, 741
- Mannosyl transferase, and long-term ethanol exposure, 894
- Maternal blood gases, fetal and, maternal chronic hypoxia and, 533
- Maternal hypoxia, chronic, effects of, on fetal growth and glucose utilization by fetal tissues, 532-537
- Maximum oxygen consumption, *see* $\dot{V}O_{2max}$
- MC3T3-E1 osteoblastic cells, ALLN effects on PTH-induced retraction of, 141-144
- Meals
- influence of frequency of, on circulating hormone levels and lipogenesis, 218-223
 - see also* Diet; Postprandial responses
- Meglitinide [4-(2-[5-chloro-2-methoxybenzamide]ethyl)-benzoic acid], effects of, on glycogen phosphorylase and F-2,6-P₂ activity in hepatocytes, 1000-1007
- Membrane transport, role of, in interorgan amino acid flow between muscle and small intestine, 719-724
- Men
- effects of milk consumption on serum ALP in, 1191
 - exercising, *see* Men, exercising
 - without GH disturbances, effects of short-term GH therapy in, 725-729
 - with metabolic syndrome, fasting serum insulin in, 35-40
 - middle-aged, *see* Middle-aged men
 - non-obese, *see* Non-obese men
 - obese, *see* Men, obese
 - older, *see* Older men
 - with SCI, suppression of hypothalamus-pituitary axis, 1116-1120
 - young, *see* Young men
 - see also* Adolescent males; Normal adult subjects; Sex
- Men, exercising
- age of, *see* Men, exercising, age and
 - with CAD, HDL subclasses associated with insulin and glucose levels, resting HR, regional adiposity, and exercise, 106-114
 - changes in insulin sensitivity, B-cell function, and glucose effectiveness in regularly exercising men, 1259-1263
 - effects of LCD on intracellular glucose in, 1264-1270
 - influence of submaximal exercise on glucose assimilation in, 833-840
- Men, exercising, age and, 834
- and exercise-induced changes in plasma NEFA and TAG concentrations in adolescent males, 681-688
 - older and young, response of aerobic power to exercise in, 188-192
 - and response of blood lipids, body composition, and aerobic power to physical conditioning and deconditioning, 161-165
 - training status, RMR, and risk for cardiovascular disease in middle-aged men, 340-347
- Men, obese
- AT in, *see* Men, obese, AT in
 - β -adrenergic stimulation of abdominal AT blood flow in, 183-187
 - fasting hyperinsulinemia and cardiovascular risk factors in non-diabetic, 914-922
 - normoinsulinemic, relationship between obesity and concentration and composition of LDL subfractions in, 1384-1390
 - pulsatile GH secretion in non-obese and, during energy restriction, 605-610
 - young men with central obesity, hemostatic function, 1417-1421
 - see also* Obesity; Weight loss by obese men
- Men, obese, AT in
- β -adrenergic stimulation of BF of subcutaneous AT in, 183-187
 - in normoinsulinemic men, 1386
 - in older obese men, effects of weight loss on NE and insulin levels in, 438-444
 - testosterone and adrenal C₁₉ steroid levels and, 513-519
- Menopause
- and effects of milk consumption on serum ALP, 1191, 1192
 - variations in body composition and AT distribution associated with age and, in healthy women, DEXA in measurement of, 369-373
 - see also* Postmenopausal women; Premenopausal women

- Menstrual cycle, plasma volume effects on LDL-cholesterol and total cholesterol during, 965-971
- Mental stress, effects of, on glucose uptake during hyperinsulinemia, 1303-1307
- Mesangial cells
AM stimulating cAMP formation in, 10-12
cardiac natriuretic peptides inhibiting CSA-induced production of ET in, 404-409
- Messenger ribonucleic acid, *see* mRNA
- Metabolic adaptation to brisk walking by sedentary middle-aged women, 393
- Metabolic rate, *see* Basal metabolic rate; Resting metabolic rate
- Metabolic syndrome, fasting serum insulin in men with, 35-40
- Methionine
deficiency in, in subjects fed soy protein, hypercholesterolemia induced by, and Lp susceptibility to peroxidation potentiated by, 1146-1152
effects of, on SM protein synthesis during sepsis, 1131
effects of overnight infusion of, on muscle proteolysis, 426
following total hip replacement, 1217-1219
plasma, *see* Plasma methionine
in TPN of burn patients, 660, 661
- N*^G-Methyl-L-arginine (NMLA), somatostatin and, decreasing blood glucose and plasma insulin and blocking ET-1-induced insulin release but not ET-1-induced hypoglycemia, 1532-1535
- Methylguanidine, urinary excretion of, in cirrhotic subjects, 586
- (-)-2-(4-Methylphenoxy)-7-(4-chlorophenyl)-heptanoic acid, sodium salt, *see* Oral (-)-BM 13.0913.Na
- Mevalonic acid, effects of nibbling versus gorging on excretion of, 551-552
- Microdialysis in study of insulin and NE in regulation of lipolysis, 1513-1518
- Microvascular angina (cardiologic syndrome X), insulin resistance in, 876-882
- Middle-aged men
with IGT, weight loss by, reduces abdominal AT and improves insulin action, 1502-1508
relationship of smoking cessation and nicotine gum use to salivary androstenedione and T in, 90-95
training status, RMR, and risk for cardiovascular disease in, 340-347
- Middle-aged women, sedentary, effects of brisk walking on insulinemia in, 390-397
- Mild hypertriglyceridemia, gemfibrozil decreasing TG levels in, without affecting glucoregulatory or antilipolytic effects of insulin in nondiabetic subjects with, 589-596
- Mild thyrotoxicosis, renal and thyroid function in, 209
- Milk consumption, effects of, on serum ALP, 1190-1193
- Minerals, total bone, and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- Minimal model
in analysis of insulin sensitivity, insulin secretion, and glucose effectiveness in obesity, 1397-1400
influence of submaximal exercise on glucose assimilation analyzed with, 833-840
in measurement of insulin response to glucose in insulin sensitivity, 1121-1125
- Mitochondrial adenine nucleotide translocase (AdNT), T₃ effects on, 193-199
- Mitochondrial ketoisocaproic acid (KIC), decarboxylation of, in hepatic macrovesicular hepatic steatosis, 699-700
- Mitomycin, effects of, on PBMNCs, 1437
- Monensin, effects of, on albumin permeation by high glucose concentration, 741-742
- Mononuclear cells (monocytes)
in combined hypercholesterolemia-hypertriglyceridemia and isolated hypercholesterolemia, adhesion of, to endothelial cells, 374-378
peripheral, from IDDM subjects, insulin secretion by pancreas of athymic subjects injected with, 1435-1441
- Monophosphate, *see* cAMP; cGMP
- Monounsaturated fatty acids (FAs) in low-fat, high-fiber diet, 750
- mRNA (messenger ribonucleic acid)
expression of macrophage TNF- α , enhanced by fish oil at transcriptional level, 800-805
glucokinase, glucagon, amylin, and insulin, age-related changes in, 322
GLUT1, in adult and fetal hepatocytes, glucose regulation of, 1553-1558
GLUT2, *see* GLUT2 mRNA
growth factor, regulation of, in eyes of diabetic subjects, 1038-1045
hepatic, *see* mRNA, hepatic
hepatic IGF-I, high-calorie TPN effects on, 152-160
levels of HSL, in STZ-DM, 1393
- mRNA (messenger ribonucleic acid), hepatic
correlation between plasma LDL apo B metabolism and, high- and low-fat diets and, 1058-1066
GLUT4, hyperinsulinemic effects on expression of, 228-233
zinc deficiency effects on expression of, 126-133
- Mucosal glutathione (GSH), insulin effects on, 1465
- Muscle
defective muscle glycogen metabolism in neonatal and obese subjects, 1298-1302
exercise and calorie restriction effects on, 190
fish oil effects on glucose uptake by, in TNF-treated subjects, 1365-1370
interorgan AA flow between small intestine and, role of membrane transport in, 719-724
 α -ketoglutarate and glutamine preventing decrease in concentration of free glutamine in, and influencing protein synthesis after total hip replacement, 1215-1222
muscle proteolysis suppressed by overnight BCAA infusions, 424-429
PDH activity in, *see* Pyruvate dehydrogenase, muscle
see also Glycogen synthase activity, muscle; Muscle cells; Musculoskeletal mass; Skeletal muscle and element: Myo-
- Muscle cells, troglitazone and M3 regulating glucose transport in, 976-981
- Musculoskeletal mass, postmenopausal women's, age-related changes in, race and, 30-34
- Myocardial ATP (adenosine triphosphate) from glucose and palmitate oxidation, 503
- Myocardial glucose, sodium pivalate effects on oxidation of, 501-503
- Myocardial ischemia, silent, obese men with reduced HDL-C and, effects of diet and weight loss on Lp levels in, 307-314
- myo-inositol, sorbinil effects on fructose, sorbitol, glucose and, in eyes of diabetic subjects, 1042
- D-myo-inositol 1,4,5-triphosphate [Ins(1,4,5)P₃], modulation of Ca²⁺-ATPase activity in RBCs, guanine nucleotide regulatory protein mediating, 865-868
- N (nitrogen)
AA, effects of β -adrenergic blockers on hepatic conversion of, in cirrhosis, 899-905
effects of, on protein concentration in AIDS patients, 1162, 1163

- N (nitrogen) (*Continued*)
see also N balance
- N (nitrogen) balance
 during fasting and after TPN of elderly subjects with femoral neck fracture, 64
 impact of chemotherapy on, 1342-1344
- Na (sodium)
 fractional excretion of, amlodipine in essential hypertension and, 316, 318
 plasma, in elderly subjects with femoral neck fracture, 61
 serum, in hypertensive NIDDM, 86
see also Na⁺/H⁺ exchanger isoform-1; Oral (-)-BM 13.0913.Na; Sodium acetate; Sodium pivalate model and entries beginning with term: Natriuretic
- NAD(P)⁺-linked redox states, hepatic free, LPS effects on cytosolic phosphorylation potential and, during fasting, 1170-1174
- Na⁺/H⁺ exchanger isoform-1, abundance of, in skin fibroblasts in IDDM with nephropathy, 791-795
- Nandrolone propionate, effects of, on tumor growth and cancer cachexia, 445-451
- Natriuretic factor, plasma atrial, angiotensin II and phenylephrine effects on, 117
- Natriuretic peptides, cardiac, CSA-induced ET production in mesangial cells inhibited by, 404-409
- NE, *see* Norepinephrine
- NEFAs, *see* Nonesterified fatty acids
- Neonatal subjects, defective metabolism of hepatic and muscle glycogen in, 1298-1302
- Nephropathy, IDDM with, abundance of Na⁺/H⁺ exchanger isoform-1 in skin fibroblasts in, 791-795
- Nerve function, peripheral, in STZ-DM, effects of acetyl-L-carnitine on, 677-680
- Nervous system, *see* Brain; Sympathetic nervous system and entries beginning with element: Neur-
- Neuropathy, IDDM with or without, low-dose CRH stimulation test in, 538-542
- Neurotensin (NT), effects of, on ventromedian nucleus of obese subjects during fasting, 972-975
- NH₃ (ammonia)
 in cirrhosis, effects of β -adrenergic blockers on, 901
 and glucose and glutamine metabolism in enterocytes, 327, 328
- Nibbling, effects of gorging versus, on cardiovascular risk factors, 549-555
- Nicotine gum, relationship between smoking cessation and use of, to salivary androstenedione and T in middle-aged men, 90-95
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nitric oxide (NO)
 impaired release of, by glomeruli in STZ-DM, 695-698
 as interstitial regulator of Leydig cell steroidogenesis, 234-238
- Nitrogen, *see* N
- NMLA (N^G-methyl-L-arginine), somatostatin and, decreasing blood glucose and plasma insulin and blocking ET-1-induced insulin release but not ET-1-induced hypoglycemia, 1532-1535
- NO, *see* Nitric oxide
- Nondiabetic subjects
 gemfibrozil decreasing TG levels in mild hypertriglyceridemia without affecting glucoregulatory or antilipolytic effects of insulin in, 589-596
 hyperinsulinemia in, *see* Nondiabetic subjects, hyperinsulinemia in
- Nondiabetic subjects, hyperinsulinemia in
 in cirrhotic subjects, proinsulin and des-31,32-proinsulin contributing to hyperinsulinemia in, 254-260
 lean and obese, fasting hyperinsulinemia and cardiovascular risk factors in, 914-922
- Nonesterified fatty acids (NEFAs)
 effects of brisk walking by sedentary middle-aged women on, 394
 effects of different dietary fat types on, 276
 following CABG, 1018
 oral (-)-BM 13.0913.Na effects on, in lean and obese subjects, 580
 plasma, *see* Plasma nonesterified fatty acids
- Nonfamilial hyperlipoproteinemia, low-dose pravastatin effects on bile acid composition and biliary lipids in, 1410-1412
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus)
 changes in SM LPL activity in response to insulin in, 786-790
 correlation between insulin binding and glycemic control in, 506-512
 early, beta-cell function at transition to, 757-764
 familial, *see* Familial non-insulin-dependent diabetes mellitus
 GHb in, *see* Glycohemoglobin in NIDDM, LPL and glucose in, *see* Glucose in NIDDM
 hyperglycemia facilitating urinary excretion of C-peptide in, by increasing glomerular filtration rate, 1194-1198
 hypertriglyceridemia in, *see* Hypertriglyceridemia in NIDDM
 IGT in, *see* Impaired glucose tolerance in NIDDM
 insulin resistance or impaired insulin secretion as primary etiology in, 940-945
 insulin sensitization with pioglitazone in liver in, 384-389; *see also* Non-insulin-dependent diabetes mellitus, insulin sensitivity in
 nonspecific abdominal symptoms in, malabsorption of sorbitol and, 796-799
 with obesity or glucose intolerance, long-term effects of fluoxetine on glycemic control in, 1570-1576
 in parents of IDDM patients, 869-875
 tissue-specific alterations in G protein expression in genetic versus diet-induced model of, 771-778
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus), insulin sensitivity in
 gemfibrozil and simvastatin effects on, 212-217
 in hypertensive NIDDM, glucose storage and insulin sensitivity improved with enalapril in, 85-88
 oral (-)-BM 13.0913.Na improving, 570-576
- Nonneoplastic gastrointestinal diseases, protein metabolism and energy expenditure in malnutrition due to, 1110-1115
- Non-obese men
 beta-adrenergic stimulation of abdominal subcutaneous AT BF in, 183-187
 effects of moderate calorie restriction on fibrinolytic factors in, 1548-1552
 fasting hyperinsulinemia and cardiovascular risk factors in, 914-922
 pulsatile GH secretion in obese and, during energy restriction, 605-610
 testosterone and adrenal C₁₉ steroid levels in, 514
- Non-obese subjects
 oral (-)-BM 13.0913.Na effects on insulin resistance in, 577-584
see also Non-obese men; Non-obese women
- Non-obese women
 effects of combined administration of GHRH, GHRP-6, and pyridostigmine on GH secretion in, 745-748

- Non-obese women (*Continued*)
 fasting hyperinsulinemia and cardiovascular risk factors in, 914-922
 with PCOS, antiandrogenic therapy of, insulin sensitivity and, 525-531
- Nonoxidative disposal of glutamine, and malnutrition due to nonneoplastic gastrointestinal diseases, 1114
- Nonsmoking women, worksite ETS effects on serum Lps in, 1536-1539
- Nonspecific abdominal symptoms in NIDDM, malabsorption of sorbitol and, 796-799
- Nonsteroidal antiinflammatory drugs (NSAIDs), effects of loop diuretics and, on TSH release by anterior pituitary cells, 1008-1012
- Noradrenaline, *see* Norepinephrine
- Norepinephrine (NE; noradrenaline)
 adrenoceptor antagonists and, 248
 in AIDS patients, 1567
 beef tallow diet effects on, *see* Norepinephrine, beef tallow diet effects on
 in cirrhosis, effects of β -adrenergic blockers on, 903
 insulin and, in regulation of lipolysis, microdialysis in study of, 1513-1518
 in obese men, *see* Norepinephrine in obese men
 plasma, *see* Plasma norepinephrine
 regular exercise effects on, 1261
 response of, to amlodipine in essential hypertension, 316, 318
 in SCI, 54
 urinary excretion of, in hyperinsulinemic subjects, arachidonate distribution in LDLs and thoracic aorta and, 807
see also entries beginning with term: β -Adrenergic
- Norepinephrine (NE; noradrenaline), beef tallow diet effects on in AT, 1276
 in hypothalamus and cerebral cortex, 1377-1379
- Norepinephrine (NE; noradrenaline) in obese men
 effects of weight loss on levels of, in older obese men, 438-444
 levels of, and β -adrenergically mediated thermogenic and HR responses in obese men, weight loss and, 521, 522
- Normal adult subjects
 age- and menopause-associated variations in AT distribution and body composition in, DEXA in measurement of, 369-373
 cephalic-phase insulin and glucagon release in recipients of pancreas transplantation and in, 1153-1158
 changes in concentrations of GHBP in acromegalic and, effects of short-term fasting on, 667-672
 chemotherapy impact on protein metabolism in, 1340-1348
 effects of combined administration of GHRH, GHRP-6, and pyridostigmine on GH secretion in, 745-748
 levels of erythrocyte uridine sugar nucleotide in classic galactosemia, in subjects with other metabolic disorders, and in, compared, 597-604
 overnight BCAA infusions suppressing muscle proteolysis in, 424-429
 protein and energy balance in, 59-66
 rate of entry of glucose into hepatic UDP-glucose in, in fasting and fed states, 172-182
 troglitazone effects on insulin action in, 1166-1169
see also Men; Women
- Normal children, RBC IGF-I receptor in, 923-928
- Normoinsulinemic men, obese, relationship between obesity and concentration and composition of LDL subfractions in, 1384-1390
- Normolipidemia, correlation between cholesterol synthesis and hepatic apo B-100 secretion in, 1052-1057
- Normoponderal subjects, *see* Non-obese subjects
- Normotensive smokers, HbA_{1c} levels and impaired insulin sensitivity in hypertensive and, 557-561
- NSAIDs (nonsteroidal antiinflammatory drugs), effects of loop diuretics and, on TSH release by anterior pituitary cells, 1008-1012
- NT (neurotensin), effects of, on ventromedian nucleus of obese subjects during fasting, 972-975
- Nutrition, *see* Diet
- O₂ (oxygen), *see* $\dot{V}O_2$; $\dot{V}O_{2max}$
- Obesity
 β -adrenergic responsiveness of adenylate cyclase in adipocyte plasma membrane in, 1288-1292
 bromocriptine inhibiting FFA oxidation and HGP in, 1349-1355
 calorie restriction in, *see* Calorie restriction in obesity
 captopril effects on glucose transport in SM in, 267-272
 defective metabolism of hepatic and muscle glycogen in, 1298-1302
 GH secretion in, *see* Growth hormone, secretion of, in obesity
 glucose in, *see* Glucose in obesity
 high-fat, high-sucrose diet effects on development of DM and, 645-651
 HP diet effects on hepatic VLDLs in, 19-29
 insulin and, *see* Insulin, obesity and
 insulin release in, *see* Insulin release and secretion in obesity
 insulin resistance in, *see* Insulin resistance in obesity
 with NIDDM, long-term effects of fluoxetine on glycemic control in, 1570-1576
 NT effects during fasting on ventromedian nucleus in, 972-975
 oral (-)-BM 13.0913.Na effects on insulin resistance in, 577-584
see also Adipose tissue; Men, obese; Women, obese
- OGTT, *see* Oral glucose tolerance test
- OHB, *see* β -Hydroxybutyrate
- 25-OHD, *see* 25-Hydroxyvitamin D
- 1,25(OH)₂D, *see* 1,25-Dihydroxyvitamin D
- Oil
 fish, *see* Fish oil
 safflower, effects of, on sympathetic activity, 934-939
- Okadaic acid (OKA), effects of, on SM DAG, 352, 354
- Older men
 acute effects of fructose and glucose ingestion with and without caffeine by, 630-638
 with femoral neck fracture, protein and energy balance in, 59-66
 with IGT, weight loss by, reduces abdominal AT and improves insulin action, 1502-1508
 obese, effects of weight loss on NE and insulin levels in, 438-444
 responses of aerobic power to exercise by, 188-192
- Older subjects
 increased concentrations of protein G₁ and G₂ in adipocytes of, altering sensitivity of adenyl cyclase to inhibitory and stimulatory agonists, 239-244
see also Older men; Older women
- Older women
 acute effects of fructose and glucose ingestion with and without caffeine by, 630-638
 energy expenditure by exercising, 1046-1051
 with femoral neck fracture, protein and energy balance in, 59-66
 [1-¹⁴C]Oleate, and HP diet effects on hepatic VLDLs in obesity, 20-23
- Omega-3 fatty acids, *see* n-3 Polyunsaturated fatty acid(s); n-3 Polyunsaturated fatty acid ethyl esters

- Oral (-)-BM 13.0913.Na [(-)-2-(4-methylphenoxy)-7-(4-chlorophenyl)-heptanoic acid, sodium salt], 570-584
 effects of, on insulin resistance in lean and obese subjects, 577-584
 insulin sensitivity improved with, in NIDDM, 570-576
- Oral diet, *see* Diet
- Oral glucose tolerance test (OGTT)
 in beta-thalassemia, 283
 in CF, 13-18
 of diabetic and nondiabetic cirrhotic subjects, 255-257
 in early NIDDM, 759, 761-762
 in essential hypertension, amlodipine effects on, 316
 fluoxetine effects on, in NIDDM subjects with obesity or glucose intolerance, 1571
 in insulin resistance with history of GDM, 1069
 oral (-)-BM 13.0913.Na improving, in STZ-DM, 572
 in overfed identical twins, 96-105
 in parents of IDDM patients, 872
 in SCI subjects, 54
- Oral salbutamol, short- and long-term effects of, on GH secretion in prepubertal asthmatic children, 149-151
- Oral vanadyl in STZ-DM, concentration-dependent lowering effects of, on glucose are maintained after treatment withdrawal, 332-339
- Organ weight
 clenbuterol and salbutamol effects on, 121
 heart, effects of long-term captopril on, 270
 impact of chemotherapy on, 1344
 liver, *see* Liver weight
- Ornithine
 following total hip replacement, 1217-1219
 plasma, in AIDS patients, 1162
 in TPN of burn patients, 661
- Orosomucoid, effects of regular oral diet on, in severely malnourished cirrhotic patients, 767
- Osmotic fragility in primary LPL deficiency, 654-656
- Osteoblastic cells, MC3T3-E1, ALLN effects on PTH-induced retraction of, 141-144
- Osteocalcin, testosterone effects on, in adolescent male hypogonadism, 420-421
- Ouabain, effects of, on albumin permeation by high glucose concentration, 741-742
- Overfeeding, plasma glucose, insulin, and glucagon before and after long-term, in identical twins, 96-105
- Overweight, *see* Obesity
- Ovulatory women, young, galanin role in regulating somatotrope and gonadotrope function in, 1028-1032
- Oxidation
 FA, *see* Oxidation, FA
 glucose, *see* Oxidation, glucose
 glutamine, *see* Oxidation, glutamine
 lipid, *see* Oxidation, lipid
 palmitate, *see* Oxidation, palmitate
 substrate, during fasting by elderly subjects with femoral neck fracture, 63
see also β -oxidation; Oxidative stress; Peroxidation; Redox cycle and states
- β (beta)-Oxidation, effects of troglitazone and bezafibrate on, in fructose-fed subjects, 1626-1630
- Oxidation, FA
 and cardiac function in sodium pivalate model of secondary carnitine deficiency, 499-505
 FFA, bromocriptine inhibiting hepatic glucose production and, in obesity, 1349-1355
 plasma NEFA, in lipid-induced insulin resistance, 639-644
- Oxidation, FA (*Continued*)
 from TGs, heparin effects on, 1590-1595
- Oxidation, glucose
 and acute increase in plasma TGs, 886, 887
 in enterocytes, 329
 myocardial glucose, sodium pivalate effects on, 501-503
 oral (-)-BM 13.0913.Na effects on, in NIDDM, 573-574
 and persistent IGT, 1102
- Oxidation, glutamine
 in enterocytes, 329
 and malnutrition due to non-neoplastic gastrointestinal diseases, 1114
- Oxidation, lipid
 during fasting and after TPPN of elderly subjects with femoral neck fracture, 63
 in lipid-induced insulin resistance, 639-644
 and persistent IGT, 1102
- Oxidation, palmitate
 bromocriptine effects on, 1351
 sodium pivalate effects on, 501-503
- Oxidative stress
 and plasma Cp in IDDM, 996-999
 role of, in relationship between DM, hypertension, and cardiovascular disease, 363-368
- Oxygen, *see* $\dot{V}O_2$; $\dot{V}O_{2max}$
- PAI (plasminogen activating inhibitor) in non-obese men, effects of moderate calorie restriction on, 1550
- PAI-1, *see* Plasminogen activating inhibitor-1
- Palmitate
 PP retinol, and PP Lp responses in hypertriglyceridemia with and without CV disease, 1093
see also Oxidation, palmitate
- Pancreas
 of athymic subjects injected with PBMCs from IDDM subjects, insulin secretion by, 1435-1441; *see also* Insulin release and secretion
 transplantation of, cephalic-phase insulin and glucagon release in normal subjects and in recipients of, 1153-1158
see also entries beginning with term: Pancreatic
- Pancreatic islet(s)
 glucose transport, phosphorylation, and utilization in, 261-266
see also Pancreatic islet cells
- Pancreatic islet cells
 age-related changes in gene expression of, 320-324
see also Beta cells
- Parathyroid hormone (PTH)
 ALLN effects on retraction of MC3T3-E1 osteoblastic cells induced by, 141-144
 in SCI subjects, 1613
 testosterone effects on, in adolescent male hypogonadism, 420-421
- Parenteral nutrition
 total, *see* Total parenteral nutrition
 total peripheral, of elderly subjects with femoral neck fracture, 59-66
- Parents of IDDM patients, NIDDM in, 869-875
- PBMCs (peripheral blood mononuclear cells) from IDDM subjects, athymic subjects injected with, insulin secretion by pancreas of, 1435-1441
- PCOS, *see* Polycystic ovary syndrome, insulin sensitivity in
- PDE (phosphodiesterase), cAMP-dependent, Cr effects on, 1317
- PDH, *see* Pyruvate dehydrogenase, muscle
- PE (phosphatidylethanolamine), platelet, n-3 PUFA ethyl ester effects on, 564

- Peptide(s), *see* C-peptides; Natriuretic peptides; Phosphopeptide;
Propeptides and entries beginning with terms: Growth hormone-releasing peptide
- Peripheral blood mononuclear cells (PBMNCs) from IDDM subjects, athymic subjects injected with, insulin secretion by pancreas of, 1435-1441
- Peripheral insulin sensitivity
doxazosin improving, in diabetic hypertensive patients, 673-676
in NIDDM, gemfibrozil and simvastatin effects on, 212-213
- Peripheral nerve function
ALC effects on, *see* Acetyl-L-carnitine, effects of, on peripheral nerve function
PLC effects on vascular supply and, in diabetes, 1209-1214
in STZ-DM, effects of acetyl-L-carnitine on, 677-680
- Peripheral parenteral nutrition, total, of elderly subjects with femoral neck fracture, 59-66
- Peroxidation
Lp susceptibility to, potentiated by methionine deficiency in subjects fed soy protein, 1146-1152
see also Oxidation
- Peroxisome, hepatic, clofibrate-induced proliferation of, pyruvate inhibiting, 166-171
- Persistent impaired glucose tolerance (IGT), metabolic defects in, related to familial NIDDM, 1099-1104
- 6-PF-1K (6-phosphofructo-1-kinase), effects of troglitazone on, in DM, 488, 489
- pH, adrenoceptor antagonists and, 248
- Phe, *see* Phenylalanine
- Phenotype(s)
apo E, *see* Apolipoprotein E phenotype
AT, in long-term overfed identical twins, 102, 104
atherogenic Lp, association of insulin and insulin propeptides with, 1481-1488
haptoglobin, in parents of IDDM patients, 869-875
- Phenylalanine (Phe)
effects of, on SM protein synthesis during sepsis, 1131
effects of overnight infusion of, on muscle proteolysis, 426, 427
following total hip replacement, 1217-1219
interorgan flow of, between muscle and small intestine, 721, 722
plasma, *see* Plasma phenylalanine
in soy protein, 1147, 1148
in TPN of burn patients, 660, 661
- Phenylephrine
effects of, on glycogen phosphorylase and F-2,6-P₂ activity in hepatocytes, 1003
effects of angiotensin II and, on urinary excretion of ET in women, 115-118
- Phenylisopropyladenosine (PIA), antilipolytic effects of, 991, 992
- Phosphatases, *see* Acid phosphatase; Alkaline phosphatase; ATPase; Biphosphatase; NADP(P)⁺-linked redox states; Protein-tyrosine phosphatases, insulin resistance and
- Phosphate, *see* ATP; cAMP; cGMP; Diphosphate; Fructose-1,6-biphosphate; Fructose-2,6-biphosphate; Fructose-6-phosphate; Galactitol 2-phosphate; Glucose-6-phosphate; Glucose-6-phosphate dehydrogenase; Phosphoribosyl-1-pyrophosphate; Ribose-5-phosphate; Triphosphate
- Phosphatidylethanolamine (PE), platelet, n-3 PUFA ethyl ester effects on, 564
- Phosphatidylserine (PS), platelet, n-3 PUFA ethyl ester effects on, 565
- Phosphocholine, insulin effects on SM content of, 352
- Phosphodiesterase (PDE), cAMP-dependent, Cr effects on, 1317
- 6-Phosphofructo-1-kinase (6-PF-1K), effects of troglitazone on, in DM, 488, 489
- 3-Phosphoglycerate, LPS effects on, 1171
- Phospholipid(s) (PLs)
in cirrhosis, 827, 828
effects of dietary fat types on, 276
fish oil effects on, 1369
hyperinsulinemia effects on, 807-809
low-dose pravastatin effects on, 1411
plasma, *see* Plasma phospholipids
platelet, and platelet functions, effects of n-3 PUFA ethyl ester on FA composition of, 562-569
- Phospholipid fatty acids (PL FAs), RBC, dietary fat intake assessed by comparing 3-day food record and composition of, 1139-1145
- Phosphopeptide, insulin resistance associated with abnormal dephosphorylation of, corresponding to autophosphorylation site of IR, 1074-1081
- Phosphoribosyl-1-pyrophosphate (PRPP), role of cellular RSP in regulation of, and de novo purine synthesis in hepatoma cell line, 1469-1474
- Phosphorylase, glycogen, glibenclamide and meglitinide effects of activity of, in hepatocytes, 1000-1007
- Phosphorylation
cytosolic, LPS effects on hepatic free-NADP(P)⁺-linked redox states and, during fasting, 1170-1174
glucose, utilization, transport and, in pancreatic islets, 261-266
see also Autophosphorylation
Physical activity, *see* Exercise
PIA (phenylisopropyladenosine), antilipolytic effects of, 991, 992
- Pioglitazone
effects of, on diet-induced hypertension, 1105-1109
and insulin sensitization in liver in NIDDM, 384-389
- Pituitary cells, anterior, effects of NSAIDs and loop diuretics on TSH release by, 1008-1012
- Pituitary deficiency, GH therapy effects on BMR in, 67-74
- PKC (protein kinase C), prednisolone and dexamethasone effects on insulin-induced activation of, in adipocytes and soleus muscle, 298-306
- PL(s), *see* Phospholipid(s)
- Plasma, whole, in postmenopausal women on HRT, 412
- Plasma acetic acid, ethanol effects on, 782
- Plasma acetoacetate in elderly subjects with femoral neck fracture, 61
- Plasma activating inhibitor (PAI) in non-obese men, effects of calorie restriction on, 1550
- Plasma alanine
in AIDS patients, 1162
and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma amino acids (AAs)
in AIDS patients, 1162
effects of fructose and glucose ingestion with and without caffeine on, 635
following total hip replacement, 1217
see also specific amino acids
- Plasma apolipoproteins (apos)
in congenital hypothyroidism, L-T₄ therapy effects on, 1283-1287
effects of exercise on, in fertile women, 701-704
- Plasma arginine (ARG)
in AIDS patients, 1162
and effects of fructose and glucose ingestion with and without caffeine, 635
kinetics of leucine and, and urea production rates in burn patients, 659-666
- Plasma asparagine in AIDS patients, 1162
- Plasma atrial natriuretic factor (ANF), angiotensin II and phenylephrine effects on, 117

- Plasma Ca (calcium) in elderly subjects with femoral neck fracture, 61
- Plasma carnitine in vitamin C deficiency, 1641
- Plasma ceruloplasmin (Cp) in IDDM, oxidative stress and, 996-999
- Plasma cholesterol (C)
in elderly subjects with femoral neck fracture, 61
fasting, of middle-aged men, training status and, 343
and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1060
- Plasma cholesteryl esters, hyperinsulinemia effects on, 807
- Plasma Cl (chloride) in elderly subjects with femoral neck fracture, 61
- Plasma copper (Cu) in IDDM, plasma Cp and, 998
- Plasma cortisol
CRH stimulation test effects on levels of, in IDDM with and without neuropathy, 541
in elderly subjects with femoral neck fracture, 62
- Plasma C-peptides (connecting peptides), *see* Fasting plasma C-peptides
- Plasma cysteine in AIDS patients, 1162
- Plasma endothelin-1 (ET-1) in hyperthyroidism, 1239-1242
- Plasma epinephrine (E)
in elderly subjects with femoral neck fracture, 62
in hypertension, effects of vasodilators on, 715
in starved exercising subjects, 1334
- Plasma fibrinogen (Fn)
in AIDS patients, 1162
simvastatin and gemfibrozil effects on, 215
- Plasma flow, renal, effects of glucagon infusion on, 456
- Plasma free fatty acids (FFAs)
in elderly subjects with femoral neck fracture, 61
in starved exercising subjects, 1334
- Plasma glucagon
in CF, 16
in elderly subjects with femoral neck fracture, 62
hepatic artery, portal vein, and hepatic vein concentrations of, during glucagon infusions, 455
HP diet effects on, in obesity, 24-28
in long-term overfed identical twins, 96-105
in normal subjects and in pancreas transplantation recipients, 1156
- Plasma glucose
bromocriptine effects on, 1351
and chronic maternal hypoxia, 534
Cr effects on, 1317
dietary fat effects on, 1491
in elderly subjects with femoral neck fracture, 61
exercise effects on, 682
fasting, *see* Fasting plasma glucose
fish oil effects on, 1367
in hyperinsulinemia, *see* Plasma glucose in hyperinsulinemia
in hypertriglyceridemia, gemfibrozil effects on, 592
of IGT subjects, serum level insulin level and, 1373
in lipid-induced insulin resistance, 641
in long-term overfed identical twins, 96-105
in NIDDM, *see* Plasma glucose in NIDDM
oral vanadyl effects on, 334-337
and pulsatile GH secretion in non-obese and obese subjects during fasting, 607
steady-state, in essential hypertension, amlodipine effects on, 316
- Plasma glucose in hyperinsulinemia
arachidonate distribution in LDLs and thoracic aorta and, 807
and lipogenic enzymes and GLUT4 mRNA expression in liver and AT, 229
- Plasma glucose in NIDDM
NIDDM etiology and, 941-942
serum level insulin level and, 1373
- Plasma glutamate in AIDS patients, 1162
- Plasma glutamine in AIDS patients, 1162
- Plasma glycerol, exercise effects on, 682
- Plasma glycine
in AIDS patients, 1162
and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma high-density lipoprotein-cholesterol (HDL-C)
fasting, in middle-aged men, training status and, 343
hyperinsulinemia effects on, 807
n-3 PUFA ethyl ester effects on, 563
- Plasma histidine
in AIDS patients, 1162
and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma β (beta)-hydroxybutyrate (OHB) in elderly subjects with femoral neck fracture, 61
- Plasma inosine, effects of ethanol on, 781-782
- Plasma insulin
bromocriptine effects on, 1351
and chronic maternal hypoxia, 534
Cr effects on, 1317
dietary fat effects on, 1491
in elderly subjects with femoral neck fracture, 62
fasting, *see* Fasting plasma insulin
fish oil effects on, 1367
GLP-1(7-37) effects on, 1233, 1234
HP diet effects on, in obesity, 24-28
of hyperinsulinemic subjects, arachidonate distribution in LDLs and thoracic aorta and, 807
in lipid-induced insulin resistance, 641
in long-term overfed identical twins, 96-105
NMLA and somatostatin decreasing blood glucose and, and blocking ET-1-induced insulin release but not ET-1-induced hypoglycemia, 1532-1535
oral vanadyl effects on, 334-336
and pulsatile GH secretion in non-obese and obese subjects during fasting, 607
- Plasma insulin-like growth factor-binding protein-3 (IGFBP-3) in acute trauma, 1205-1208
- Plasma isoleucine
in AIDS patients, 1162
and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma K (potassium) in elderly subjects with femoral neck fracture, 61
- Plasma ketones in elderly subjects with femoral neck fracture, 61
- Plasma lactate
in elderly subjects with femoral neck fracture, 61
exercise effects on, 682
- Plasma lecithin-cholesterol acyltransferase (LCAT), dietary effects on, 860
- Plasma leucine, and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma lipids
beta-CD effects on, 200-206
CHO-dietary fat exchange effects on, 857-858
effects of dietary fat types on, 276
in NIDDM, 941
see also specific plasma lipids

- Plasma lipoproteins (Lps)
 changes in concentrations of, in response to low-fat, high-fiber diet associated with changes in serum estrogen in premenopausal women, 749-756
 CHO-dietary fat exchange and regulation of metabolism of, 855-864
 in congenital hypothyroidism, L-T₄ therapy effects on, 1283-1287
 effects of exercise on, in fertile women, 701-704
 relationship of insulin and insulin propeptides to, 1483-1484
- Plasma low-density lipoprotein apolipoprotein B (LDL apo B), relationship of hepatic mRNA level with metabolism of, low- and high-fat diets and, 1058-1066
- Plasma low-density lipoprotein-cholesterol (LDL-C)
 fasting, in microvascular angina, 877
 hyperinsulinemia effects on, 807, 808
- Plasma lysine
 in AIDS patients, 1162
 and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma membrane, *see* Adipocyte plasma membrane
- Plasma methionine
 in AIDS patients, 1162
 and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma Na (sodium) in elderly subjects with femoral neck fracture, 62
- Plasma nonesterified fatty acids (NEFAs)
 exercise-induced changes in concentrations of, in adolescent males, 681-688
 fasting, in microvascular angina, 877
 role of oxidation of, in lipid-induced insulin resistance, 639-644
- Plasma norepinephrine (NE)
 in elderly subjects with femoral neck fracture, 62
 in hypertension, effects of vasodilators on, 715
 in starved exercising subjects, 1334
- Plasma ornithine in AIDS patients, 1162
- Plasma phenylalanine (Phe)
 in AIDS patients, 1162
 and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma phospholipids (PLs)
 and hemolysis in primary LPL deficiency, 654-655, 657
 hyperinsulinemia effects on, 807
 n-3 PUFA effects on, 1225
- Plasma purine bases, ethanol effects on, 781
- Plasma pyrazinamide, ethanol effects on, 782-783
- Plasma pyruvate in elderly subjects with femoral neck fracture, 61
- Plasma serine in AIDS patients, 1162
- Plasma threonine in AIDS patients, 1162
- Plasma thyroxine (T₄), fasting, in middle-aged men, training status and, 343
- Plasma total cholesterol (TC)
 fasting, in microvascular angina, 877
 and hemolysis in primary LPL deficiency, 654
 hyperinsulinemia effects on, 807
 n-3 PUFA ethyl ester effects on, 563
- Plasma triacylglycerol (TAG), exercise-induced changes in concentrations of, 681-688
- Plasma triglycerides (TGs)
 bezafibrate therapy effects on, 1407
 effects of acute increase in, on glucose metabolism, 883-889
 in elderly subjects with femoral neck fracture, 61
 fasting, *see* Fasting plasma triglycerides
 and hemolysis in primary LPL deficiency, 654
 hyperinsulinemia effects on, 807
- Plasma triglycerides (TGs) (*Continued*)
 n-3 PUFA effects on, 1225
 n-3 PUFA ethyl ester effects on, 563
 and relationship of hepatic mRNA level to metabolism of plasma LDL apo B, 1060
- Plasma triiodothyronine (T₃), fasting, in middle-aged men, training status and, 343
- Plasma tryptophan in AIDS patients, 1162
- Plasma tyrosine
 in AIDS patients, 1162
 and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma valine
 in AIDS patients, 1162
 and effects of fructose and glucose ingestion with and without caffeine, 635
- Plasma volume, effects of, on LDL-cholesterol and total cholesterol during menstrual cycle, 965-971
- Plasminogen activating inhibitor-1 (PAI-1)
 in non-obese men, effects of calorie restriction on, 1550
 in obesity, *see* Plasminogen activating inhibitor-1 in obesity
- Plasminogen activating inhibitor-1 (PAI-1) in obesity
 in centrally obese subjects, hemostatic function and, 1419
 with PCOS, effects of VLCD on, 613, 614
- Platelet phosphatidylethanolamine (PE), n-3 PUFA ethyl ester effects on, 564
- Platelet phosphatidylserine (PS), n-3 PUFA ethyl ester effects on, 565
- Platelet phospholipids (PLs), effects of n-3 PUFA ethyl ester on FA composition of, 562-569
- PLC (propionyl-L-carnitine), effects of, on peripheral nerve function and vascular supply in diabetes, 1209-1214
- Polycystic ovary syndrome (PCOS), insulin sensitivity in antiandrogenic therapy and, in non-obese women, 525-531
 effects of VLCD on fibrinolytic capacity and insulin sensitivity in PCOS with obesity, 611-616
- Polymorphism, TNF- β , associated with hypertriglyceridemia in NIDDM, 691-694
- Polyunsaturated fatty acid(s) (PUFA), middle-aged men intake of, training status and, 342
- n-3 Polyunsaturated fatty acid(s) (PUFA), effects of, on intravascular lipolysis of VLDLs, 1223-1230
- n-3 Polyunsaturated fatty acid (PUFA) ethyl esters, effects of, on FA composition of platelet phospholipids and on platelet function, 562-569
- Portal blood flow (BF) in cirrhosis, effects of β -adrenergic blockers on, 903
- Portal vein, plasma glucagon concentrations in, during glucagon infusions, 455
- Postheparin hepatic lipase (HL), effects of diet and weight loss on activity of, in obese men with silent myocardial ischemia and reduced HDL-C, 310
- Postmenopausal women
 age-related changes in musculoskeletal mass of, race and, 30-34
 continuous low-dosage HRT effects on Lp metabolism in, 410-417
 milk consumption effects on serum ALP in, 1191, 1192
- Postprandial (PP) responses
 of Lps, *see* Lipoprotein, PP responses of
 of serum glucose and insulin to high- and low-fiber diets, 848-854
- Posture, upright, effects of weight loss on hemodynamic responses to, in obese men, 440-441
- Potassium, *see* K
- PP, *see* Postprandial responses

- Pravastatin, effects of low-dose, on biliary lipids and bile acid composition in nonfamilial hyperlipoproteinemia, 1410-1412
- Prealbumin, serum, in AIDS patients, 1162
- Prednisolone (PSL), effects of dexamethasone and, on insulin-induced activation of PKC in adipocytes and soleus muscles, 298-306
- Pregnancy
with HFH in patient undergoing LDL apheresis by dextran sulfate adsorption, 929-933
hypertension in, erythrocyte insulin and IGF-I receptor tyrosine kinase activity in, 1308-1313
insulin secretion in insulin resistance in patients with history of GDM, 1067-1073
Lp(a) in IDDM during, 1606-1611
- Premenopausal women
changes in concentrations of plasma Lps in response to low-fat, high-fiber diet associated with changes in serum estrogen in, 749-756
effects of milk consumption on serum ALP in, 1191, 1192
LPL and HL activity and protective Lp profile in, 491-498
- Prepubertal asthmatic children, short- and long-term effects of oral salbutamol on GH secretion in, 149-151
- Prevention of atherosclerosis with bezafibrate therapy of patients with isolated low LDL-C levels, 1401-1408
- Primary etiology of NIDDM, impaired insulin secretion or insulin resistance as, 940-945
- Primary hypercholesterolemia, serum retinol in, with 2 years of cholesterol-lowering therapy, 398-403
- Primary lipoprotein lipase (LPL) deficiency, hemolysis in, 652-658
- Progesterone
in AIDS, 950
serum, effects of low-fat, high-fiber diet on, in premenopausal women, 753
- Proinsulin
contribution of, to hyperinsulinemia in diabetic and nondiabetic cirrhosis, 254-260
insulin propeptides and, 1483, 1485
radioimmunoassay blind to, in measurement of serum insulin level in IGT and NIDDM, 1371-1376
- Prolactin
in AIDS, 950
in men with SCI, 1117
- Proline
and arginine synthesis, isotopic evidence for differential regulation of, 466-473
effects of, on SM protein synthesis during sepsis, 1131
in soy protein, 1147, 1148
in TPN of burn patients, 660, 661
- Promoter region of IR gene, cDNA amplification in analysis of, in leprechaunism with severe insulin resistance, 430-437
- Propeptides, insulin, association of insulin and, with atherogenic Lp phenotype, 1481-1488
- Propionyl-L-carnitine (PLC), effects of, on peripheral nerve function and vascular supply in diabetes, 1209-1214
- Protein
balance of energy and, following femoral neck fracture in elderly subjects, 59-66
binding, *see* Acyl-CoA binding protein; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s)
C-reactive, *see* C-reactive protein
chemotherapy impact on metabolism of, in healthy and tumor-bearing subjects, 1340-1348
G, *see* G protein; Gi protein
- Protein (*Continued*)
guanine nucleotide regulatory, mediating modulation of D-myo-inositol 1,4,5-triphosphate Ca^{2+} -ATPase activity in RBCs, 865-868
 α -ketoglutarate and glutamine preventing decrease in concentration of muscle free glutamine and influencing synthesis of, after total hip replacement, 1215-1222
long-term aerobic exercise and energy restriction effects on synthesis of, 188-192
in low-fat, high-fiber diet, 750
malnutrition due to nonneoplastic gastrointestinal diseases and metabolism of, 1110-1115
N- and O-glycosylated, effects of long-term ethanol exposure on glycosylation of, 779-785
skeletal muscle, synthesis of, modulated by AAs and insulin during sepsis, 1130-1138
zinc deficiency effects on synthesis of, in liver, 126-133
see also Dietary protein; Protein C; Protein kinase C; Protein-tyrosine phosphatases, insulin resistance and; Proteolysis; Restricted dietary protein
- Protein C, level of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919
- Protein kinase C (PKC), prednisolone and dexamethasone effects on insulin-induced activation of, in adipocytes and soleus muscle, 298-306
- Protein-tyrosine phosphatases (PTPases), insulin resistance and, 1074-1081
SM PTPases in insulin-resistant obesity and DM, 1175-1184
- Proteolysis, muscle, overnight BCAA infusions suppressing, 424-429
- Prothrombin time (PT) in cirrhosis, 900
in severely malnourished cirrhotic patients, 767
- PRPP (phosphoribosyl-1-pyrophosphate), role of cellular RSP in regulation of, and de novo purine synthesis in hepatoma cell line, 1469-1474
- PS (phosphatidylserine), platelet, n-3 PUFA ethyl ester effects on, 565
- PSL (prednisolone), effects of dexamethasone and, on insulin-induced activation of PKC in adipocytes and soleus muscles, 298-306
- PT, *see* Prothrombin time in cirrhosis
- PTH, *see* Parathyroid hormone
- PTPases, *see* Protein-tyrosine phosphatases, insulin resistance and PUFAs, *see* Polyunsaturated fatty acid(s); n-3 Polyunsaturated fatty acid(s); n-3 Polyunsaturated fatty acid ethyl esters
- Pulsatile growth hormone (GH), secretion of, in non-obese and obese men during energy restriction, 605-610
- Pulse rate, *see* Heart rate
- Purine, de novo synthesis of, in hepatoma cell line, role of cellular RSP in, 1469-1474
- Purine bases, plasma, effects of ethanol on, 781-782
- Pyrazinamide, plasma, ethanol effects on, 782-783
- Pyridostigmine, effects of combined administration of GHRH, GHRP-6 and, on secretion in normal and obese subjects, 745-748
- Pyrophosphate, phosphoribosyl-1-, role of cellular RSP in regulation of, and de novo purine synthesis in hepatoma cell line, 1469-1474
- Pyruvate
clofibrate-induced hepatic peroxisome proliferation and free radical production inhibited by, 166-171
in diabetic ketoacidosis, 288
and glucose and glutamine metabolism in enterocytes, 327, 328
LPS effects on, 1171
plasma, in elderly subjects with femoral neck fracture, 61

- Pyruvate (*Continued*)
 see also Pyruvate dehydrogenase, muscle; Pyruvate transaminase
 Pyruvate carboxylase, T₃ effects on substrate cycling between malic enzyme and, in liver, 1380-1383
 Pyruvate dehydrogenase (PDH), muscle
 activity of, in NIDDM, 44-45
 LCD effects on, in exercising men, 1267
 Pyruvate transaminase, serum glutamic, in obese children, as risk factor for development of complications, 479, 481, 482
 Pyruvic acid, ethanol effects on, 782, 783
- Race and ethnicity
 and differences in age-related changes in musculoskeletal mass of postmenopausal women, 30-34
 effects of AT distribution and, on insulin resistance in adipocytes of obese women, 987-995
 and fasting hyperinsulinemia, 916, 918, 919
 fasting plasma insulin level as risk factor for development of complications in Japanese obese children, 478-485
 Radioimmunoassay blind to proinsulin in measurement of serum insulin level in IGT and NIDDM, 1371-1376
 Rb (rubidium) uptake, tissue, clenbuterol and salbutamol effects on, 119-125
 RBCs (red blood cells), see *entries beginning with term*: Erythrocyte
 Recombinant human growth hormone, see *Growth hormone*, therapy with
 Red blood cells, see *entries beginning with term*: Erythrocyte
 Redox cycle and states
 free hepatic NADP(P)⁺-linked, LPS effects on cytosolic phosphorylation potential and, during fasting, 1170-1174
 GSH, effects of insulin and fasting on, hydroperoxide detoxification in intestine of STZ-DM subjects and, 1462-1468
 see also *Oxidation*; *Peroxisation*
 Reduced-obese subjects, see *Weight loss by obese men*
 Reductase, see *Hepatic HMG-CoA reductase*
 REE, see *Resting energy expenditure*
 Reesterification of FAs from TGs, heparin effects on, 1590-1595
 Regional blood flow (BF), NE and changes in, 1516
 Regional adiposity
 associated with HDL subclasses in men with CAD, 106-114
 see also *Abdominal adipose tissue*; *Epididymal adipose tissue*
 Regular exercise, see *Exercise*
 Regulatory protein, guanine nucleotide, mediating D-myo-inositol 1,4,5-triphosphate modulation of Ca²⁺-ATPase in RBCs, 865-868
 Relatives, see *First-degree relatives and entries beginning with term*: Familial
 Renal artery, plasma glucagon concentrations in, during glucagon infusions, 456
 Renal clearance
 of glucagon in conscious subjects, 455
 see also *Urinary excretion*
 Renal function
 angiotensin II and phenylephrine effects on, 116
 in hyperthyroidism, subacute thyroiditis, and hypothyroidism, 208, 209
 Renal handling of carnitine in vitamin C deficiency, 1639-1643
 Renal plasma flow, effects of glucagon infusion on, 456
 Renal vein, plasma glucagon concentrations in, during glucagon infusions, 456
 Replication, beta cell, in spontaneous hypertension, 1360-1364
 Respiratory quotient (RQ), and adrenoceptor antagonists, 247
 Resting energy expenditure (REE)
 by acute trauma patients, 1206
 by AIDS patients, 1566
 Resting energy expenditure (REE) (*Continued*)
 and effects of weight loss on β -adrenergically mediated thermogenic and HR responses, 521
 Resting heart rate (HR) associated with HDL subclasses in men with CAD, 106-114
 Resting metabolic rate (RMR)
 and effects of fructose and glucose ingestion with and without caffeine in young and elderly subjects, 631-633
 of middle-aged men, training status, cardiovascular disease risk and, 340-347
 Restricted diet, see *Calorie restriction*; *Restricted dietary protein*
 Restricted dietary protein
 changes in insulin action and insulin secretion following calorie restriction and, 1519-1526
 effects of, on UDP-hexose levels, 601-602
 Retinol, serum, in primary hypercholesterolemia with 2 years of cholesterol-lowering therapy, 398-403
 Retinol palmitate, postprandial, and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1093
 Retinopathy, and abundance of Na⁺/H⁺ exchanger isoform-1 in skin fibroblasts in IDDM, 792
 rhGH (recombinant human growth hormone), see *Growth hormone*, therapy with
 Ribonucleic acid, see *mRNA*
 Ribose-5-phosphate (RSP), role of cellular, in regulation of PRPP and de novo purine synthesis in hepatoma cell line, 1469-1474
 Ribosome parameters following total hip replacement, 1217, 1220
 Risk and risk factors
 cardiovascular, see *Cardiovascular risk factors*
 for development of complications in obese Japanese children, fasting plasma insulin level as, 478-485
 for IGT and DM during first postoperative year following CABG, 1016-1027
 see also *specific risk factors*
 RMR, see *Resting metabolic rate*
 RNA (ribonucleic acid), see *mRNA*
 RQ (respiratory quotient), and adrenoceptor antagonists, 247
 RSP (ribose-5-phosphate), role of cellular, in regulation of PRPP and de novo purine synthesis in hepatoma cell line, 1469-1474
 Rubidium (Rb) uptake, tissue, clenbuterol and salbutamol effects on, 119-125
- S (sucrose), effects of high-fat, high-sucrose diet on development of obesity and diabetes mellitus, 645-651
 Safflower oil, effects of, on sympathetic activity, 934-939
 Salbutamol
 effects of, on tissue Rb uptake, 119-125
 long-term effects of oral, on GH secretion in prepubertal asthmatic children, 149-151
 short-term effects of, see *Short-term effects of salbutamol*
 Salivary androstenedione (Δ^4 -DIONE), and testosterone, in middle-aged men, relationship of smoking cessation and nicotine gum use to, 90-95
 Salmon calcitonin, diabetogenic effects of, due to its amylin-like activity, 1581-1589
 Saturated fatty acids (SFAs)
 in low-fat, high-fiber diet, 750
 middle-aged men intake of, training status and, 342
 SBP (systolic blood pressure), see *Blood pressure*
 SCFAs (short-chain fatty acids), cecal, beta-CD effects on, 201-202
 SCI, see *Spinal cord injury*
 Secondary carnitine deficiency, sodium pivalate model of, fatty acid oxidation and cardiac function in, 499-505

- Sedentary women, middle-aged, brisk walking effects on insulinemia in, 390-397
- Sepsis, effects of AAs and insulin on synthesis of SM proteins during sepsis, 1130-1138
- Serine
effects of, on SM protein synthesis during sepsis, 1131
effects of overnight infusion of, on muscle proteolysis, 426
following total hip replacement, 1217-1219
hippurate and, compared as precursor equivalents in measurement of VLDL apo B rates of synthesis with [¹⁵N]glycine, 1253-1258
plasma, in AIDS patients, 1162
in soy protein, 1147, 1148
in TPN of burn patients, 660
- Serum α (alpha)-N-acetylarginine, levels of, in cirrhotic subjects, 585
- Serum albumin
in AIDS patients, 1162
in cirrhotic subjects, 255
and malnutrition in nonneoplastic gastrointestinal diseases, 1112
- Serum alkaline phosphatase (ALP), milk consumption effects on, 1190-1193
- Serum androstenedione (Δ^4 -DIONE), effects of low-fat, high-fiber diet on, in premenopausal women, 752-753
- Serum apolipoproteins (apos)
age and response of, to physical conditioning and deconditioning, 163
in hypertriglyceridemic subjects, gemfibrozil effects on, 591
- Serum arginine (ARG), levels of, in cirrhosis, 585
- Serum bilirubin in cirrhosis, 255
- Serum calcium (Ca), amylin effects on, 709
- Serum catecholamines, response of, to amlodipine in essential hypertension, 316, 318
- Serum cholesterol (C)
in obese normoinsulinemic men, 1386
see also Serum total cholesterol
- Serum cholinesterase in beta-thalassemia, 282
- Serum corticosterone, effects of high-CHO diet on, 1544
- Serum C-peptides (connecting peptides)
fasting, in microvascular angina, 877
in hypertensive NIDDM subjects, 86
in normal subjects and in pancreas transplantation recipients, 1156
- Serum creatine, levels of, in cirrhosis, 585
- Serum creatinine
and effects of hyperglycemia on urinary excretion of C-peptide, 1195
in hypertensive NIDDM subjects, 86
levels of, in cirrhosis, 585
- Serum D-dimer in PCOS with obesity, effects of VLCD on, 613, 614
- Serum estradiol, effects of low-fat, high-fiber diet on, in premenopausal women, 752-753
- Serum estrogen, changes in concentrations of plasma Lps in response to low-fat, high-fiber diet associated with changes in, in premenopausal women, 749-756
- Serum estrone, effects of low-fat, high-fiber diet on, in premenopausal women, 752, 753
- Serum fasting insulin, *see* Fasting serum insulin
- Serum free fatty acids (FFAs)
acipimox potentiating GH response to GHRH by decreasing levels of, in hyperthyroidism, 1509-1512
and persistent IGT, 1102
- Serum free insulin in normal subjects and in pancreas transplantation recipients, 1156
- Serum glucose
in CF, 16
in chronic hypoinsulinemia and hyperinsulinemia, 983, 984
effects of high-CHO diet on, 1544
in GH-secreting tumors, 77
postprandial, responses of, of high-fiber and low-fiber diets, 848-854
in STZ-DM, 1392, 1458
- Serum glutamic pyruvate transaminase (GPT) in obese children, as risk factor for development of complications, 479, 481, 482
- Serum γ (gamma)-glutamyl transpeptidase (γ -GTP) in obese children, as risk factor for development of complications, 479, 481, 482
- Serum glycerol, beef tallow diet effects on, 1273
- Serum growth hormone (GH) in GH-secreting tumors, 77
- Serum guanidine, levels of, in cirrhosis, 585
- Serum guanidino compounds in cirrhosis, 584-588
- Serum guanidinoacetic acid, levels of, in cirrhosis, 585
- Serum γ -guanidinobutyric acid, levels of, in cirrhosis, 585
- Serum guanidin succinic acid (GSA), levels of, in cirrhosis, 585
- Serum high-density lipoproteins (HDLs)
in hypertensive NIDDM subjects, 86
in hypertensive and normotensive smokers, 559
- Serum homoarginine, levels of, in cirrhosis, 585
- Serum insulin
beef tallow and safflower oil effects on, compared, 937
effects of nibbling versus gorging on, 552
fasting, *see* Fasting serum insulin
in GH-secreting tumors, 77
and hepatic UDP-glucose synthesis, 178
high-CHO diet effects on, 1544
of hypertriglyceridemic subjects, gemfibrozil effects on, 590-592
high-calorie TPN effects on, 155
level of, in IGT and NIDDM, 1371-1376
postprandial, responses of, of high- and low-fiber diets, 848-854
- Serum insulin-like growth factor-binding proteins (IGFBPs)
high-calorie TPN effects on, 152-160
influence of zinc deficiency-induced anorexia on distribution of, 1495-1501
- Serum K (potassium)
in elderly subjects with femoral neck fracture, 61
in hypertensive NIDDM subjects, 86
- Serum α (alpha)-keto- δ -guanidin valeric acid, levels of, in cirrhotic subjects, 585
- Serum lactate, and persistent IGT, 1102
- Serum D-lactate in diabetic ketoacidosis, 287-290
- Serum lipids
and fasting serum insulin in metabolic syndrome, 36, 37
in hypertriglyceridemic subjects, gemfibrozil effects on, 590
in NIDDM, *see* Serum lipids in NIDDM
response of, to amlodipine in essential hypertension, 316
- Serum lipids in NIDDM
gemfibrozil and simvastatin effects on, 214-216
in hypertensive NIDDM, 86, 87
oral (-)-BM 13.0913.Na effects on, 573
- Serum lipoprotein(s) (Lps)
gemfibrozil and simvastatin effects on, in NIDDM, 214-216
postprandial, responses of, to high-fiber and low-fiber diets, 848-854
worksite ETS effects on, in nonsmoking women, 1536-1539
see also specific types of lipoproteins
- Serum lipoprotein(a) [Lp(a)], levels of, before and after subtotal thyroidectomy for hyperthyroidism, 4-7
- Serum low-density lipoproteins (LDLs)
in hypertensive NIDDM, 86

- Serum low-density lipoproteins (LDLs) (*Continued*)
 in hypertensive and normotensive smokers, 559
- Serum Na (sodium) in hypertensive NIDDM subjects, 86
- Serum prealbumin in AIDS patients, 1162
- Serum progesterone, effects of low-fat, high-fiber diet on, in premenopausal women, 753
- Serum protein in AIDS patients, 1162
- Serum retinol in primary hypercholesterolemia with 2 years of cholesterol-lowering therapy, 398-403
- Serum sex hormone-binding globulin (SHBG), effects of low-fat, high-fiber diet on, in premenopausal women, 752
- Serum sialic acid, as indicator of change in CAD, 147-148
- Serum testosterone (T), effects of low-fat, high-fiber diet on, in premenopausal women, 752-753
- Serum thromboxane X_2 (TXB₂), n-3 PUFA ethyl ester effects on, 565
- Serum thyrotropin (TSH) before and after subtotal thyroidectomy for hyperthyroidism, 5, 6
- Serum thyroxine (T₄) before and after subtotal thyroidectomy for hyperthyroidism, 5, 6
- Serum total cholesterol (TC)
 in hypertensive NIDDM subjects, 86
 in hypertensive and normotensive smokers, 559
- Serum triglycerides (TGs)
 and fasting serum insulin in metabolic syndrome, 36-38
 in hypertensive NIDDM subjects, 86
 in hypertensive and normotensive smokers, 559
 low-dose pravastatin effects on, 1411
 in obese normoinsulinemic men, 1386
- Serum triiodothyronine (T₃) before and after subtotal thyroidectomy for hyperthyroidism, 5, 6
- Serum urea, levels of, in cirrhosis, 585
- Serum uric acid (UA), effects of nibbling versus gorging on, 549-555
- Serum very-low-density lipoproteins (VLDLs) in hypertensive and normotensive smokers, 559
- Severe insulin resistance, leprechaunism with, cDNA amplification in analysis of promoter region of IR gene in, 430-437
- Severe malnutrition in cirrhosis, and short-term changes in EE after 1 month of regular oral diet, 765-770
- Sex
 of AIDS patients, 1161
 of beta-thalassemia subjects, 282
 of burn patients, 660
 of CF subjects, 14
 of cirrhotic patients, 826
 and development of hyperlipidemia and atherosclerosis, 1326-1331
 of early IDDM subjects, natural course of insulin sensitivity in, 618
 and effects of fructose and glucose ingestion with and without caffeine, 631
 of GH-deficient children, 1200
 and heparin effects on release, oxidation, and reesterification of FAs from TGs, 1591
 of hepatic steatosis subjects, 700
 of hypercholesterolemic subjects, 376, 399
 of hyperinsulinemic subjects, *see* Sex of hyperinsulinemic subjects
 of hypertensive subjects, *see* Sex of hypertensive subjects
 of hypertriglyceridemic subjects, *see* Sex of hypertriglyceridemic subjects
 of hypothyroid patients, 1284
 of IGT patients, serum insulin level and, 1373
- Sex (*Continued*)
 and influence of submaximal exercise on glucose assimilation, 834
 and insulin resistance in GH-deficient adults, 1127
 and intra-abdominal AT contribution to insulin resistance of aging, 955-957
 LPL and HL activity, Lp levels and, 491-498
 and malnutrition due to non-neoplastic gastrointestinal diseases, 1112
 of microvascular angina patients, 877
 milk consumption effects on serum ALP and, 1191
 of NIDDM subjects, *see* Sex of NIDDM subjects
 of normolipidemic subjects, 1053
 of normotensive smokers, HbA_{1c} levels and insulin sensitivity in, 558
 of obese subjects, *see* Sex of obese subjects
 of pituitary deficiency subjects, 68
 and relationship of hepatic mRNA level with metabolism of plasma LDL apo B, 1060
 of SCI subjects, 53
see also Men; Women
- Sex hormone(s)
 in AIDS, 947-951
see also specific sex hormones
- Sex hormone-binding globulin (SHBG)
 abdominal AT in obese men and levels of, 513-519
 in AIDS, 948-950
 in PCOS with obesity, effects of VLCD on, 613, 614
 serum, effects of low-fat, high-fiber diet on, in premenopausal women, 752
- Sex of hyperinsulinemic subjects
 of fasting hyperinsulinemic subjects, 916, 918, 919
 of hyperinsulinemic first-degree relatives of NIDDM patients, 1279
- Sex of hypertensive subjects
 of essential hypertension subjects, 316
 of hypertensive smokers, HbA_{1c} levels and insulin sensitivity in, 558
- Sex of hypertriglyceridemic subjects
 with NIDDM, 692
 nondiabetic, 590
- Sex of NIDDM subjects
 and effects of hyperglycemia on urinary excretion of C-peptide, 1195
 with glucose intolerance, fluoxetine effects and, 1571
 hypertriglyceridemia and, 692
 insulin binding and glycemic control and, 507
 serum level insulin level and, 1373
- Sex of obese subjects
 of centrally obese subjects, hemostatic function and, 1418
 insulin resistance, insulin secretion, glucose effectiveness and, 1399
 with NIDDM, fluoxetine effects and, 1571
 of obese children, and fasting plasma insulin level as risk factor for development of complications, 479, 481, 482
- SFAs, *see* Saturated fatty acids
- SHBG, *see* Sex hormone-binding globulin
- Short-chain fatty acids (SCFAs), cecal, beta-CD effects on, 201-202
- Short stature, idiopathic, GHRP-2 and GHRH in children with GH deficiency and, 1199-1204
- Short-term effects
 of captopril on insulin-stimulated glucose transport in SM of obese subjects, 268-269
 of clenbuterol on tissue Rb uptake and body temperature, 121

Short-term effects (*Continued*)

- of fasting on changes in GHBP concentrations in normal and acromegalic subjects, 667-672
- of GH therapy on lipids and Lps in men and women without GH disturbances, 725-729
- glucagon-dependent GLP-1(7-37), 1231-1237
- of regular oral diet on EE in severely malnourished cirrhotic patients, 765-770
- of salbutamol, *see* Short-term effects of salbutamol
- Short-term effects of salbutamol
 - of oral salbutamol on GH secretion in prepubertal asthmatic children, 149-151
 - on tissue Rb uptake and body temperature, 121
- Sialic acid, serum, as indicator of change in CAD, 147-148
- Sialyl transferase, and long-term ethanol exposure, 894
- Silent myocardial ischemia, obese men with reduced HDL-C and, effects of diet and weight loss on Lp levels in, 307-314
- Simvastatin, effects of, on insulin sensitivity in NIDDM and hyperlipoproteinemia, 212-217
- Skeletal muscle (SM)
 - carnitine in, in vitamin C deficiency, 1641
 - effects of exercise and fed state on LPL gene expression in, 1596-1605
 - increase in Ca and voltage-sensitive Ca channel blockers in, in STZ-DM, 1455-1461
 - insulin and, *see* Insulin, SM and
 - in obesity, captopril effects on glucose transport in, 267-272
 - synthesis of protein of, modulated by AAs and insulin during sepsis, 1130-1138; *see also* Insulin, SM protein and
 - see also* Muscle
- Skin fibroblasts, abundance of Na⁺/H⁺ exchanger isoform-1 in IDDM with nephropathy, 791-795
- SM, *see* Skeletal muscle
- Small intestine, interorgan AA flow between muscle and, role of membrane transport in, 719-724
- Smoking
 - by AIDS patients, 1566
 - as cardiovascular risk factor in fasting hyperinsulinemia, 917, 918
 - cessation of, relationship of nicotine gum use and, to salivary androstenedione and testosterone in middle-aged men, 90-95
 - dietary fat intake, RBC phospholipid FA composition and, 1141
 - and effects of milk consumption on serum ALP, 1191, 1192
 - and effects of n-3 PUFA ethyl ester on platelet phospholipid composition and platelet functions, 563
 - effects of worksite environmental, on serum Lps in nonsmoking women, 1536-1539
 - HbA_{1c} levels and impaired insulin sensitivity in hypertensive and normotensive smokers, 557-561
 - and mononuclear cell adhesion to endothelial cells in combined hypercholesterolemia-hypertriglyceridemia and in isolated hypercholesterolemia, 376
 - by patients on bezafibrate therapy, 1403, 1406
- Sodium, *see* Na; Sodium acetate; Sodium pivalate model
- Sodium acetate, effects of, on xanthine dehydrogenase, 783
- Sodium pivalate model of secondary carnitine deficiency, fatty acid oxidation and cardiac function in, 499-505
- Somatostatin, NMLA and, decreasing blood glucose and plasma insulin and blocking ET-1-induced insulin release but not ET-1-induced hypoglycemia, 1532-1535
- Somatotrope, galanin role in regulating function of gonadotrope and, in young ovulatory women, 1028-1032
- Sorbinil, effects of, on glucose, sorbitol, *myo*-inositol, and fructose in eyes of diabetic subjects, 1042

Sorbitol

- galactose and concentration of, in lens, 1528
- malabsorption of, and nonspecific abdominal symptoms in NIDDM, 796-799
- sorbinil effects on *myo*-inositol, fructose, glucose and, in eyes of diabetic subjects, 1042
- Soy protein, hypercholesterolemia induced by, and Lp susceptibility to peroxidation potentiated by methionine deficiency in subjects fed, 1146-1152
- SP (substance P), effects of, on basal and TRH-stimulated TSH release, 474-477
- Spectroscopy, gas-phase Fourier infrared, doubly labeled water determination by, 1-3
- Spinal cord injury (SCI)
 - chronic, vitamin D deficiency in, 1612-1618
 - suppression of hypothalamus-pituitary axis in men with, 1116-1120
 - sympathetic nervous system influence on insulin sensitivity and AT metabolism in, 52-58
- Spleen mitochondria, T₃ effects on AdNT activity in, 197
- Spontaneous hypertension, beta cell function and replication in, 1360-1364
- SSPG (steady-state plasma glucose) in essential hypertension, amlodipine effects on, 316
- Starvation
 - in exercising subjects, metabolic and hormonal responses to adrenoceptor antagonists in, 1332-1339
 - tissue-related changes in insulin receptor number and autophosphorylation stimulated by STZ-DM and, 291-297
- Steady-state plasma glucose (SSPG) in essential hypertension, amlodipine effects on, 316
- Steatosis, hepatic macrovesicular, mitochondrial KIC decarboxylation in, 699-700
- Steroid(s)
 - anabolic, effects of, on tumor growth and cancer cachexia, 445-451
 - C₁₉, levels of adrenal, in older men, 513-519
 - cecal and fecal, beta-CD effects on, 202-203
 - see also* Glucocorticoids; Steroidogenesis and specific steroids
- Steroidogenesis, NO as interstitial regulator of, in Leydig cells, 234-238
- Streptozotocin-induced diabetes mellitus (STZ-DM)
 - concentration-dependent lowering effects of oral vanadyl on glucose in, are maintained after treatment withdrawal, 332-339
 - HSL regulation in, 1391-1396
 - hydroperoxide detoxification in intestine in, effects of insulin and GSH redox cycle on, 1462-1468
 - impaired NO release by glomeruli in, 695-698
 - increase in Ca and voltage-sensitive Ca channel blockers in SM in, 1455-1461
 - malnutrition with, insulin resistance and, 1422-1427
 - oral (-)-BM 13.0913.Na improving insulin sensitivity in, 570-576
 - peripheral nerve function in, effects of acetyl-L-carnitine on, 677-680
 - starvation and, inducing tissue-related changes in insulin receptor number and autophosphorylation, 291-297
- Stress
 - mental, effects of, on glucose uptake during hyperinsulinemia, 1303-1307
 - see also* Oxidative stress
- STZ-DM, *see* Streptozotocin-induced diabetes mellitus
- Subacute thyroiditis, thyroid and renal function in, 208, 209

- Subcutaneous abdominal adipose tissue (AT)
 β -adrenergic stimulation of BF of, in obese, lean and reduced-obese women, 183-187
 estimating, from anthropometric measurements, 1617-1625
- Subcutaneous adipose tissue (AT)
 abdominal, *see* Subcutaneous abdominal adipose tissue
 beef tallow diet effects on, 1273-1274
 lipolytic response of, to NE, 1515
- Submaximal exercise, influence of, on glucose assimilation, minimal model in analysis of, 833-840
- Substance P (SP), effects of, on basal and TRH-stimulated TSH release, 474-477
- Substrates
 oxidation of, during fasting by elderly subjects with femoral neck fracture, 63
 T_3 effects on cycling of, between pyruvate carboxylase and malic enzyme in liver, 1380-1383
see also specific substrates
- Subtotal thyroidectomy for hyperthyroidism, serum Lp(a) levels before and after, 4-7
- Succinate dehydrogenase, and long-term ethanol exposure, 892
- Sucrose (s), effects of high-fat, high-sucrose diet on development of obesity and diabetes mellitus, 645-651
- Sugars, *see specific sugars*
- Sulfate, *see* Dextran sulfate
- Sumatriptan, alcoholism suppressing GH response to, 1577-1580
- Supplementation, vitamin C, effects of, on plasma Cp in IDDM, 997-998
- Sympathetic nervous system
 effects of beef tallow and safflower oil on activity, compared, 934-939
 influence of, on insulin sensitivity and AT metabolism in SCI subjects, 52-58
 responsiveness of, to mental stress, glucose uptake during hyperinsulinemia and, 1303-1307
- Syndrome X, cardiologic, insulin resistance in, 876-882
- Synthase
 HMG-CoA, relationship of hepatic mRNA level with metabolism of plasma LDL apo B and, 1060, 1061, 1065
see also Glycogen synthase, activity of muscle
- Systolic blood pressure, *see* Blood pressure
- T, *see* Testosterone
- T_3 , *see* Triiodothyronine
- T_4 , *see* Thyroxine; L-Thyroxine effects in hypothyroidism
- TAG, *see* Triacylglycerol
- Taurine
 effects of overnight infusion of, on muscle proteolysis, 426
 following total hip replacement, 1217-1219
- TBBB (total body bone density), and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- TBBM (total body bone mineral), and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- TBK (total body potassium), and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- TC, *see* Total cholesterol
- Temperature
 body, short-term effects of clenbuterol and salbutamol on, 121, 122
 transendothelial permeation of albumin by high glucose concentration dependent on, 741
- Testes mitochondria, T_3 effects on AdNT activity in, 197
- Testicular dysfunction in HIV infection, 946-953
- Testosterone (T)
 in adolescent males, *see* Adolescent males, T effects in
- Testosterone (T) (*Continued*)
 levels of adrenal C_{19} steroids and, in obese men, 513-519
 in men with SCI, 1117
 in PCOS, *see* Testosterone in PCOS
 salivary androstenedione and, in middle-aged men, relationship of smoking cessation and nicotine gum use to, 90-95
 serum, effects of low-fat, high-fiber diet on, in premenopausal women, 752-753
- Testosterone (T) in PCOS
 flutamide effects on, 527
 with obesity, effects of VLCD on, 613, 614
- TGs, *see* Triglycerides
- β (beta)-Thalassemia, homozygous, hyperinsulinemia and insulin resistance in, 281-286
- Thermogenesis
 effects of weight loss on β -adrenergically mediated thermogenic responses in obese men, 520-524
see also Calorie(s) and entries beginning with term: Energy
- Thoracic aorta, arachidonate distribution in LDLs and, in hyperinsulinemia, 806-811
- Threonine
 effects of, on SM protein synthesis during sepsis, 1131
 effects of overnight infusion of, on muscle proteolysis, 426
 following total hip replacement, 1217-1219
 plasma, in AIDS patients, 1162
 in soy protein, 1147, 1148
 in TPN of burn patients, 660, 661
- Thromboxane X_2 (TXB₂), serum, n-3 PUFA ethyl ester effects on, 565
- Thyroid function, *see* Hyperthyroidism; Hypothyroidism
- Thyroidectomy, subtotal, for hyperthyroidism, serum Lp(a) levels before and after, 4-7
- Thyroiditis, subacute, thyroid and renal function in, 208, 209
- Thyrotoxicosis, mild, renal and thyroid function in, 209
- Thyrotropin (TSH)
 in adolescent males with constitutional delay of growth, 1014
 effects of NSAIDs and loop diuretics on release of, by anterior pituitary cells, 1008-1012
 in hyperthyroidism, *see* Thyrotropin in hyperthyroidism
 in hypothyroidism, *see* Thyrotropin in hypothyroidism
 in NIDDM with obesity or glucose intolerance, fluoxetine effects on, 1571
 SP effects on basal and TRH-stimulated release of, 474-477
- Thyrotropin (TSH) in hypothyroidism, 1284
 L- T_4 on, 1559-1563
- Thyrotropin (TSH) in hyperthyroidism
 and plasma ET-1 level and, 1240
 serum, before and after subtotal thyroidectomy, 5, 6
- Thyrotropin-releasing hormone (TRH)
 glucocorticoid effects on GH response to, in acromegaly, 379-383
 SP effects on basal and TRH-stimulated TSH release, 474-477
- Thyroxine (T_4)
 fasting plasma, in middle-aged men, training status and, 343
 in hyperthyroidism, *see* Thyroxine in hyperthyroidism
 in men with SCI, 1117
 in NIDDM with obesity or glucose intolerance, fluoxetine effects on, 1571
 in pituitary deficiency subjects, 70, 71
- Thyroxine (T_4) in hyperthyroidism
 plasma ET-1 level and, 1240
 serum, before and after subtotal thyroidectomy, 5, 6
- L-Thyroxine (T_4) effects in hypothyroidism
 on Lp fractions in hypothyroidism, 1559-1563
 on plasma Lps and apos in congenital hypothyroidism, 1283-1287

- Tissue plasminogen activator (tPA)
in non-obese men, effects of moderate calorie restriction on, 1550
in obesity, *see* Tissue plasminogen activator in obesity
- Tissue plasminogen activator (tPA) in obesity
in central obesity, hemostatic function and, 1419
with PCOS, effects of VLCD on, 613, 614
- Tissue-related changes in insulin receptor number and autophosphorylation induced by starvation and STZ-DM, 291-297
- Tissue rubidium (Rb), clenbuterol and salbutamol effects on uptake of, 119-125
- Tissue-specific alterations in G protein expression in genetic versus diet-induced models of NIDDM, 771-778
- Tissue weight
fetal, and maternal chronic hypoxia, maternal food intake and, 534, 535
see also Organ weight
- TNF, *see* Tumor necrosis factor
- Tobacco, *see* Smoking
- Tolbutamide, effects of, on insulin secretion in CF patients with impaired glucose tolerance, 13-18
- Tolerance of chemotherapy, and its impact on protein metabolism, 1341
- Total bile acid, low-dose pravastatin effects on, 1411
- Total bilirubin in cirrhosis, 900
- Total body bone density (TBBD), and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- Total body bone mineral (TBBM), and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- Total body potassium (TBK), and age-related changes in musculoskeletal mass of postmenopausal women, 31-33
- Total cholesterol (TC)
cholestyramine and fluvastatin effects on, 1449, 1450
in cirrhosis, 828
in DM with hypertension, doxazocin effects on, 674
effects of nibbling versus gorging on, 551, 552
exercise effects on, *see* Total cholesterol, exercise effects on
and fasting serum insulin in metabolic syndrome, 36-38
following CABG, 1018
of hypercholesterolemic subjects, 399, 400
in hyperthyroidism before and after subtotal thyroidectomy, 5
in hypertriglyceridemia, *see* Total cholesterol in hypertriglyceridemia
low-dose pravastatin effects on, 1411
low-fat, high-fiber diet effects on, 750-754
in NIDDM, 941
in nonsmoking women, effects of worksite ETS on, 1537
in obese children, as risk factor for development of complications, 479, 482
in patients on bezafibrate therapy, 1406
in PCOS, effects of VLCD on, 613, 614
plasma, *see* Plasma total cholesterol
plasma volume effects on, during menstrual cycle, 965-971
in pregnancy with HFH treated by dextran sulfate LDL apheresis, 930
n-3 PUFA effects on, 1225
serum, *see* Serum total cholesterol
L-thyroxine effects on, in hypothyroidism, 1561
- Total cholesterol (TC), exercise effects on
effects of brisk walking by sedentary middle-aged women on, 394
effects of exercise by fertile women on, 703
- Total cholesterol (TC) in hypertriglyceridemia
in borderline hypertriglyceridemia, 1294, 1295
with and without CV disease, postprandial Lp responses and, 1086-1088
- Total hip replacement, α -ketoglutarate and glutamine preventing decrease in concentration of muscle free glutamine and influencing protein synthesis after, 1215-1222
- Total parenteral nutrition (TPN)
of burn patients, 659-666
high-calorie, effects of, on hepatic IGF-I mRNA and serum IGFBPs, 152-160
- Total peripheral parenteral nutrition (TPPN) of elderly subjects with femoral neck fracture, 59-66
- Total testosterone (T), flutamide effects on, in PCOS, 527
- tPA, *see* Tissue plasminogen activator
- TPN, *see* Total parenteral nutrition
- TPPN (total peripheral parenteral nutrition) of elderly subjects with femoral neck fracture, 59-66
- Training, physical, *see* Exercise
- Transaminase, serum glutamic pyruvate, in obese children, as risk factor for development of complications, 479, 481, 482
- Transendothelial permeation of albumin by high glucose concentration, 739-744
- Transferase, *see* Galactosyl transferase; Lecithin-cholesterol acyltransferase; Mannosyl transferase; Sialyl transferase
- Transferrin
in AIDS patients, 1566
and long-term ethanol exposure, 892-893
- Translocase, mitochondrial adenine nucleotide, T₃ effects on, 193-199
- Transpeptidase, serum γ -glutamyl, in obese children, as risk factor for development of complications, 479, 481, 482
- Transplantation, pancreas, cephalic-phase insulin and glucagon release in normal subjects and in recipients of, 1153-1158
- Transthyretin in severely malnourished cirrhotic patients, 767
- Trauma and injury, 52-66
acute, plasma IGFBP-3 in, 1205-1208
femoral neck fracture in elderly subjects, protein and energy balance in, 59-66
plasma arginine and leucine kinetics, and urea production rates in burn patients, 659-666
spinal cord, *see* Spinal cord injury
- TRH, *see* Thyrotropin-releasing hormone
- Triacylglycerol (TAG)
insulin sensitivity and hepatic LDL secretion in fructose-fed subjects and, 841-847
plasma, exercise-induced changes in concentrations of, 681-688
- Triglycerides (TGs)
in AIDS patients, 1566
in centrally obese subjects, hemostatic function and, 1418
cholestyramine and fluvastatin effects on, 1449, 1450
in DM with hypertension, doxazocin effects on, 674
effects of dietary fat types on, 276
effects of exercise by fertile women on, 703
effects of nibbling versus gorging on, 551, 552
FAs from, heparin effects on release, oxidation, and reesterification of, 1590-1595
in hepatic steatosis, 700
in hypercholesterolemia, 399, 400
in hyperinsulinemia, *see* Triglycerides in hyperinsulinemia
in hyperthyroidism before and after subtotal thyroidectomy, 5
in hypothyroidism, *see* Triglycerides in hypothyroidism, L-T₄ effects on
insulin propeptides and, 1483
in lipid-induced insulin resistance, 641
low-fat, high-fiber diet effects on, 750-754
and LPL activity, *see* Triglycerides, LPL activity in
in men with CAD, 108

Triglycerides (TGs) (*Continued*)

- in NIDDM, *see* Triglycerides in NIDDM
- in nonsmoking women, effects of worksite ETS on, 1537
- in normolipidemic subjects, 1053
- in obesity, *see* Triglycerides in obesity
- oral vanadyl effects on, 334
- in patients on bezafibrate therapy, 1403
- plasma, *see* Plasma triglycerides
- plasma volume effects on, during menstrual cycle, 967, 968
- in postmenopausal women on HRT, 411
- postprandial response of, to high- and low-fiber diets, 849-851
- and pulsatile GH secretion during fasting, 606
- in SCI, 54
- serum, *see* Serum triglycerides
- short-term effects of GH therapy on, 726-728
- simvastatin and gemfibrozil effects on, 215
- in STZ-DM, 1392
- see also* Hypertriglyceridemia
- Triglycerides (TGs), LPL activity in
 - changes in SM LPL activity in NIDDM, 787
 - in hypertension, 714, 715
 - TG level and LPL and HL activity, sex differences in, 493, 494
- Triglycerides (TGs) in hyperinsulinemia
 - and arachidonate distribution in LDLs and thoracic aorta, 807-809
 - levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917
 - and lipogenic enzymes and GLUT4 mRNA expression in liver and AT, 229
- Triglycerides (TGs) in hypoglycemia, L-T₄ effects on, 1561
- in congenital hypothyroidism, 1284-1286
- Triglycerides (TGs) in NIDDM, 941
 - in obese women, 1476
 - with obesity or glucose intolerance, fluoxetine effects on, 1571
 - SM LPL activity in, 787
- Triglycerides (TGs) in obese women
 - with NIDDM, 1476
 - with PCOS, VLCD effects on, 613, 614
- Triglycerides (TGs) in obesity
 - effects of diet and weight loss on TGs in obese men with silent myocardial ischemia and reduced HDL-C, 309
 - with NIDDM, fluoxetine effects on, 1571
 - in obese children, as risk factor for development of complications, 479, 482
 - oral (-)-BM 13.0913.Na effects on, in lean and obese subjects, 580, 581
 - see also* Triglycerides in obese women
- Triiodothyronine (T₃)
 - in congenital hypothyroidism, effects of L-T₄ on levels of, 1284-1286
 - effects of, in liver, *see* Liver, T₃ effects on
 - effects of, on mitochondrial AdNT, 193-199
 - effects of, on TSH release by anterior pituitary cells, 1010
 - fasting plasma, in middle-aged men, training status and, 343
 - in men with SCI, 1117
 - in pituitary deficiency subjects, 70, 71
 - and plasma ET-1 level in hyperthyroidism, 1240
 - serum, before and after subtotal thyroidectomy for hyperthyroidism, 5, 6
- ε (epsilon)-N-Trimethyllysine, carnitine synthesis from, vitamin C deficiency and, 624-629
- Triphosphatase, *see* ATPase
- Triphosphate
 - D-myo-inositol 1,4,5-, modulating mediation of RBC Ca²⁺-

Triphosphate (*Continued*)

- ATPase activity by guanine nucleotide regulatory protein, 865-866
- see also* ATP
- Troglitazone (CS-045)
 - acute effects of, on insulin action in normal subjects, 1166-1169
 - effects of, on dietary fat-induced insulin resistance, 1489-1494
 - effects of bezafibrate and, on glucose tolerance, liver glycogen synthase activity, and β-oxidation, in fructose-fed subjects, 1626-1630
 - long-term therapy with, suppressing hepatic gluconeogenesis in DM, 487-490
 - M3 and, regulating glucose transport in muscle cells, 976-981
- Tryptophan
 - effects of, on SM protein synthesis during sepsis, 1131
 - plasma, in AIDS patients, 1162
 - in soy protein, 1147, 1148
 - in TPN of burn patients, 660
- TS (Turner's syndrome), obesity-related insulin status and blunted GH secretion in, 1033-1037
- TSH, *see* Thyrotropin
- Tumor(s)
 - anabolic steroid effects on cachexia and growth of, 445-451
 - chemotherapy for, impact of, on protein metabolism, 1340-1348
 - GH-secreting, insulin resistance with, 75-84
- Tumor necrosis factor (TNF)
 - fish oil effects on muscle glucose uptake in subjects treated with, 1365-1370
 - soluble receptors for, as markers for clinical course but not for major metabolic changes in AIDS, 1564-1569
 - see also* specific tumor necrosis factors
- Tumor necrosis factor-α (TNF-α), gluconeogenesis stimulation in hepatocytes by, 146
- Tumor necrosis factor-α (TNF-α) mRNA (messenger ribonucleic acid), expression of macrophage, enhanced by fish oil at transcriptional level, 800-805
- Tumor necrosis factor-β (TNF-β), polymorphism of, associated with hypertriglyceridemia in NIDDM, 691-694
- Turner's syndrome (TS), obesity-related insulin status and blunted GH secretion in, 1033-1037
- Twins
 - identical, long-term overfeeding of, plasma glucose, insulin, and glucagon in, 96-105
 - LBM in, 1442-1446
- TXB₂ (thromboxane X₂), serum, n-3 PUFA ethyl ester effects on, 565
- Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Type III (familial) hyperlipoproteinemia with FH, 460-465
- Tyrosine
 - effects of, on SM protein synthesis during sepsis, 1131
 - effects of overnight infusion of, on muscle proteolysis, 426
 - following total hip replacement, 1217-1219
 - plasma, *see* Plasma tyrosine
 - in soy protein, 1147, 1148
 - in TPN of burn patients, 660
 - see also* Protein kinase; Protein-tyrosine phosphatases, insulin resistance and
- Tyrosine kinase
 - activity of erythrocyte IGF-I receptor, in hypertensive pregnancy, 1308-1313
 - dexamethasone and PSL effects on activity of, 304
- UA, *see* Uric acid

- UDP, *see* Uridine diphosphogalactose; Uridine diphosphoglucose; Uridine diphosphohexoses
- Underfeeding, *see* Calorie restriction; Restricted dietary protein
- Upright posture, effects of weight loss on hemodynamic responses to, in obese men, 440-441
- Urea
in cirrhosis, *see* Urea in cirrhosis
plasma arginine and leucine kinetics and production rates of, in burn patients, 659-666
- Urea in cirrhosis:
effects of β -adrenergic blockers on synthesis of, 899-905
serum, 585
urinary excretion of, 586
- Uric acid (UA)
levels of, in obese children, as risk factor for development of complications, 479, 482
serum, effects of nibbling versus gorging on, 549-555
- Uridine diphosphate (UDP) in normal subjects and in galactosemia, 599, 600
- Uridine diphosphogalactose (UDP-galactose) in normal subjects and in galactosemia, 599, 600
- Uridine diphosphoglucose (UDP-glucose), hepatic, rate of entry of glucose into, in fasted and fed states in normal subjects, 172-182
- Uridine diphosphohexoses (UDP-hexoses) in normal subjects and in galactosemia, 600-602
- Uridine sugar nucleotide, levels of erythrocyte, in normal subjects, classic galactosemia, and subjects with other metabolic disorders, 597-604
- Urinary excretion
albumin, *see* Urinary excretion, albumin
cortisol, CRH stimulation test effects on levels of, in IDDM with or without neuropathy, 541
C-peptide, *see* Urinary excretion, C-peptide
dopamine, E, and NE, in hyperinsulinemic subjects, arachidonate distribution in LDLs and thoracic aorta and, 807
ET, angiotensin II and phenylephrine effects on, in women, 115-118
fractional Na, amlodipine in essential hypertension and, 316, 318
of guanidino compounds in cirrhosis, 584-588
mevalonic acid and creatinine, effects of nibbling versus gorging on, 551-552
of purine bases, ethanol effects on, 781
- Urinary excretion, albumin
and abundance of Na^+/H^+ exchanger isoform-1 in skin fibroblasts in IDDM, 792
and effects of hyperglycemia on urinary excretion of C-peptide, 1195
in hypertensive NIDDM subjects, 86, 87
- Urinary excretion, C-peptide
hyperglycemia facilitating, by increasing glomerular filtration rate in NIDDM, 1194-1198
in IGT and NIDDM subjects, serum level insulin level and, 1373
- $\dot{V}\text{CO}_2$, adrenoceptor antagonists and, 247
- $\dot{V}\text{O}_2$, adrenoceptor antagonists and, 247
- $\dot{V}\text{O}_{2\text{max}}$ (maximum O_2 consumption)
exercise and, *see* $\dot{V}\text{O}_{2\text{max}}$, exercise and
in IGT subjects, 1504, 1505
in obese men, effects of weight loss on, 439-440
- $\dot{V}\text{O}_{2\text{max}}$ (maximum O_2 consumption), exercise and
age, physical conditioning and deconditioning and, 162
in fertile women, 702
in middle-aged men, training status and, 342
- Valine
effects of, on SM protein synthesis during sepsis, 1131
effects of overnight infusion of, on muscle proteolysis, 426
following total hip replacement, 1217-1219
interorgan flow of, between muscle and small intestine, 721, 722
plasma, *see* Plasma valine
in soy protein, 1147, 1148
in TPN of burn patients, 660, 661
- Vanadate, effects of, on PTPase, 1078
- Vanadyl, oral, in STZ-DM, concentration-dependent lowering
effects of, on glucose are maintained after treatment withdrawal, 332-339
- Vascular supply, ALC and PLC effects on peripheral nerve function and, in diabetes, 1209-1214
- Vasodilators, and LPL activity in hypertension, 714-715
- VAT, *see* Visceral adipose tissue
- Venous blood gases, adrenoceptor antagonists and, 248
- Ventromedian nucleus of obese subjects, NT effects during fasting on, 972-975
- Very-low-calorie diet (VLCD), effects of, on insulin sensitivity and fibrinolytic capacity in PCOS with obesity, 611-616
- Very-low-density lipoprotein(s) (VLDLs)
dietary fat effects on levels of, 859
effects of short-term GH therapy on, 727
[^{15}N]glycine in measurement of synthetic rate of apo B of, serine and hippurate as precursor equivalents in, compared, 1253-1258
and hemolysis in primary LPL deficiency, 654
hepatic, *see* Hepatic very-low-density lipoproteins
in obese normoinsulinemic men, 1386
and persistent IGT, 1101
in postmenopausal women on HRT, 412
and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1087
n-3 PUFA effects on intravascular lipolysis of, 1223-1230
serum, in hypertensive and normotensive smokers, 559
see also Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein-cholesterol (VLDL-C)
effects of exercise by fertile women on, 703
insulin propeptides and, 1483
low-fat, high-fiber diet effects on, 750-754
postprandial response of, to high- and low-fiber diets, 849-851
- Visceral adipose tissue (VAT)
contribution of, to insulin resistance of aging, 954-959
estimating, from anthropometric measurements, 1617-1625
long-term effects of lipectomy and dexamethasone on metabolic variables and, 1631-1638
- Vitamin C
deficiency in, *see* Vitamin C deficiency, carnitine and
effects of supplementation with, on plasma Cp in IDDM, 997-998
- Vitamin C deficiency, carnitine and
and carnitine synthesis from ϵ -N-trimethyllysine or γ -butyrobetaine, 624-629
renal handling of carnitine in, 1639-1643
- Vitamin D, chronic SCI and deficiency in 1612-1618
- VLCD (very-low-calorie diet), effects of, on insulin sensitivity and fibrinolytic capacity in PCOS with obesity, 611-616
- VLDL(s), *see* Very-low-density lipoprotein(s)
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol
- Voltage-sensitive calcium channel blockers, increase of, in SM of STZ-DM subjects, 1455-1461
- Von Willebrand factor (vWF), levels of, as cardiovascular risk factor in fasting hyperinsulinemia, 917, 919

Waist-to-hip ratio (WHR)

and age-related changes in musculoskeletal mass, 31-33
 of borderline hypertriglyceridemic subjects, 1294
 as cardiovascular risk factor in fasting hyperinsulinemia, 917
 and estimates of visceral and subcutaneous abdominal AT, 1619
 exercise effects on, *see* Waist-to-hip ratio, exercise effects on
 and fasting serum insulin in metabolic syndrome, 36, 37
 of hypertensive subjects, *see* Waist-to-hip ratio of hypertensive subjects

of IGT subjects, 1504, 1505

and insulin resistance of aging, 956, 957

and insulin sensitivity, 1122, 1123

of men with CAD, 108

of normotensive smokers, HbA_{1c} levels and insulin sensitivity and, 558

in obesity, *see* Waist-to-hip ratio of obese subjects

and persistent IGT, 1101

and postprandial Lp responses in hypertriglyceridemia with and without CV disease, 1086

weight loss and, *see* Waist-to-hip ratio, weight loss and

Waist-to-hip ratio (WHR), exercise effects on

by fertile women, 702

by middle-aged men, 342

Waist-to-hip ratio (WHR), weight loss and

and effects of weight loss on norepinephrine and insulin levels, 440

weight loss effects on WHR, 1414, 1415

Waist-to-hip ratio (WHR) of hypertensive subjects

HbA_{1c} levels and insulin sensitivity in hypertensive smokers, 558
 with NIDDM, 86

Waist-to-hip ratio (WHR) of obese men

of centrally obese men, hemostatic function and, 1418

normoinsulinemic, 1386

with silent myocardial ischemia and reduced HDL-C, effects of diet and weight loss on Lp levels in, 309

testosterone and adrenal C₁₉ steroid levels in, 514, 517

Waist-to-hip ratio (WHR) of obese subjects

with NIDDM, fluoxetine effects on, 1571

of obese children, and fasting plasma insulin level as risk factor for development of complications, 479-481

see also Waist-to-hip ratio of obese men; Waist-to-hip ratio of obese women

Waist-to-hip ratio (WHR) of obese women

of centrally obese women, hemostatic function and, 1418

insulin resistance in adipocytes and, 988

with PCOS, effects of VLCD on, 613, 614

Waist-to-thigh ratio (WTR)

of early NIDDM subjects, 758

and fasting serum insulin in metabolic syndrome, 36, 37

Walking, effects of brisk, on insulinemia in sedentary middle-aged women, 390-397**Water, doubly labeled, determination of, by gas-phase FTIR spectroscopy, 1-3****WBCs, *see* White blood cell count and specific white blood cells****Weight, *see* Body weight; Tissue weight; Weight gain; Weight loss****Weight gain**

beta-CD effects on, 201-202

with clenbuterol and salbutamol, 121

differential effects of HF diet varying in FAs on efficiency of lean and fat tissue deposition during, following low food intake, 273-279

with oral vanadyl, 334

pioglitazone effects on, 1106

in STZ-DM, 1423

Weight loss

β-adrenergic responsiveness of adenylate cyclase in adipocyte plasma membrane after, 1288-1292

AIDS with, effects of increased dietary protein intake and nutritional status on whole-body protein metabolism in, 1159-1165

to ideal body weight, effects of, on AT distribution, 1413-1416

by middle-aged and older men with IGT reduces abdominal AT and improves insulin action, 1502-1508

by obese men, *see* Weight loss by obese men

by obese women, β-adrenergic stimulation of BF in AT and, 183-187

Weight loss by obese men

β-adrenergic stimulation of abdominal subcutaneous AT BF and, 183-187

and β-adrenergically mediated thermogenic and HR responses, 520-524

effects of, on norepinephrine and insulin levels in older obese men, 438-444

with silent myocardial ischemia and reduced HDL-C, effects of diet and weight loss on Lp level in, 307-314

White Americans, *see* Race and ethnicity**White blood cell (WBC) count**

in elderly subjects with femoral neck fracture, 61

in hypertensive and normotensive smokers, 559

Whole body protein, effects of increased dietary protein intake and nutritional status on metabolism of, in AIDS patients with weight loss, 1159-1165**Whole plasma in postmenopausal women on HRT, 412****WHR, *see* Waist-to-hip ratio****Withdrawal**

cigarette smoking, relationship of nicotine gum use and, to salivary androstenedione and testosterone in middle-aged men, 90-95

oral vanadyl, concentration-dependent lowering effects of, on glucose are maintained after, 332-339

Women

angiotensin II and phenylephrine effects on urinary excretion of ET in, 115-118

arginine and proline synthesis in, 466-473

exercising, *see* Women, exercising

without GH disturbances, effects of short-term GH therapy in, 725-729

menopausal, *see* Menopause

non-obese, *see* Non-obese women

nonsmoking, worksite ETS effects on serum Lps in, 1536-1539

obese, *see* Women, obese

older, *see* Older women

with PCOS, *see* Polycystic ovary syndrome, insulin sensitivity in plasma volume effects on LDL-cholesterol and total cholesterol during menstrual cycle, 965-971

pregnant, *see* Pregnancy

young, *see* Young women

see also Normal adult subjects

Women, exercising

brisk walking effects on insulinemia in sedentary middle-aged women, 390-397

and effects of exercise on plasma Lps and apos in fertile women, 701-704

energy cost of exercise in healthy elderly women, 1046-1051

influence of submaximal exercise on glucose assimilation, 833-840

Women, obese

β-adrenergic stimulation of BF in abdominal AT of reduced-obese and, 183-187

Women, obese (*Continued*)

- effects of combined administration of GHRH, GHRP-6, and pyridostigmine on GH secretion in, 745-748
 - fasting hyperinsulinemia and cardiovascular risk factors in non-diabetic obese women, 914-922
 - insulin resistance in adipocytes of, effects of AT distribution and race on, 987-995
 - with NIDDM, relation between ATLPL response to insulin and glucose with GHb levels in, 1475-1480
 - with PCOS, effects of VLCD on fibrinolytic capacity and insulin sensitivity in, 611-616
 - young women with central obesity, hemostatic function in, 1417-1421
 - see also* Obesity
- Worksite environmental tobacco smoke (ETS), effects of, on serum Lps in nonsmoking women, 1536-1539
- WTR, *see* Waist-to-thigh ratio

Xanthine dehydrogenase inhibitor, ethanol as, 779-785

X-ray absorptiometry, dual-energy, age- and menopause-associated variations in AT distribution and body composition in healthy women measured with, 369-373

Young men

- acute effects of fructose and glucose ingestion with and without caffeine by, 630-638
- centrally obese, hemostatic function in, 1417-1421
- response of aerobic power to exercise by, 188-192

Young subjects

- obese hyperglycemic, insulin secretion in, 906-913
- see also* Adolescent males; Young men; Young women

Young women

- acute effects of fructose and glucose ingestion with and without caffeine by, 630-638
- with central obesity, hemostatic function in, 1417-1421
- ovulatory, galanin role in regulating function of somatotrope and gonadotrope in, 1028-1032

Zidovudine, use of, by AIDS patients, 1566

Zinc deficiency (Zn)

- effects of, on protein synthesis and mRNA expression in liver, 126-133
- influence of anorexia induced by, on distribution of serum IGFBPs, 1495-1501